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Theophylline is one of the few preparations available for the treatment of apnoea of 
prematurity. Currently little data is available on the pharmacokinetics and the 
pharmacokinetic/pharmacodynamic relationships of theophylline for premature neonates 
during the first few days of life, a time when neonates undergo profound physiological 
changes and when the drug is most often used. Furthermore, the influence of 
theophylline on hypoxaemic episodes has not yet been quantified. 
The study aimed to investigate optimal theophylline dosing in this group by establishing 
pharmacokinetic parameters, assessing the effectiveness of the drug in abolishing apnoea 
and hypoxaemic episodes and investigating the concentration/effect relationship. 
The project was conducted in the neonatal wards of King Edward VIII Hospital, Durban, 
South Africa. The study group comprised a total of 105 Black, apnoeic, premature 
neonates, with respiratory distress syndrome, who were receiving intravenous 
theophylline. Serum samples (263), collected from patients during routine care, were 
analysed for theophylline. Forty-six patients were monitored before and after 
theophylline therapy with a neonatal capnograph linked to a data acquisition. 
Apnoea incidents were classified into total (all apnoea 2::5 seconds) and pathologic (an 
apnoea 2::20 seconds) and a hypoxaemic episode was defined as a 2::10% fall for > 10 
seconds in peripheral oxygen saturation. Within each of these groups patients were 
assessed as responders (2::50% reduction in the clinical effect from baseline to the last 
xx 
recording) and non-responders. Patient characteristics were identified as possible 
markers of non-response to theophylline therapy. 
The Nonlinear Mixed Effects Model (NONMEM) was used to derive population 
pharmacokinetic models and parameters for theophylline as well as to assess the 
concentration-effect relationship. 
The pharmacokinetic analysis estimated a low clearance and volume of distribution, with 
oxygen support enhancing clearance. Relatively high inter-individual and residual 
variability values were obtained prompting testing for inter-occasion variability. This 
resulted in a decrease of inter-individual variability for clearance and volume of 
distribution as well as in residual variability. 
In the theophylline doses used, a significant reduction in total and pathologic apnoea but 
not in hypoxaemic episodes occurred over the first three days after birth. The most 
positive improvement was seen on the first day of treatment after the loading dose. A 
statistically significant increase in the average pulse rate and a decrease in episodes of 
bradycardia from baseline to all three days of monitoring were recorded. 
Most patients responded at serum theophylline concentrations of 3 to 9 mglL. Most 
serum theophylline concentration measurements were also in this range and it was not 
possible to clearly define a concentration-effect relationship. The cumulative percentage 
of non-responders was relatively high for total apnoea (48%) and hypoxaemic episodes 
(45%), but low for pathological apnoea (13%). Being one ofa set of twins was identified 
XXI 
as a marker of poor response for both total apnoea and hypoxaemic episodes. Other 
possible markers for poor response, in terms of total hypoxaemic episodes, were being 
born by caesarean section and having more than the 75th percentile pathologic apnoea per 
hour at baseline. It was interesting to note that, with regard to total apnoea, there were 
some features that seemed to predict a favourable response to theophylline. These were 
birth weight and 5 minute Apgar score below the 25th percentile, and patients with 
baseline total apnoea counts above the 75th percentile. 
The cumulative graphs of the responders and non-responders resembled the fixed effect 
model, which is the simplest model to explain drug-effect relationships. More 
sophisticated analysis of the concentration-effect relationship, using NONMEM and the 
count model proved difficult. None of the models tested were found to be satisfactory, 
but that which included the influence of a hypothetical respiratory depressant factor gave 
the most realistic value of EC50. It is suggested that further even more complex 
modelling may be required to accurately define the concentration-effect relationship (and 
hence the therapeutic range) for theophylline in neonatal apnoea. 
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INTRODUCTION 
The first report of the use of theophylline in neonates was published in 1973 (Kuzemco 
and Paala) and since then it has been widely used for the treatment of apnoea of 
prematurity. The development of specific serum assays for theophylline prompted 
therapeutic monitoring of the drug and provided information necessary for calculation of 
paediatric doses. Although a number of studies have been published on the use of 
theophylline in babies and infants, the therapeutic range and hence good dosing 
guidelines are not available for apnoeic premature neonates especially during the first 
few days after birth. 
Premature neonates differ substantially from full term infants in the way they handle and 
respond to drugs (Rane 1992) and, therefore, form a subgroup of the population. 
Especially during the first few days after birth, the physiology of the premature neonate 
changes substantially to adapt to extra-uterine life. It has, for instance, been noted that 
the premature neonate has a markedly low clearance for theophylline and a unique 
methylation metabolic pathway to caffeine (Dothey et a11989). Moreover, about 50% of 
the theophylline dose is excreted in the urine unchanged (Tsemg et aZ1983) compared to 
the 7 to 15% in children and adults. It is known that renal function develops slowly after 
birth and that this function is influenced by factors such as hypoxia and arterial pH 
(Chevalier 1996, Richter and Lam 1993). The pharmacokinetics of theophylline in 
premature neonates could, therefore, be expected to be very different to that in term 
babies and older infants. 
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The efficacy of theophylline in the treatment of apnoea in premature neonates is 
controversial. While Muttitt et al (1988) showed some efficacy, others have questioned 
this (Shannon et al 1975) and some even showed that the development of maturity is as 
important as drug therapy (Sims et al 1985). Most studies were undertaken in apnoeic 
but otherwise healthy neonates. However, in neonates with concomitant disorders the 
average reduction of apnoea incidents was reported to be only 58% (Roberts et aI1982). 
It is not known why certain neonates with apnoea do not respond to theophylline therapy 
and no markers or characteristics of non-response have been identified. 
Even less is known about the effect of theophylline on hypoxaemia as such. 
Hypoxaemia may be a consequence of apnoea, but isolated hypoxaemic episodes are also 
common in the premature neonate (Miller and Martin 1992, Southall et al 1993). This 
could be due to ventilation/perfusion inequalities (Poets et al 1992). Theophylline has a 
wide spectrum of pharmacological actions and the potential to Improve 
ventilation/perfusion and therefore oxygenation. As hypoxaemia may have serious 
consequences, the aetiology and management of these incidents have been investigated 
by a number of researchers (Poets et a11992, Southall et a11993). 
Unfortunately theophylline has a narrow therapeutic range and toxic effects are dose 
related (Hendeles and Weinberger 1983, O'Donnell 1994). Currently various dosage 
guidelines are available for calculating theophylline dosages in neonates and infants. 
However, no consensus exists as to the best method to predict the appropriate dosage of 
theophylline in premature neonates. This is because ( a) the therapeutic range at which it 
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is most effective and least toxic has not been established and (b) the phannacokinetics 
have not been well described. 
Some of the earlier investigators observed that apnoea could only be controlled with 
theophylline plasma concentrations greater than 5 mglL and that cardiovascular side 
effect were associated with plasma concentrations greater than 13 mglL (Shannon et al 
1975, Jones and Baillie 1979). On the contrary, in other studies with neonates of 
comparable postconceptual ages, theophylline concentrations as low as 2 to 4 mglL 
could control apnoea and also bradycardia (Milsap et at 1980, Myers et at 1980). 
However, in a dose-response study a poor response was demonstrated in neonates with 
theophylline serum concentrations between 4 to 8 mgIL (Muttitt et al 1988). After 
increasing mean serum concentrations to 12.7 mglL, an additional 63% response rate 
was noted by the authors (Muttitt et aI1988). 
Based on these studies Aranda et al (1992) in a subsequent review stated that the desired 
serum concentration of theophylline should range from 5 to 15 mglL. However, recently 
a revised Food and Drug Administration (FDA) of the United States of America labelling 
guideline for theophylline oral dosage, recommended a therapeutic range of 5 to 10 mglL 
for premature neonates less than 24 days old (Hendeles et al 1995). Despite the 
recOlmnendations by the FDA, a number of different dosage schedules are found in the 
literature with serum theophylline concentrations ranging from 2 to 15 mglL. Most of 
these guidelines do not take the very low birth weight neonate into consideration. 
Theophylline is also known as a drug with a high inter- and intra-patient variability 
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(Hendeles and Weinberger 1983, Milsap and Jusko 1994) and this could adversely affect 
the already fragile premature neonate (Bhatt-Mehta et aI1995). 
Thus, a number of questions remain: 
1. How effective is theophylline in reducing the number of apnoea and hypoxaemic 
episodes during the first few days after birth? 
If so, then: 
2. What serum theophylline concentrations are required? 
3. What doses are required to achieve these concentrations in premature neonates? 
If some neonates do not respond to theophylline therapy: 
4. Can characterisiicsof non-response be identified? 
Accordingly the objectives of the study were: 
1. To determine, in a population of premature apnoeIC neonates, the 
pharmacokinetic parameters, clearance and volume of distribution, for 
theophylline and investigate possible influences on these parameters. 
2. To re-evaluate the effect of theophylline on neonatal apnoea and also hypoxaemia 
and, if appropriate, to identify markers of response and non-response. 
3. To define the theophylline concentration-effect relationship in neonatal apnoea. 
This investigation is described in three parts: 
Section A: The pharmacokinetics of theophylline in premature neonates during the first 
few days after birth. 
4 
Section B: The efficacy of theophylline in apnoea and hypoxaemia. 
Section C: Population concentration-effect modelling of theophylline in premature 
neonates suffering from apnoea during the first few days after hirth. 
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SECTION A 
THE PHARMACOKINETICS OF THEOPHYLLINE IN 
PREMATURE NEONATES DURING THE FIRST FEW DAYS 
AFTERBIRTH 
SECTION A: CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
1.1 THE PHARMACOKINETICS OF THEOPHYLLINE IN THE PREMATURE 
NEONATE 
Pharmacokinetics is defined as the study of the time course of drug absorption, 
distribution, metabolism and excretion. Mathematical models are used to describe these 
processes. These models allow estimation of a number of pharmacokinetic parameters 
such as clearance (eL), volume of distribution (V), half-life and rate of absorption of a 
drug. Use of these phannacokinetic parameters allows for dose adjustment to target 
plasma concentrations in the therapeutic range thus leading to safer, more effective and 
appropriate management of patients. 
One of the major clinical uses of theophylline is the treatment of apnoea of prematurity. 
In the neonate, and even older child, drug administration and the determination of a 
target concentration, is affected by a number of factors such as age and stage of 
development. The immaturity of the premature neonate, especially the relative inability 
to metabolise and excrete drugs, might have profound effects on the pharmacokinetics of 
theophylline. 
1.1.1 Absorption and bioavailability of theophylline 
Absorption is the passage of a drug from the site of administration through tissues or cell 
membranes to reach the systemic circulation. The bioavailability (F) of a drug is the 
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percentage of the dose administered that reaches the systemic circulation. 
Administration of a drug by intravenous (IV) bolus is assumed to provide full systemic 
availability, thus F = l. With oral administration, diug absorption depends upon the 
physiochemical properties of the drug and a variety of patient factors. Some of these 
factors include surface area available for absorption, blood flow at absorption site, gastric 
emptying time, gastric and duodenal acidity, underlying disease states and the presence 
or absence of food in the intestine (Rowland and Tozer 1995). In the premature infant 
oral administration may result in aspiration and poor absorption especially during the 
first few weeks after birth (Behrman and Kliegman 1994). 
The rate of drug absorption (ka) is slower in the neonate than in the adult (Siegner and 
Fridrich 1975, Milsap and Jusko 1994). This could be due to the relative achlorhydria, 
the prolonged gastric emptying time and the unpredictable peristalsis that is 
characteristic of the premature neonate (Morselli 1976). The gastric pH is above 7 at 
birth but falls to values of 1 to 3 within a day or two (Rane 1992). Physiological factors 
that influence drug absorption develop slowly, but also at different rates after birth 
(Hemgren et aI1983). 
Theophylline, when administered orally to infants as a liquid formulation, is rapidly and 
completely absorbed (Giacoia et al 1976, Hendeles and Weinberger 1983), and the 
bioavailability is >0.9 (Moore et al 1989, Lee et al 1996). The presence of food may 
decrease the rate but not the extent of theophylline absorption (Heimann et al 1982): 
these researchers found that the mean time to peak serum concentration in premature 
infants was l.7 hours in a fasting state and 4.7 hours in a fed state. 
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Some theophylline formulations are available for rectal administration either as enemas, 
solutions or suppositories. The rate and extent of absorption from rectally administered 
theophylline in neonates is more variable than the orally administered drug (Aranda et al 
1992). In a recent population study with neonates the ka for rectally administered 
theophylline was found to be 0.43 (± 0.18) h-1 (Karlsson et alI991). 
1.1 .2 Distribution of theophylline in the neonate 
Once absorption is complete, the drug distributes into various tissues and other body 
fluids. The rate at which particular tissue-plasma concentration equilibrium is achieved 
depends on the rate of perfusion of the organ. The term V is used to describe the 
relationship between the amount of the drug in the body and its plasma concentration: 
Amount in the body = V * Cp 
Where Cp represents the plasma concentration. 
The amount and character of plasma proteins, and the relative size of the fluid, fat and 
tissue compartments of the body, all influence distribution of the drug (Rowland and 
Tozer 1995). Some age-related differences in these factors are known. For example, 
total body water expressed as a percentage of total body weight is as much as 85% in 
premature neonates compared to 78% in full-term neonates and 60% in adults (Friis-
Hansen 1971). Thus drugs that distribute in paranel with body water content have higher 
volumes for neonates than for adults when expressed per kilogram body weight. 
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The binding of drugs to plasma proteins is dependent on multiple factors, all of which 
may be underdeveloped in the neonate. The total plasma protein, plasma albumin and 
aI-acid glycoprotein concentrations are decreased in the neonate and do not approach 
adult values until about one year of age (Hemgren et al 1983). In addition, inadequate 
oxygenation due to an underdeveloped respiratory control system may cause acid-base 
disturbances that might affect distribution and binding of drugs. The neonate often 
develops neonatal jaundice thus competition for binding sites by increased circulatory 
concentrations of endogenous bilirubin may occur (Brodersen et alI983). This may all 
contribute to an increased variability of V in neonatal patients compared to other 
popUlation groups. 
In the adult, after absorption of theophylline about 60% of the drug is bound to plasma 
proteins and the remaining free drug is distributed throughout the body water (Lesko et 
al 1981). In the neonate, the capacity of theophylline to bind to plasma proteins is only 
about 28% to 36% (Aranda et al1976, Butts et al1991). The results of Butts et al (1991) 
showed a significant negative correlation (r = -0.825, p<O.OOI) between unbound 
theophylline and serum albumin, suggesting that theophylline binds mainly to albumin. 
The binding of theophylline to plasma proteins in the premature neonate may change 
gradually as both the concentrations of total protein and albumin show an increase of 
50% from 28 weeks to 40 weeks gestation (Reading et al1990, Butts et al1991). 
In both adults and children the V of theophylline ranges from 0.3 to 0.7 Llkg (30% to 
70% ideal body weight) and averages about 0.45 Llkg (Hendeles and Weinberger 1983). 
In the neonate mean V values ranging from 0.2 to 2.9 Llkg have been recorded in the 
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traditional phannacokinetic studies (see Table Al.l). In two of the published population 
studies the mean values were 0.94 Llkg (Lee et al 1996) and 0.86 Llkg (Moore et at 
1989) respectively, and in a third population study, where theophylline was administered 
rectally, VIF was 1.3 Llkg (see Table A 1.2). 
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TABLE A1.1 
Theophylline pharmacokinetic data from traditional studies in neonates 
Reference Number of Gestational Postnatal CL (ml/kg/h) V (L/kg) 
subjects and age (wks) age mean (SD) mean (SD) 
route of (days) (Range) (Range) 
administration 
Arandaetal 6 25 - 32 3 - 15 17.6 0.7 
1976 IV (12.1- 25 .9) (0.4-1) 
Giacoia et al 8 26 - 32 25 - 57 39 (18) 0.9 
1976 Oral (23 - 68) (0.7 - 2.9) 
Neese et al 12 28 - 36 2 - 21 8.56 0.3 
1977 Rectal (4.3 - 12.4) (0.2 - 0.54) 
Latini et al 7 26 - 33 4-8 12.9 0.4 
1978 IV (6.3 - 29.9) (0.2 - 1.0) 
Brazier et al 20 27 - 37 2.9 (±2) 24.0 (5.1) 1.0 (0.2) 
1979 Oral 
Jones et al 14 25 - 31 0-36 18.6 (4.8) 0.7 (0.2) 
1979 IV (12 - 28) (0.4 - 1.2) 
Hilligoss et al 17 25 - 36 1 - 26 22.9 (3.9) 0.6 (0.2) 
1980 Oral (16 - 30) (0.4 - 0.9) 
Gal et al 30 26 - 34 6 - 14 10.8 in 0.76 in 
1982 IV asphyxia asphyxia 
20.1 in non- 0.82 in non-
asphyxia asphJXi:a 
Lonnerholm el at 17 28 - 34 6 - il 16.8 (0.4) -
1983 Oral 
Gihnan et al 179 30 (± 3) 14 (± 10) AGA 18.8 0.77 (0.2) 







Stile el at 9 25 - 30 1 46 (14) 1.0 (0.1) 
1986 IV 
Kraus et al 52 24 -40 14 - 483 30 -40 
1993 IV and oral wks:21.5 
(6.9) 
40 - 50 wks: 
30.3 (10.3) 
AbbrevlatlOns. CL - clearance, V - volume of dIstnbutiOn, wks = weeks, IV = mtravenous, 
AGA = average for gestational age, SGA = small for gestational age. 
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TABLE A. 1.2 
Theophylline phannacokinetic data from population studies in neonates 
Reference Number of Gestational Postnatal CL (ml/kg/h) V (L/kg) 
subjects and age (wks) ages (days) mean (SD) mean (SD) 
route of (range) (range) 
administration 
Moore etal 108 24 -42 3 - 182 17.5 0.86 
1989 IV and Oral (15.5 - 19.5) (0.79 - 0.92) 
Karlsson et al 35 26 - 35 2 - 80 40 (2) 1.3 (0.2) 
1991 Rectal CLIF VIF 
Lee et al 182 24 - 32 1 - 111 12.3 (0.74) 0.94 (0.08) 
1996 IV and Oral 
AbbreviatIOns: CL = clearance, V = volume of dlstnbutIOn, wks = weeks, IV = mtravenous. 
1.1.3 Elimination of theophylline in the neonate 
A drug can be eliminated from the body by a number of organs with hepatic metabolism 
and renal excretion representing the major routes. The pharmacokinetic parameter CL is 
used to describe the overall elimination in terms of volume of plasma from which a drug 
is completely removed per unit of time: 
Rate of elimination (LIh) = Cp * CL 
The metabolism of a drug is dependent on the physiological variables of hepatic blood 
flow, binding in blood and intrinsic hepatocellular activity (Rowland and Tozer 1995). 
Most enzymatic microsomal systems responsible for drug metabolism are present at 
birth, but their activity is slow during the neonatal period (Rylance 1992) and increases 
with advancing postconceptual age (PCA) (Morselli et af 1980). In the adult, hepatic 
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metabolism is the main route of theophylline elimination, but in the premature neonate 
the hepatic metabolism of theophylline is relatively less important (Hendeles and 
Weinberger 1983, Tserng et at 1983, Baird-Lambert et at 1984). The differences 
between neonate, child and adult are depicted in Figure A.l .l . A number of different 
metabolic routes are found of which C-8-hydroxylation seems to be important in the 
neonate as well as the adult. In contrast, in the neonate about half of the theophylline is 
excreted unchanged. 
It should be noted that, caffeine, which is also a central nervous system stimulant, is a 
major metabolite of theophylline in the premature neonate, but not in the adult. The 
metabolism of theophylline to caffeine reduces significantly with peA as the infant 
matures (Tserng et al 1983, Rylance 1992, Kraus et al 1993). Apparently urine 
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Tsemg et al1983 and Baird-Lambert et a11984. 
In the premature neonate, but not in the child or adult, renal clearance of theophylline is 
as important as hepatic degradation of the drug. Renal excretion is dependent on three 
processes, namely, glomerular filtration, tubular secretion and tubular reabsorption. 
Thus, 
Rate of excretion = rate of filtration + rate of secretion - rate of reabsorption. 
These processes differ between the premature neonate, the term infant and also the older 
infant. For example, in the premature neonate the glomerular filtration rate (GFR) at 
birth is 0.6 to 0.8 ml/min, whilst in term infants it is 2 to 4 ml/min (Van den Anker 
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1996). Adult GFR-values of approximately 130 mllmin are reached at 2 to 2.5 months of 
age. Van den Anker et al (1995) determined the GFR in premature neonates with both 
the inulin clearance and the reciprocal of the serum creatinine values. A positive linear 
relationship (r = 0.6) between GFR and gestational age (GA) on day three of life was 
found. On the contrary, Seikaly and Arant (1992) insisted that GFR does not change 
very much in premature neonates up to 34 weeks gestation, but at around 34 weeks after 
conception and regardless of postnatal age (PNA), the GFR increases very rapidly within 
a week (Arant 1978, Robillard et aI1979). Thirty-four weeks gestational age would be 
about the time nephrogenesis is complete. Factors responsible for this rapid increase 
include increasing mean arterial blood pressure, increasing renal blood flow, and 
increasing glomerular permeability and filtration surface area (Chevalier 1996). 
Apparently the renin-angiotensin system and prostaglandins modulate this change in 
GFR (Chevalier 1996). Thus, CL of a drug that is excreted by the kidneys is likely to be 
influenced by the changing GFR in the postnatal period. 
Tubular function matures at a slower rate than glomerular function and tubular transport 
capacity reaches adult values by 30 weeks PCA (Kaapa et al 1995). The capacity to 
reabsorb drugs from the renal tubule seems to be reasonably developed in the neonate as 
drugs that are known to be reabsorbed in this way are excreted slowly during the first 
few days of life (Rylance 1992). It is also known that the premature neonate of less than 
34 weeks gestational age reabsorbs 97%, 93% and 87% of filtered sodium, glucose and 
phosphate respectively (Arant 1978). Thus if the renal clearance of a drug is less than the 
amount of drug filtered then it could be assumed that some of the filtered drug is 
reabsorbed (see equation on page 14). 
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If a drug is only filtered, then renal clearance may be calculated as: 
CLR = fu * GFR 
Where CLR = renal clearance, fu = fraction unbound drug (Rowland and Tozer 1995). 
As the GFR for the premature neonate is low (0.6 to 0.8 ml/min, Van den Anker 1996) 
and the fraction of unbound theophylline is approximately 0.7 (Aranda et a11976, Butts 
et aI1991), the calculated renal clearance (taken as ± 0.7 x 0.7 = 0.49 ml/min or 0.0294 
Llh, see page 15) would be larger than the estimated CL for most of the population 
studies reported above (e.g. Lee et al 1996, CL = 0.0123 Llhlkg). Therefore, the 
possibility exists that some of the filtered theophylline might be reabsorbed. 
The mean values for theophylline CL in healthy non-smoking adult volunteers range 
from 40 to 52 mllkglh and in children less than 12 years old from 96 to 102 mllkglh 
(Hendeles and Weinberger 1983). However, the CL of theophylline is markedly less in 
neonates as the mean value for CL in the traditional studies ranged from 4.3 to 68 
mVkg/h. In two of the published population studies in neonates the mean values were 
12.3 (Lee et al 1996) and 17.5 mllkglh (Moore et al 1989) respectively. The CLiF in 
neonates obtained from rectally administered theophylline was 40 mllkglh (Karlsson et 
aI1991). 
Factors that may alter the CL of drugs include changes in severity of pulmonary 
obstruction, hypoxia and variation in arterial pH (Richter and Lam 1993). It is well 
known that GFR is lower than normal in infants with respiratory distress syndrome 
(RDS) (Guignard et at 1976). During RDS vascular resistance in the pulmonary circuit 
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remains elevated resulting in a distended right atrium (Kojima et al 1990). This is 
associated with an increase in circulating antinatriuretic peptide levels, which should 
cause diuresis. However, decreased GFR, tubular immaturity, and a generalised decrease 
in renal blood flow may attenuate the effects of this antinatriuretic peptide (Kojima et al 
1990, Brem 1992). 
Vasopressin (anti-diuretic hormone) is elevated in RDS (Kojima et al 1990) and free 
water clearance is diminished in parallel with the elevated plasma vasopressin levels 
(Robillard et al 1979, Wiriyathian et al 1986). In addition, hypoxia itself may also 
stimulate the release of vasopressin (Kojima et al 1990, Brem 1992). The neonatal 
ventilatory system responds to reduced oxygen availability by shunting the blood 
preferentially to the brain, heart and adrenal glands away from the intestine, kidney, lung 
and skin (Behrman et al 1994). 
RDS usually resolves by day 3 to 4 after birth of the baby. Recovery from hypoxia and 
RDS may result in lower renal and systemic vascular resistance (Van den Anker 1996), 
which will then improve GFR. The variability in oxygen levels, and also the fact that 
pulmonary mechanisms vary up to 26% over the three days after birth (Goyal et al 
1995), could contribute to an increased variability in theophylline CL in and also 
between premature neonates. 
In three population studies with theophylline, it was found that PNA and weight (Moore 
et al 1989, Lee et al 1996) or weight alone (Karlsson et al 1991) accounted for 
variability in CL of theophylline. In traditional studies, Aranda et al (1976) found no 
17 
correlation between theophylline half-life and weight or age, whereas Lonnerholm et at 
(1983) and Gilman et at (1986) showed that PNA influenced CL. Driscoll et at (1989) 
and Kraus et at (1993) found that age was the major factor affecting CL. This indicated 
a close relationship between the demographic factors, age and weight, and the degree of 
development of the major drug clearance organs such as the liver and the kidneys. In 
addition to these demographic factors, attempts were also made to identify specific 
patient factors that may differentiate groups of patients with altered theophylline CL. 
Although Hilligoss et at (1980) found a weak correlation between CL and duration of 
therapy, it could not be shown in subsequent studies. Also, Gilman et at (1986) and Gal 
et at (1982) indicated that neonates who suffered birth asphyxia cleared theophylline 
slower than those who did not. However, these factors did not have a significant 
influence on the estimated values of the pharrnacokinetic parameters obtained in the 
population studies. 
Theophylline elimination appears to be a linear process but in some patients the 
metabolic processes may become saturated at serum concentrations within the 
therapeutic range (Lesko 1986). Thus, a disproportionate increase in serum drug 
concentration may occur for a given increase in dosage, resulting in toxicity, particularly 
in children (Sarrazin et at 1980). This is due to the fact that the C-8-hydroxylation and 
N-demethylation pathways, as depicted in Figure A1.1 , may exhibit saturable 
pharmacokinetics over the usual therapeutic range (Tang-Lui et at 1882). 
The Michaelis-Menten equation for enzyme kinetics is used to describe how clearance 
may vary with the concentration of the drug: 
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Total plasma clearance = Vm / (Km + Cp) 
Where V m is equal to the maximal rate of elimination (in units of mass/time), Km is the 
plasma concentration at which half of the maximal rate of elimination is reached (in units 
of mass/volume) and Cp the plasma concentration of the drug (Rowland and Tozer 
1995). 
Recently, Anderson et af (1997) obtained a Michaelis-Menten constant (Km) of 32.5 
(±33.5) mglL in a three month-old infant. This value is lower than the 67 mgIL that was 
obtained in an adult by Butts et af (1991). The lower value found in infants could 
indicate that non-linear elimination might occur at a lower plasma concentration in 
infants than in adults. · No consensus has been reached regarding the linear- or dose-
dependent pharmacokinetics of theophylline, as some investigators have found no 
evidence of non-linearity in dose-ranging trials (Rovei et af 1982). In the premature 
neonate the saturability of the C-8-hydroxylation process might however be significant, 
as it is responsible for 24% to 34% of metabolite formation. 
Most premature infants undergo a phase of spontaneous diuresis during the first week of 
life (Lorenz et al1995, Oliver et a/1995) with an eventual decrease in extracellular fluid 
volume (Heimler et a1 1990, Ramiro-Tolentino et af 1996). In 87% of neonates the 
median age of onset and cessation of this diuresis is 24 and 96 hours respectively. In 
addition, theophylline may also cause a diuresis. In a recent study in a group of 
neonates, Mazkereth et af (1997) found that the initial loading dose of theophylline 
caused a marked diuresis with a loss of sodium, potassium, calcium and uric acid. This 
did not occur during maintenance therapy. 
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Theophylline is known as a drug with high inter- and intra-patient variability in CL 
(Hendeles and Weinberger 1983, Jenne 1986, Milsap and Jusko 1994). In the adult and 
child this appears to be due to differences in rate of hepatic biotransformation that 
changes with age, concurrent illness and other drugs, smoking habits and aberrations in 
diet (Hendeles and Weinberger 1983). In the premature neonate the variability in CL 
could be due to the immaturity of the hepatocellular activity and renal function, the level 
of oxygenation, and the physiological changes that take place after birth to adapt to 
extra-uterine life. 
Although information on theophylline pharmacokinetics in the neonate is available, there 
is relatively little information specifically relating to premature neonates with apnoea 
during the immediate time after birth. Thus the objectives of the study were to estimate 
the pharmacokinetic parameters CL and V, of theophylline in premature neonates during 
the first few days after birth, and to identify influential effects such as demographic 
characteristics or disease states on these parameters. 
1.2 PHARMACOKINETIC METHODOLOGY 
In practice a number of methods can be followed to estimate the relevant 
pharmacokinetic parameters. These methods may be broadly classified into the 
traditional approaches, which use experimental data, and the alternative population 
approaches, using routine patient data (Sheiner and Beal 1980). 
1.2.1 The traditional approach to pharmacokinetic studies 
With traditional studies, also known as the standard two-stage (STS) approach (Sheiner 
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and Beal 1981), a small number of patients is selected and about ten to twenty serum 
samples for measurement of the study drug are collected from each patient according to a 
pre-set sampling time schedule. The patients may be healthy volunteers or patients 
carefully selected to represent a particular aspect or disease state that has to be 
investigated. The data collected from each patient is analysed using weighted or 
unweighted non-linear regression with the least-squares criterion to calculate that 
individual's pharmacokinetic parameters. The population values are then determined by 
pooling the values from each patient. The relationship between the pharmacokinetic 
parameters and the physiological factors such as age, weight and sex, which are most 
often statistically linear, are calculated using least-squares regression (Sheiner and Beal 
1980, Sheiner and Beal 1980a). Extensions of the STS approach such as the iterative 
two-stage and the global two-stage method have been developed (Jelliffe et aI1993). 
The traditional approach has several advantages (Sheiner and Beal 1980, Sheiner and 
Beal 1981a): 
i) It has been used for a long time and is known to be reliable. 
ii) Studies are relatively quick to perform. 
iii) Data has little variability as the studies are stringently designed and adhered to. 
iv) The statistical models are relatively simple and easily computed. 
v) Data analysis with standardised computer programmes is generally rapid and 
. . 
mexpenslve. 
There are also several disadvantages of the method (Sheiner et a11977, Sheiner and Beal 
1980): 
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i) The source of the pharmacokinetic data may not be truly representative of the 
population for whom the drug would most often be used. Study subjects are 
usually healthy volunteers or carefully selected patients with a mild form of the 
disease who will be able to withstand the rigours of the trial. 
ii) These studies may be expensive due to compensation of volunteers, temporary 
hospitalisation in clinical research wards and assaying numerous samples. 
iii) As study conditions are strictly controlled the chance discovery of other factors 
influencing pharmacokinetics is limited. 
iv) When ordinary least-squares methods are used for the first stage in the analysis, it 
is assumed that all errors between the predicted and the measured levels are 
independent from one concentration to another, are additive and of the same 
typical magnitude. 
In the premature neonate the traditional approach has two very important further 
disadvantages: 
i) It is often unethical to conduct a study where a large number of samples must be 
withdrawn during a relative short period of time from a patient at risk such as a 
neonate. It is also often impossible to get written informed consent from the 
parents of the neonate. 
ii) The small blood volume of a premature neonate (approximately 90 - 100 ml in 
this age group) makes it impossible to withdraw adequate blood volumes for 
extensive concentration measurements. 
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1.2.2 Population approach 
As a result of the limitations imposed by the traditional approach, alternative population 
methods, such as the Nonlinear Mixed Effects Model (NONMEM) (Sheiner et al1977, 
Sheiner and Beal 1980), have been developed to utilise data generated during routine 
patient care (Sheiner et al 1977, Sheiner and Beal 1980, Whiting et al 1986). The 
alternative population approach treats the population as the unit of analysis and focuses 
on how measurable physiological and demographic features relate to the 
pharmacokinetic parameters. In these methods a few samples are collected from each of 
a large number of subjects. This usually occurs during routine therapeutic drug 
monitoring (TDM) where sampling times and dosing regimens may vary according to 
the judgement of the physician. The data collected in this manner can be used to 
determine the population pharmacokinetic parameters in a target population. Drug dose 
and dosing time must be recorded rigorously and it is important to record all clinical and 
demographic factors that are likely to influence the pharmacokinetic parameters. 
The population approach has a number of advantages: 
i) As the samples can be collected in the target treatment population, the data is 
more likely to be representative of the specific population. Rational dosage 
guidelines for specific risk groups can be developed. 
ii) Data from different sources may be combined to accommodate varying spectra of 
disease states, dosing regimens, different routes of administration or different 
degrees of organ dysfunction. 
iii) Few ethical problems arise, as few samples are required per patient. 
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iv) Costs are relatively low as samples are collected during patient care and sample 
analysis would form part of routine patient care. 
v) As many types of patients form a population, the possibility of a chance 
discovery of a previously unknown influence, whether physiological or 
demographic, on drug kinetics exists. 
Some of the most important disadvantages of the population approach include: 
i) The data may be less reliable as it is collected routinely and not according to a 
strict experimental protocol. In the nonnal busy clinical setting it may not always 
be possible to accurately record times of dosing, serum sampling and all pertinent 
patient features .. 
ii) The analysis of routine clinical data requires a more sophisticated statistical 
approach than that required for experimental data. 
iii) The possibility of bias due to the effects of unknown concomitant variables that 
are correlated with included variables, for example an undisclosed drug 
interaction, may lead to erroneous conclusions about the influence of included 
variables on CL (Sheiner et aI1977). 
IV) The use of the wrong model, that IS, model misspecification, may lead to 
incorrect results (Sheiner and Beal 1980). 
Application of the population approach was for many years limited due to the complexity 
and the lack of . general acceptance of the proposed statistical methodology. The 
available software was not user-friendly and expert guidance was needed to adequately 
use the programmes. The need for further development of the population approach was 
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recognised and, following a European Co-operation in Science and Technology (COST) 
meeting in 1991, a Working Party on Population Approaches was formed. Since then a 
number of meetings have been held and other groups interested in the population 
approach have been established for example PAGE (Population Approach Group 
Europe). The requirements of appropriate software were investigated by the Working 
Party and presented to interested parties. Some of the requirements stated were, for 
example, continuing update of programmes, complete and adequate documentation and 
regular training courses. As the population approach gained more support in drug 
development, the need to build it into the drug development plan by pharmaceutical 
companies was recognised and formalised. 
There are various alternative methods commercially available to the pharmacokineticist. 
Examples include NPML (non-parametric maximum likelihood, Mallet 1986), P-Pharm 
(Mentre and Gomeni 1995), NPEM (non-parametric expectation maximisation method, 
Jelliffe et at 1993) and Non-linear mixed effects model (NONMEM, Beal and Sheiner 
1992). Other new theoretical developments are the full Bayesian estimation method 
using the Gibbs sampler (Wakefield et at 1994) and the nonpararnetric EM algorithm 
(Schumitzky 1991, Mentre and Gomeni 1995). 
A conference report of COST in 1996 (Aarons et aI), stated that when only sparse data is 
available, as in studies in neonates, the population approach represents the only way to 
define pharmacokinetic/phannacodynamic (PKlPD) models of a drug. The computer 
packages for population pharmacokinetic analyses are costly, sophisticated and training 
in their use is essential. NONMEM is established in our institution and trained 
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phannacokineticists with expenence are accessible. Additionally, a NONJ\.1EM 
repository site and users group is available on the Internet to assists in solving problems. 
It is also the programme that is most widely used and the statistical properties of the 
extended least squares estimation are well established. Thus NONMEM was chosen for 
use in the present study. 
1.2.2.1 The NONMEM system 
Sheiner and colleagues have extensively described the principles and mechanisms 
pertaining to NONMEM analysis (Sheiner et al 1977, Sheiner and Beal 1980). The 
programme analyses all the data simultaneously while taking into account the correlation 
among samples from the same individual. It is based on the premise that individual 
phannacokinetic parameters arise from a random distribution, the first two statistical 
moments of which are directly estimated from the pool of individual data. The influence 
of patient covariates on drug handling can be assessed by incorporating regression 
relations of these to the phannacokinetic parameters. The first-order method 
implemented in NONMEM estimates the inter-individual variability in the 
pharmacokinetic parameters not explained by the regression relations and the residual 
intra-individual variability in the drug concentrations. 
The programme NONMEM (Beal and Sheiner 1992) is extensively used to estimate 
phannacokinetic/phannacodynamic parameters and has become an important tool in 
drug development and simulation studies (Jonsson 1998). Estimates for the PK 
parameters clearance and volume of distribution, as well as values for the PKlPD 
parameters, can be obtained. The programme models fixed (measurable) as well as 
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random effects and can determine which effects significantly influence the estimated PK 
parameters or the PKlPD measures. Dosing guidelines for specific patient population 
groups can be determined and the influence of disease states on the pharmacokinetics 
and the pharmacodynamics are identified. A step-wise model building procedure is 
followed to estimate the PK parameters and measures of drug effect. The analyst may 
use the available subroutines of the NONMEM programme or may construct his own 
subroutines. 
1.2.2.1.1 The model building procedure 
The NONMEM programme is based on the principle of extended least squares (ELS) as 
applied to a non-linear mixed effect statistical model. In this case the method of ELS is 
simply the maximum li~elihood method. However, since most pharmacokinetic models 
to which it is applied are statistically non-linear, it is actually an approximate maximum 
likelihood method. Therefore the method can describe the time course of the amount of 
drug in the body using non-linear mixed effects models as follows (Beal and Sheiner 
1992): 
Yij = f (Xij , ~i) + £ij 
Where Yij is the jth observation from the ith individual, fO is the structural model that 
relates the independent variables, Xij , such as time and dose, to the response given the ith 
individuals vector of model parameters, ~i. The random effects in the residual errors are 
denoted by £ij. This is usually assumed to be independently symmetrically distributed 
with a variance of (52. 
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The random effects (Th) influencing the parameters ~i, that is the parameter model, can be 
written as follows, assuming an additive structure: 
~i = g (Zi, 8) + Th 
Where g is a structural, though non-kinetic type model that is a function of fixed effects 
Zi, and fixed effects parameter, 8. 
Non-linear mixed effects models may be regarded as consisting of three sub-models: 
i) The structural sub-model (PK or PD) which describes the main tendency in the 
data. 
ii) The covariate sub-model which describes the relationships between the fixed 
effects parameters and the covariates. 
iii) The statistical sub-model which includes the models for inter- and intra-
individual variability. 
Although these three sub-models overlap and also interact to some extent as shown by 
Wade et al (1994), each model is selected separately and the model building process 
usually proceeds in a step-wise fashion (Beal and Sheiner 1992, Mandema et al 1992, 
Ette and Ludden 1995). 
At first the structural model is determined using the appropriate subroutines from the 
NONMEM PREDPP library, or a user-written subroutine. When analysing PK data the 
order in which the models are tested is usually defined by the number of compartments 
in the model. The difference in the objective function value (OFV) and plots of 
individual predictions versus observations as well as weighted residuals versus the 
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independent variable may be used to discriminate between rival structural models. The 
difference in the OFV approximates the X: distribution. 
Secondly, the covariate model is constructed. At this stage in the analysis of the data, a 
programme such as Xpose may be used to facilitate and expedite covariate identification. 
The Xpose programmea is an S-PLUS based model-building aid for population analysis 
using the NONMEM programme. It contains a stepwise-generalised additive modelling 
procedure (GAM) (Mandema et at 1992) which can be used to find a subset of the 
available covariates that could be most useful in explaining the variability in either CL or 
V. The building of the GAM is done using a stepwise multiple linear regression 
procedure allowing each covariate to enter the model in any of several functional 
representations. The model discrimination is made by comparison of the Akaike 
information criteria (AlC) (Jonsson and Karlsson 1997). The programme produces a plot 
of the 30 most important covariate models tried in a stepwise search for the final model. 
With this plot it is possible to evaluate how much better the final model is compared to 
the other models by evaluating the AlC. The AIC is the sum of the deviance and the 
product of the number of parameters and the dispersion factor: 
AIC = D+ p~ 
Where D = the deviance (the residual sum of squares), p = number of parameters 
and ~ = dispersion factor. 
In addition, the Bootstrap of the GAM can be used to assess the stability of covariate 
a XPOSE 2.0 E.N. Jonsson and M.O. Karlsson "Xpose - an S-PLUS based model building aid for 
population analysis with NONMEM". 
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inclusion and the most common covariate combinations. 
If the GAM or similar programme is not used to find the important covariates, a stepwise 
covariate model building procedure is followed. This process could be tedious and time-
consuming as the covariates are added to the base model in turn and the change in OFV 
is noted. After selecting the most important single covariates, combination of these are 
then tested. To investigate which factors (covariates) might influence the population 
estimates of CL and V significantly, the weighted residual (WRESh) can be plotted 
against demographic and clinical data. If a clear trend in the plot is observed, it indicates 
that the factor might influence the pharmacokinetics of the drug and that it could be built 
into the population model. Stepwise selection depends very much on covariates selected 
in the early steps and on influential data points. Wade et at (1994) also pointed out the 
interaction between structural, statistical and covariate models and how the choice of the 
structural model may be affected by the choice of the covariate model and vice versa. 
The alternative to the step-wise model building is the initial fonnation of a full model 
and then to reduce it to include only the relevant features. An advantage of this type of 
model building is that any change that is made to the model, will be representative of the 
possible true model. Disadvantages include the possibility that the data will not support 
the full model, and that computer run times could be very long (Jonsson 1998). 
Thirdly, the inter-:-individual variability of CL and V, as well as the residual variability 
b WRES: The squared difference of the observed concentrations minus the predicted concentrations 
weighted by the reciprocal of the variance. . 
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between the observed response and that predicted by the model, may be estimated 
according to a number of different error models. Residual variability is due to intra-
patient variability such as differences in the timing of blood collections, drug assay 
errors, dosing times and model misspecification. 
During initial data analysis, the default First Order method (FO) in NONMEM is usually 
used to estimate the typical values of the population parameters. The FO method makes 
expansions around the population average predicted value by using a first-term Taylor 
series expansion in the approximation. This expansion in eta takes place around eta 
equals to zero (Beal and Sheiner 1992). NONMEM can also obtain conditional 
estimates of eta variables as part of the computation of population parameter estimates. 
This is called the First Order Conditional Estimation Method (FOCE). This method is 
more accurate, but more time-consuming than the FO method (Beal and Sheiner 1992) 
and therefore not routinely used. When conditional estimates are obtained after 
estimation is carried out by the FO method, they are referred to as 'POSTHOC' 
estimates. 
1.2.2.1.2 Inter-occasion variability 
While building PK-models, it is important to investigate the possibility of inter-occasion 
variability (lOV). This is present when a parameter of the population model for example 
CL, varies within subjects between study occasions (Karlsson and Sheiner 1993). 
Failure to identify LOY, when present, may result in model misspecification, biased 
parameter estimates and false covariate relationships (Karlsson and Sheiner 1993). To 
account for and quantify lOY, Karlsson and Sheiner (1993) developed a new level of 
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random effects, 1£, between the inter-individual and the residual error variability. Thus to 
test for IOV a different type of eta is assigned to the parameter in question on each 
occasion studied. As the metabolic processes are changing continuously in the 
premature neonate as described above, the possibility of IOV should be investigated. 
1.2.2.1 .3 Assumption testing 
Recently Karlsson et al (1998) discussed the problems associated with assumptions made 
during population pharrnacokinetic modelling. As population PK and PKlPD models are 
now often used for simulation of clinical trials to optimise the design of the trials, a 
correct model as well as the acknowledgement of all assumptions made during the model 
building process is required. Most assumptions are related to the variability components 
of the population model. For example, a general assumption in population analyses is 
that the residual errors from all individuals arise from the same distribution. Assay 
imprecision was always given as the source of the residual error. It is now recognised 
that additional error sources such as model misspecification, imprecise dosing and 
sampling histories seem to be more important sources of variation (Jelliffe et al 1993, 
Jelliffe et al 1994, Karlsson et al 1995). The importance of assumptions should be 
recognised, as violations of these assumptions might have a m3:.ior impact on the 
parameter estimates of the structural or covariate models. It is speculated that future 
population PK-programmes will automatically take care of most assumptions made 
during the model building process. 
1.2.2.1.4 The importance of infonnative graphics 
A well-designed graph or graphical technique is powerful diagnostics tool and may 
32 
assist the model builder to explore data effectively (Ette and Ludden 1995) and also to 
test assumptions (Karlsson et at 1998). Graphical displays can be used initially as 
exploratory data analysis to examine distributions and correlation between covariates. 
After a basic pharmacokinetic model has been constructed and Bayesian individual 
parameter estimates obtained, the distributions of the estimates of the parameters can be 
determined. Also, certain model building-aid programmes (such as Xpose) can 
graphically display the influence an individual or an observation has on the bulk of the 
data. 
The goodness of fit of each NONMEM analysis can also be assessed by the visual 
examination of scatterplots. For example, predicted versus measured drug concentrations 
and weighted residuals may be plotted. The use of graphics is also extensively employed 
to test assumptions and the influence of assumptions on data analysis (Karlsson et al 
1998). 
1.2.2.1.5 Validation 
The reliability of results obtained from population analysis depends on the quality of the 
data collected and on the correctness of the model building procedure. Providing 
evidence for the quality of the results is important for the application of the model in 
dose recommendations. Thus validation of the analysis is important and should be 
considered in any study. Validation can be defined as the evaluation of the predictive 
performance of the developed model and the model parameter estimates. Thus how close 
the model predictions are to the validation data. This may be judged in clinical rather 
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than statistical terms. A number of validation methods are available and are briefly 
discussed below. 
a) External validation 
This is a test of predictive accuracy of the developed population model on a new data set 
from another study. The objective of the validation is to determine how well the 
population model derived from an ' index' data set describes data, none of which was 
used to develop the model itself. In this case the data set is called the 'validation' or 
'test' set. This is the most stringent validation test available at present. Often Bayesian 
predictions of serum concentrations are performed in an independent cohort of patients 
by fixing the structural and statistical parameters to the values obtained in the final 
model and invoking the POSTHOC function in the $ESTIMATION procedure without 
allowing NONMEM to iterate. Predictive performance in terms of bias and precision 
can then be calculated using a method developed by Sheiner and Beal (1981a) and 
described below. 
b) Internal validation 
i) Data splitting 
Data splitting is an effective method when it is not practical to collect a new set of data 
to test the model. Thus usually about a third of the data is set aside for the test set. A 
disadvantage of this method is that the size of the data will be decreased, which may 
negatively affect the predictive accuracy of the model, as this is a function of the model 
size. Thomson et al (1996) in a population analysis of caffeine in neonates tried to 
overcome this disadvantage by combining the index and the test sets after validation of 
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the model to obtain the final parameter estimates. Although unbiased results were 
obtained when comparing the data sets, one of the covariates that had an influence on CL 
in the index set, could not be identified in the test set. The method of data splitting was 
also used by Lee et al (1996) in their population analysis of theophylline in neonates. 
ii) Boot-strapping 
This is another method of internal validation when no test data set is available. It has the 
advantage of using the entire data set that has been used for model development. In the 
bootstrap approach, sampling with replacement generates a large number of data points 
for example 200 bootstrap replicates of the original data set. It is of particular importance 
in the paediatric setting where ethical and medical concerns limit the number of 
individuals recruited into studies. Bootstrapping can be done using NONMEM by 
compiling it as a 'dynamic link library' . 
iii) Jack-knifing 
Population parameter estimates may be evaluated using the jack-knife technique. This 
technique involves a one-at-a-time omission and the creation of new data sets and then 
reanalysing them with NONMEM. A naIve Student t approximation for the standardised 
jack-knife estimator can be used. Ette (1997) calculated the magnitude of bias reduction 
as the reciprocal of the total number of blocks of individuals (10 individuals per block) 
omitted. 
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iv) Predictive performance using POSTHOC estimates of the final model as the 
"true" value 
In the absence of a test data set the predictive perfonnance in terms of bias and precision 
for the final and base model can be calculated using the population values and comparing 
these with the POSTHOC estimates of the final model (regarded as the "true" model) 
parameters (Sheiner and Beal 1981a). The prediction error is the difference between the 
predicted and the "true" value. This is a measure of bias and will show how well 
predictions match true values. The squared prediction error (or the absolute error) 
indicates the prediction precision. The smaller the prediction error the greater the 
precision of the model. The plausible range of these values is given by the Confidence 
Intervals of these values. The performance of models relative to each other may also be 
evaluated. 
v) Posterior predictive check 
This method has been described by Belin and Rubin (1995) and has been used by Girard 
et at (1998) for the validation of a compliance model. The purpose of this method is to 
simulate the posterior distribution of a non-sufficient statistic and to compare this 
distribution with the observed statistic on the actual data. If there is no contradiction 
betwe~n the two, the model may be accepted. Girard et at (1998) validated the 
compliance model by using either the longest drug holiday or the non-therapeutic 
coverage posterior distribution (the distribution of the percentage time during which the 
concentrations were within a therapeutic window). Unfortunately NONMEM does not 
give a posterior distribution of parameters. The software programmes POPKAN and 
PHARM-BUGS allow the defining of prior distributions of all parameters and thus the 
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estimation and computation of the posterior distributions of any statistic. 
1.3 MEASUREMENT OF METHYLXANTHINE CONCENTRATIONS 
A number of analytical methods for the determination of theophylline and caffeine in 
serum are available. These include spectrophotometry, gas-liquid chromatography, 
radioimmunoassay, high performance liquid chromatography and enzyme immunoassay. 
The various methods available differ in sensitivity, specificity, sample size needed, 
technical difficulty, amount of technician time required and initial equipment cost. The 
high performance liquid chromatography method remains the method of choice in 
laboratories whose goal is extreme accuracy. The enzyme multiplied immunoassay 
technique (EMIT) has become particularly popular as it is more rapid than most other 
conventional methods and also very accurate. Comparison of the EMIT® assay with 
high-performance liquid chromatography gave correlation coefficients of 0.95 to 0.98 
(Syva Laboratories). 
The equipment used for EMIT® is adaptable to processing large batches and the same 
equipment can be used for many other drugs. Commercial immunoassay methods for 
theophylline include the Syva EMIT® method the Abbott TDX® systems (fluorescence 
polarisation immunoassay). 
An advantage of the EMIT® is that only a small volume of serum is necessary for the 
assay. This is particularly important in the premature neonate where only a very small 
sample of blood may be withdrawn at any time. A 200 ilL serum sample is sufficient to 
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determine both theophylline and caffeine in duplicate. Thus the EMIT® Assay 
techniqueC, which was also available locally, was selected for the assay. 
1. 4 OBJECTIVES 
In view of the variable pharmacokinetics in the neonate and the likelihood that this will 
be especially problematic in the apnoeic premature neonate during the few days after 
birth, this part of the study aimed to determine the pharmacokinetic parameters, 
clearance and volume of distribution, for theophylline in premature neonates with apnoea 
during the first few days after birth. Because of the ethical constraints the population 
approach was used in the analysis. 
C Syva Company, P.O.Box 10058, Palo Alto, California 94303. 
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SECTION A: CHAPTER 2 
METHODS 
2.1 THE PATIENTS 
2.1.1 Ethics approval and consent 
The study was approved by the Ethics Committee of the Faculty of Medicine, University 
of Natal and was conducted in the Nursery of King Edward VIII Hospital Durban, South 
Africa. Informed written consent was obtained from the mother for each patient entered 
into the study (see Appendix Al for ethics approval and Appendix A2 for the consent 
form). 
2.1.2 Inclusion and exclusion criteria 
Any premature neonate under two days old, for whom theophylline was prescribed to 
reduce neonatal apnoea, was eligible for the study. Exclusion criteria were congenital 
malformations and intra-ventricular haemorrhage of grade III or greater. Intra-ventricular 
haemorrhage was diagnosed and classified by the attending paediatrician and verified 
after an ultrasound scan. 
2.1.3 Demographic and clinical data 
The following demographic data was collected: birth weight, birth length, gestational 
age, postnatal age, and gender. Gestational age, if not available from sonar scans or 
menstrual dates, was estimated using the method described by Parkin et at (1976) and 
verified by comparison of birth weight, length and occipital frontal circumference on an 
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anthropometric chart which was developed by Lubchenco et al (1966). Body surface 
area (m2) was calculated using the formula of Mosteller (1987) shown below: 
length( cm) x weight(kg) 
3600 
The following clinical data was captured and recorded: Apgar score at one minute and at 
five minutes, respiratory Apgar, and whether the neonate was asphyxiated at birth 
(determined by the attending paediatrician). 
A daily record was kept of weight, development of neonatal jaundice or sepsis, presence 
of hypo- or hyperglycaemia, full blood count, values of urea and electrolytes, other drugs 
prescribed and all clinical interventions. 
2.2 MEDICATION AND SERUM SAMPLING 
2.2.1 Drug administration 
Aminophyllined was administered through an IV -line and flushed in with 2 ml of nonnal 
saline over 2 minutes. Loading doses varied from 4 to 7.7 mg/kg. Maintenance doses 
ranged from 1.4 to 6 mg/kg per day and were given in two to four divided doses. All 
doses were determined by the physician in charge and not by any requirements of the 
study. 
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2.2.2 Serum sample collection 
Accurately timed blood samples were collected approximately one hour after the loading 
dose. Thereafter, a sample was obtained each day if possible; these samples were drawn 
immediately prior to the next dose. A few samples were collected after the drug 
administration was stopped. All samples were immediately centrifuged and the resultant 
serum kept frozen at _700 C until analysis. Total serum theophylline concentrations were 
measured by Emit assay. The EMIT® assay is a homogenous enzyme immunoassay 
technique based on competition between the drug in the sample and drug labelled with 
the enzyme glucose-6-phosphate dehydrogenase (G6P-DH) for antibody binding sites. 
The enzyme activity decreases upon binding to the antibody. Thus, the drug 
concentration in the sample can be measured in terms of enzyme activity. The active 
enzyme converts oxidised nicotinamide adenine dinucleotide (NAD) to the reduced 
form, NADH This causes a change in the absorbance that is measured 
spectrophotometrically. Endogenous serum G6P-DH does not interfere, because the 
coenzyme functions only with the bacterial enzyme employed in the assay. The 
coefficient of variation is approximately 6% for both between run (7.5 mglL) and within 
run (10 mglL) measurements. 
2.3 PHARMACOKINETIC ANALYSIS 
Data analysis was performed using the computer package NONMEM version V level 1.0 
double precision (Beal and Sheiner 1992). The analysis of the data set and the building 
of the models to describe the pharmacokinetic parameters were done in consecutive 
steps. 
d Sabax Aminophylline 250 mg/l0mI, Adcock-Ingram,Sabax Rd, Isando, South Africa. 
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2.3.1 The pharmacokinetic data 
2.3.1.1 The phannacokinetic data file 
A NONMEM data-file was constructed with the following parameters (abbreviation in 
parenthesis ): 
Patient number (ID) 
Weight in kg (WGT) 
Body surface area (BSA) m2 
Gestational age in weeks (GA) 
Postnatal age (PNA) in days 
Postconceptual (PCA) age in weeks 
Gender (GEN) with males = 1 and females = 2 
Apgar score at 1 minute (AP), and at 5 minutes (AQ) 
Whether the neonate received respiratory support (OXY) at the time of sampling: 
yes = 1 and no = 2 
The time the sample was taken (TIME) in hours 
The dose of theophylline in mg (AMT) 
The serum theophylline concentration mgIL (DV) 
Whether the mother received a corticosteroid before or during labour (DEX) 
1 = yes, 2 = no. 
The day i.e. day 0, 1, etc (DAY) 
The route (RT): 1 = IV, 0 = none 
The presence of neonatal jaundice (NNJ) at time of sampling: 1 = yes, 2 = no 
(See Appendix A.3 for an example of the pharmacokinetic data file). 
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2.3.l.2 Data checkout 
Initially the data was checked for outliers and encoding errors using the data checkout 
facility of the NONMEM programme. 
2.3.2 Model building 
2.3 .2.1 The pharmacokinetic model 
a) Selection of a one- or two compartment model 
Initially one- and two compartment models were compared. For the one 
compartment model the ADV ANI subroutine from the NONMEM PREDPP-
library was implemented, using the TRANS2 subroutine to re-parameterise the 
models in terms ofCL and V (Beal and Sheiner 1992). For the two compartment 
model the ADVAN2 and TRANS3 subroutines were used (see Appendix A4 and 
A5 for examples of the NONMEM control stream for the one and two 
compartment models respectively). 
b) Selection of a bolus- or a rate model 
Intravenous doses are usually modelled as bolus administration, but as 
theophylline was administered over two minutes a bolus administration model 
was compared with a rate model of drug administration. As the results of 
paragraph a) above indicated that a one compartment model is adequate to 
describe the data, a one compartment model was used for this comparison (see 
Appendix A.6 for an example of a control stream for the rate model). 
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c) Parallel first- and zero order elimination 
The possibility of non-linear elimination was investigated by fitting the data to a 
control stream with parallel first and zero-order elimination (see Appendix A. 7 
for an example of a control stream for parallel first and zero-order elimination). 
d) Construction of a base model 
After the above initial analysis, a one compartment, bolus model with first-order 




Where TVCL and TVV are the typical values of CL and V respectively. 
2.3.2.2 The statistical error models 
Estimates for the inter-individual differences i.e. the deviations of the drug's CLj and Vj 
of the jth individual from population mean values were estimated according to the 
following inter-patient error models: 
Additive model: CL· = TVCL + n .CL J • IJ 
Proportional model: 
Exponential model: CLj = TVCL * EXP (YJjCL) 
Where CLj is the estimate from the jth individual, and TVCL represented the population 
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mean estimate of CL. 111 is a normally distributed random term with mean zero and 
variance (f/. Similar models were used to describe the variability in V. 
The residual error, which accounts for the difference between the observed 







Cij = Cpred.ij + Cij 
Cij = Cpred.ij * (1 + cij) 
Log Cij = Log Cpred.ij + ( Cij * 83) 
Cj = Cpredij * EXP (ERRI ) 
Where Cj was the observed and Cpred.ij the predicted concentrations of the ith individual 
at the fh sampling time and 83 a factor estimated by the NONMEM programme. 
The residual errors were assumed to be normally distributed with a mean of zero and a 
variance of (i. These differences ({>ij) were attributable to intra-patient pharmacokinetic 
variability. Statistical model selection was based on assessment of goodness of fit, 
graphical analysis, evaluation of the size of the individual variability and the residual 
errors and the relative standard errors of the parameters. 
2.3.2.3 The influence of possible outliers 
The possibility of outliers was investigated as follows: Using the Xpose programme 
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(XPOSE 2.0), plots showing the Cooks distance versus leverage were constructed to 
determine the individual influence of the patients on the GAM fit. Cooks distance is a 
measure of the influence a certain data point has, that is, how much the fit will change if 
that data point is omitted from the analysis. A high value indicates a high influence. The 
leverage is a measure of how a data point influence the certainty with which the fit is 
obtained (Jonsson and Karlsson 1997). A point with a high value of Cooks distance and 
leverage is important to the fit and often affects the covariate selection. Thus if an 
individual point has a high leverage and influence on the GAM, this point will also be 
important for the covariate model in NONMEM (Jonsson 1998). 
2.3.2.4 Covariate model building 
The following covariates were available for testing WGT, BSA, GA, PNA, PC A, GEN, 
-
AP, AQ, OXY, DAY, NNJ, and DEX The GAM in Xpose was used for the 
identification of covariates on CL and V (Jonsson and Karlsson 1997). Akaike plots 
were obtained of the most important models tested by the GAM with the corresponding 
AlC values. In addition, the bootstrap of the GAM was used to assess the importance of 
the covariates. Plots showing covariate inclusion frequency and most common covariate 
combinations were obtained. 
Using NONMEM, the covariates selected by the GAM analysis were then tested, in a 
stepwise fashion, singly and in combination on CL and V, respectively. The covariates 






CL = 8] + 82 * factor 1 
+ 83 * factor 2 
CL = 8] * factor 1 
Where the factors (1, 2, etc.) were continuous variables such as age, 
weight, body surface area etc., CL represented clearance and 8] .. 82 were 
the parameters to be estimated. 
Nonlinear model: CL = 8] * (factor or median of factor) 92 
Similar models were used for the estimation of V. Initially the best model for CL was 
determined, followed by the best model for V. Thereafter the best model for CL was 
combined with the best model for V. All covariate model building was performed using 
the default First Order estimation method (FO). Thereafter the base and final models 
were run using the first order conditional estimation method (FOCE). 
2.3.2.5 Inter-occasion variability 
The presence of inter-occasion variability (lOV) in CL and V was tested at the very end 
(Karlsson and Sheiner 1993). An 'occasion' was a different day, i.e. days 1, 2 and 3. All 
days after day 3 were grouped together as occasion 4 (see Appendix A8 for the control 
stream for the final model). 
2.3.2.6 Model evaluation 
Successive models were evaluated and selected on the basis of: 
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(i) The differences in the objective function values (OFV). This value is minus 
twice the log likelihood of the data, approximately chi-squared (X2) distributed 
with q degrees of freedom equal to the difference in the number of parameters 
between the two models. A reduction in OFV of 6.8 (p<O.OI) or greater was 
used. 
(ii) Plots ofDV vs PRED. These plots showed the distribution of the data and where 
the observations were lower or higher than the predictions. 
(iii) The size of the relative standard errors of the estimates. 
2.3.2.7 Predictive perfonnance testing 
As it was not possible to obtain enough patients for external validation, internal 
validation methods were used. 
2.3.2.7.1 Predictive perfonnance using POSTHOC estimates of the final model as the 
"true" value 
The pre?ictive perfonnance in tenns of bias (mean prediction error) and precision (mean 
squared prediction error) for the base and final models was calculated using the 
population values and comparing these with the POSTHOC estimates of the final model 
(regarded as the ' true' model) parameters (Sheiner and BeaI1981a). 
To measure absolute bias, the following was calculated: 
The difference in mean prediction error (i\me), thus 
i\me = me2 - mel . 
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Where mel is the mean prediction error for the "true" model and me2 is the mean 
prediction error for the base or final models. The percentage bias was calculated 
by dividing L1me by the mean value of the "true" model and multiplying the 
number by 100. 
Absolute precision was calculated as follows: 
Difference in mean squared prediction error (L1mse\ thus 
2 2 2 L1me = me2 - mel . 
Where msel2 is the mean squared prediction error for the "true" model and mse/ 
is the mean squared prediction error for the base or final models. The root mean 
squared prediction error was then calculated as --.1L1me2. The percentage precision 
was calculated as above for bias. 
The percentage standard errors and the corresponding 95% Confidence Intervals of the 
above parameters were calculated. If the Confidence Intervals derived did not overlap, 
the models were judged significantly different at the a level (0.05) used to compute the 
Confidence Intervals. 
2.3 .2.7.2 The Jack-knife 
The stability of the developed pharmacokinetic models was also tested using the Jack-
knife technique (Efron and Tibshirani 1993). This was done by leaving one patient out 
of the data set at a time and rerunning the final models with NONMEM. The resultant 
parameter estimates and their standard errors were noted and compared. If a patient has 
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a possible influence, the precision of the estimated parameters of the run without that 
specific patient will have a markedly different value compared with those of the other 
runs. Patients who might influence the results may thus be identified. 
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SECTION A: CHAPTER 3 
RESULTS 
3.1 THE PATIENTS 
All the patients were Black premature neonates with apnoea. Demographic and clinical 
data are summarised in Table A.3 .1 (see Appendix A.9 for an example of a data 
collection fonn). 
TABLEA.3.1 
Demographic and clinical data of the study population 
Demographic and Clinical Data at Entry 
Patients = 105 Males = 52 
Mean SD Median Range 
Birth weight (kg) 1.3 0.3 1.3 0.7 - 1.9 
Gestational ag€ (weeks) 30.8 1.8 31.0 26 - 34 
*Postnatal age (days) 1.1 0.3 1.0 1-2 
Postconceptual age (weeks) 31.0 1.8 31.1 26.1 - 34.1 
Body surface area (m2) 0.117 0.017 0.115 0.081 - 0.146 
Apgar at 5 min 9 1 9 5 - 10 
*Day of birth = day 1 
Of the 105 patients, 97 (92%) had respiratory distress syndrome (RDS) at the time of 
serum sampling. Sixty-four, 59 and 48% of the neonates received oxygen support by 
headbox on days one, two and three respectively. The peripheral oxygen saturation was 
measured at intervals of 4 hours and was kept above 90%. Oxygen supply was removed 
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when the peripheral oxygen concentration was higher than 97%. Antenatal 
corticosteroids were given to 30% of the mothers. None of the mothers smoked or took 
caffeine-containing beverages during labour. Most of the neonates (96%) received beta-
lactam and aminoglycoside antibiotic combinations for proven or suspected sepsis. See 
Appendix AlO for frequency distribution graphs of the covariates such as patients' 
weight etc. 
3.2 SERUM THEOPHYLLINE CONCENTRATION MEASUREMENTS 
There were two hundred and sixty-three concentration measurements taken \\lith a 
median of two samples per patient and a range of one to seven. See Figure A3.1 for the 
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Fig.A3.l Frequency distribution of theophylline concentration measurements. 
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Of the theophylline measurements, approximately 60% and 94% were obtained in the 
first 3 days and within one week of birth respectively. Average (SD) serum theophylline 
concentrations for days 1, 2, and 3 were 5.6 (3.1), 7.5 (3 .9), and 8.8 (5.7) mg/L 
respectively. Because of the long half-life of theophylline in neonates, very few of these 
samples could be expected to be steady state concentrations. 
3.3 PHARMACOKINETIC ANALYSIS 
3.3.1 The pharmacokinetic data file 
The pharmacokinetic data file was constructed as described in Chapter 2 (see Appendix 
A. 3 for an example of the phannacokinetic data file). All errors indicated by the data 
checkout run were corrected on the data file. 
3.3.2 Model building 
3.3.2.1 The pharmacokinetic model 
a) One- or two compartment model 
. As there was no significant difference in OFV between one- and two compartment 
models, the one compartment model was selected for further analysis. Previous studies 
of theophylline have shown that a one compartment model with first order absorption 
(Weinberger and Ginchansky 1977, Aranda et al 1981, Lee et al 1996) adequately 
describes the pharmacokinetics of the drug (see Table A.3.2 for results of the 
comparison of a one and two compartment model). 
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TABLEA.3.2 
Results of a comparison of the one and two compartment models 
Parameter One compartment Two compartment 
, OFV 1035.56 1034.52 
CL (Llh) 0.0084 0.0078 
VeL) 0.67 -
VI (L) - 0.00034 
V2 (L) - 0.574 
Q (Llh) - 0.1 
Eta (CL) 83% 74% 
Eta (V) 49% -
Eta (VI) - 260% 
Eta (V2) - 0.0004% 
~. 
Eta (Q) - 47% 
Omega 32% 32% 
OFV = Objective function value, CL = clearance, V = volume of distribution, 
VI = central volume, V2 = peripheral volume, Q = inter-compartmental clearance, 
Eta = inter-individual variability, Omega = residual error. 
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b) Rate versus bolus model 
The results of a comparison of a rate and a bolus model of theophylline administration 
showed no difference. The bolus model was thus chosen for further analysis (see Table 
A.3 .3. for a comparison of the results of the analysis). 
TABLE A.3.3 
Results of a comparison of a rate and a bolus model (relative standard errors) 
Parameter Rate model Bolus model 
OFV 1035.56 1035.56 
CL (Llh) 0.0084 (17%) 0.0084 (17%) 
V (L) 0.66 (9%) 0.67 (9%) 
~ 
Eta (CL) 83% (36%) 83% (36%) 
Eta (V) 49% (23%) 49% (23%) 
Rate 0.00017 (200%) -
Residual error 32% (26%) 32% (26%) 
OFV = Objective function value, CL = clearance, V = volume of distribution, Eta = 
inter -individual variability. 
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c) Parallel first- and zero-order elimination 
The value obtained for the maximum elimination rate, V m, was negligibly small. The 
first-order elimination model was selected for further analysis (see Table A.3.4 for 
results of parallel first- and zero-order elimination). 
TABLE A.3.4 




KIO (h-1) 0.0104 
Vm (mg/h) 1.38 x 1O-1l 
Km (mg/L) 9.12 
~ 
OFV = Objective function value, V = volume of distribution, KIO = elimination 
rate constant, V m = maximum elimination rate, Km = drug concentration at which 
metabolism proceeds at half its maximum rate. 
Thus the basic pharmacokinetic model was a one compartment, bolus model with first 
order elimination (see Appendix A.4 for the control stream of the base model). 
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3.3.2.2 The statistical model 
As both the additive and the proportional error models showed that certain estimated CL 
values were negative, inter-patient variability in CL and V were modelled as an 
exponential error model. The residual error was modelled as exponential, log, 
proportional, additive and a combination model. Inspection of frequency distribution 
graphs of weighted residuals of these various types of residual error models (prior to 
covariate inclusion) indicated that the exponential error model gave the more normal 
distribution and this was thus used for subsequent analysis. This was re-evaluated at the 
completion of the model building process, at which point the important covariates had 
been included (see Appendix A 11 for frequency distribution graphs of the various error 
models). 
3.3.2.3 The influence of outliers 
-
Graphs of the individual influence of patients on the GAM obtained by the Xpose 
programme, showed that 6 patients (numbers 9, 21, 86, 125, 140 and 142) might be 
outliers. This meant that their presence might influence the results of the 
pharmacokinetic analysis adversely (see Appendix A 12 and A 13 for the identification 
of influential individuals on the GAM fit for CL and V). Four of these patients (number 
9, 86, 140 and 142) were on the extremes of the weight scale that could have an 
influence on CL and Y However, after inspection of the demographic and clinical data 
of these patients, no real reason could be found for the exclusion of these patients (see 
Appendix A 14 for demographic and clinical details of these patients). To determine the 
influence of each patient on the parameter estimation, they were deleted one at a time 
from the data file and the NONMEM base run was performed (see Appendix A 15 for 
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results of this NONMEM analysis). As shown in Appendix A15 these patients did not 
have a significant influence on the NONMEM analysis. This confirmed their inclusion 
in the data set. 
3.3.2.4 Covariate model building 
The GAM on CL indicated that oxygen support and gestational age featured as 
significant covariates (see Appendix A16 for the Akaike plots for CL). Additionally the 
bootstrap of the GAM showed that the most common two-covariate combinations for CL 
were oxygen support with gestational age or day, or day with gestational age or body 
surface area (see Appendix AI7 for the graphs of the most common covariate 
combinations for CL). 
The GAM on V indicated that postconceptual age and gestational age were significant 
covariates (see Appendix A.I8 for the Akaike plots for V). The bootstrap of the GAM 
showed that the most common two-covariate combinations for V were gestational age 
and postnatal age, neonatal jaundice and body surface area or postnatal age, and body 
surface area and postnatal age (see Appendix A19 for the graphs of the most common 
covariate combinations for V). 
Although not indicated by the GAM analysis, weight was also selected for testing on 
both CL and V. Because, besides being the most accurately and commonly measured 
covariate, it was also highly correlated (r2 = 0.8) with both gestational age and 
postconceptual age (see Appendix A20 for correlation matrix of the developmental 
covariates). In addition the presence or absence of antenatal corticosteroid therapy was 
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tested as a covariate. 
3.3.2.4.l. Building the regression model for CL 
At first the regression models for CL were built by keeping V constant, thus V = 82. The 
influence of the covariates selected by the GAM, as well as weight, was investigated. 
Models incorporating each of these singly were constructed in a variety of ways: e.g. 
linear and non-linear functions (see page 47). 
Weight was modelled as a continuous and as various exponential functions on CL. These 
exponential functions included the general model of WGTo.75 as proposed by Holford 
(1996) and the specific value of WGTl.28 found by Moore et al (1989). In addition an 
attempt was made to estimate an exponent on WGT. As the OFV of the WGT models 
did not differ significantly, various criteria were applied to assist in selecting the best 
\VGT model. Visual inspection of the graphs, DV versus PRED, showed no obvious 
difference, but the relative standard errors of the WGTO.75 model were marginally smaller 
than the other WGT models. Thus the WGTO. 75 model was selected for further model 
building. The other single covariate that decreased the OFV significantly was oxygen . 
support. The presence or absence of antenatal corticosteroid therapy did not feature as a 
significant covariate. 
Next the combinations of covariates on CL, as indicated by the bootstrap of the GAM, 
were tested in NONMEM. The resultant OFV of these combinations did not differ 
significantly from each other and decreased the OFV by approximately 20 points. This 
decrease in OFV was not significantly better than the decrease caused by the single 
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covariate, oxygen support. Therefore the best single covariates, as indicated by the 
NONMEM analysis, namely WGTo 75 and oxygen support, were combined. When tested 
in NONMEM, this combination caused a larger decrease in the OFV than the other 
combinations indicated by the bootstrap of the GAM. The standard errors of the 
estimated parameters of this covariate combination were also slightly smaller than those 
of the other combinations. Thus the best covariate model for CL was WGTo.75 plus 
oxygen support (full details of the model building process are shown in Appendix A21). 
3.3.2.4.2 Building regression model for V 
Regression models for V were then developed in a similar fashion as for CL while 
keeping CL = 81. At first the covariates selected by the GAM, postconceptual age and 
gestational age, were tested in NONMEM. Both caused a similar decrease in the OFV. 
For reasons mentioned above, WGT was then also tested. This covariate reduced the 
OFV to a greater extent than did postconceptual or gestational age and was thus selected 
as the best single covariate on V. Next, the combinations of covariates as indicated by 
the bootstrap of the GAM, were tested. In the NONMEM analysis all these 
combinations increased the OFV Thus WGT, as a single covariate on V, was selected 
as the best covariate model for V (see Appendix A21 for details of the model building 
process). 
3.3.2.4.3 The full covariate model 
The best models for CL and V were then combined with a resultant drop in OFV of 54 
from the base model. As a result the full covariate models were: 
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CL (Lib) = 91 * WGTO.75 * 93 
V (L) = 92 * WGT 
Where WGT = weight (kg) and 63 = with or without oxygen support. 
Table A.3.5 summarises the main runs of the covariate model building process showing 
the base model, the covariate models on CL and V respectively, and the full covariate 





Results of the covariate model building process showing selected models only and using the FO-method 
CL Model V Model Parameter estimates (RSE Eta 1 Eta2 OFV i10FV Res error 
%) (RSE %) (RSE %) (RSE %) 
CL V 93 
9, 92 0.0084 0.67 - 83 49 1035.56 - 32 
(17) (9) (36) (23) (26) 
9,*OXY 82 0.0060 0.63 1.87 74 55 1019.52 16.1 29 
(22) (9) (22) (41) (24) (23) 
9,*WGT 92 0.0078 0.65 - 78 47 1024.02 11.6 32 
**0.75 (17) (9) (35) (25) (27) 
9,*WGT 92 0.0057 0.62 1.84 68 52 1007.l2 28.48 30 
**0.75*OXY (21) (10) (20) (37) (23) (24) 
9, 82*WGT 0.0078 0.58 - 82 43 1000.62 35 31 
(13) (7) (34) (28)- (25) I 
8,*WGT 82*WGT 0.0052 0.54 1.94 69 49 981.24 54.12 29 
**0.75*OXY (20) (8) (21) (38) (29) (24) 
I 
CL = clearance, V = volume of distribution, RSE = relative standard error, e parameter, Etaj = inter-individual variability CL, Eta2 = inter-individual 
variability V, OFV = objective function value, ,iOFV = change in OFV, 
Res error = residual error. 
3.3.2.5 Finalisation of the full covariate model 
a) FOCE-method 
Parameter values appeared, in general, to be more precisely estimated when the FOCE 
estimation method ofNONMEM was used. Therefore the base and full covariate models 
were next run with FOCE instead of the default FO-method. 
b) Inter-occasion variability 
Using FOCE, the inter-individual variability for CL, V and the residual variability were 
60%,53% and 29% respectively, which is relatively high (see Table A.3.5). As a result 
it was thought important to check for inter-occasion variability (lOV). Therefore 
implementing FOCE, the full covariate model was re-run with estimation of lOV. This 
resulted in the final model. On the introduction of lOY, the inter-individual variability 
for CL, V and the residual variability decreased to 56%, 47% and 16% respectively. The 
~ 
OFV decreased from 962.3 to 927.9. Parameter details for these models are presented in 
Table A.3.6. The relationship between the measured concentrations and those predicted 
for the base and the final models are shown in Figure A.3.2a and A.3.2b respectively. 
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TABLE A.3.6. 
Parameter details for base, full covariate and final models (relative standard error %) 
using FOCE 
Base Model Full Covariate Final Model 
Model (with lOY) 
(without lOY) 
8 1 0.0074 0.0056 0.0060 
(16) (19) (14) 
83 - 1.61 1.47 
(23) (18) 
82 0.75 0.58 0.63 
(9) (8) (7) 
Inter -individual variability 73 60 56 
inCL (%) (27) (29) (25) 
Inter-occasion yariability - - 34 
inCL (%) (77) 
Inter-individual variability 57 53 47 
in V (%) (20) (23) (28) 
Inter-occasion variability - - 35 
in V (%) (29) 
Residual error ( %) 30 29 16 
(22) (22) (35) 
OFV 1000.9 962.3 927.9 
83 = 1.0 ifno oxygen support. 
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Fig.A.3.2b Predictions vs dependent variable for final model 
3.3.2.6 Final phannacokinetic values 
Calculated using the final model, the mean values (95% Confidence Intervals) for CL in 
this population, were 0.0074 (0.0070, 0.0078) for neonates without oxygen support, and 
0.0104 (0.0099, 0.0109) Lih for neonates receiving oxygen support. The mean V for the 
neonates was 0.81 (0.77, 0.85) L. This results in mean predicted popUlation half-lives, 
without and with oxygen support, of 76 and 54 hours respectively. For comparative 
purposes the weight normalised mean values for CL without and with oxygen 
support are 0.0056 and 0.0084 Llh/kg respectively; and for V 0.63 L/kg. 
3.3.2.7 Predictive perfonnance testing 
3.3.2.7.1 Bias and precision 
The percentage bias (prediction error) and precision (squared prediction error) of the 
base and final models, when compared with the POSTHOC estimates of CL and V from 
~ 
the final model (taken as the "true value"), are given in Table A.3.7. 
The results show that there is an improvement from the base to the final model in all 
categories. As the prediction errors of the final models were smaller than those of the 
base models, the precision of the final model is better than the base model. 
3.3.2.7.2. Results of the Jack-knife 
To check whether the developed phannacokinetic models were stable, the Jack-knife 
technique was applied to the data set of the final model. The results, when each patient 
was left out one at a time, are shown in Appendix A22. When certain patients (3, 13,27, 
71,82, 112, 114, 125 and 126) were left out of the data set the relative standard errors of 
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some of the parameter estimates increased. However, in no case did the parameter 
estimates change markedly. On inspection it was found that most of these individuals 
contributed 3 or more serum samples to the data set, or they had serum samples taken 
after the drug has been stopped. As a result the final pharmacokinetic model was 
considered not to be unduly dependent upon any particular individuals. 
TABLEA.3.7 
Percentage Bias and Precision (95% CI) for the Base and Final Models 
CLEARANCE 
Base Model Final Model 
Bias 24 5 
(17,31) (0, 12) 
Precision 51 38 
(39,58) (29,43) 
J VOLUME 
Base Model Final Model 
Bias 14 8 
(5 , 22) (0, 15) 
Precision 52 44 
(40,58) (35, 49) 
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SECTION A: CHAPTER 4 
DISCUSSION 
4.1 DISCUSSION 
The present study differs from prevIOUS population pharmacokinetic analyses of 
theophylline in the premature neonate as it describes the pharmacokinetics of the drug 
during the first few days after birth. This is when theophylline is most often used for the 
treatment of apnoea of prematurity in our neonatal wards. Other unique features are the 
all Black population, and the high incidence of respiratory distress syndrome (92%). 
The CL values normalised for weight, for neonates without and with oxygen support 
were 0.0056 and 0.0084 Lib/kg respectively. These values are lower than those reported 
in other NONMEM studies. Por example, using the model by Lee et al (1996), CL for 
babies one day old would be 0.012 (± 0.00074) Llhlkg. Moore et al (1989) reported a 
CL value of 0.0175 (range 0.0155 to 0.0195) Llhlkg and Karlsson et al (1991) a CLIP of 
0.040 (± 0.002) Llhlkg. The values obtained in the present study are closer to the lower 
end of the CL values reported in some of the traditional pharmacokinetic studies. In a 
traditional study with neonates with postnatal ages ranging from 4 to 8 days, which is 
only slightly older than the present study, the CLIP values ranged from 0.0063 to 0.0299 
Llhlkg (Latini et al 1978). In another traditional study, using rectal data, the CL values 
ranged from 0.0043 to 0.0124 Llh/kg in neonates with postnatal ages ranging from 2 to 
21 days (Neese and Soyka 1977). The value of V normalised for weight, 0.63 Llkg, is 
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also lower than that found in other population studies that reported a range from 0.8 to 
0.9 Llkg (Moore et al1989, Lee et al1996). However, this lower value is well within 
the range (0.2 to 1.0 Llkg) recorded in some of the traditional pharmacokinetic studies 
with gestational- and postnatal-ages closer to those in the present study (Latini et al 
1978, Stile et al1986). 
In the final model, weight was found to be an important determinant of CL and the 
WGTo.75 (weight exponent of 0.75) model was accepted as the preferred weight model. 
This model was marginally better than the continuous weight model or the WGT1.28 
model proposed by Moore et al (1989). This 0.75 exponent model was based on the 
arguments by Peters (1983) who described the allometric % power law as a good 
predictor of body functions. This concept :was supported by subsequent work by Holford 
~ 
(1996) and Anderson et al (1997) who argued that clearances should be standardised 
using the % power law. The results of the NONMEM analysis showed that the standard 
errors of the estimated parameters of the WGTo.75 model were also smaller than the other 
weight models. 
In the two other NONMEM studies of theophylline in neonates, weight was used as a 
continuous factor affecting CL (Karlsson et al 1991, Lee et al 1996). Weight as a 
covariate on CL in the neonate is important but complex, as the neonate loses weight 
during the first few days and then gains weight faster than any other type of patient. 
69 
In the present study postnatal age (range 1 to 9 days) did not have an influence on the 
estimation of CL. This correlates with the results of a traditional type analysis with a 
neonatal population with a similar small range (4 to 8 days) of postnatal ages (Latini et al 
1978). However, in another traditional type analysis with a slightly wider range of 
postnatal ages (1 to 24 days), a weak but statistically significant correlation between CL 
and postnatal age (p<0.005) and postconceptual age (p<O.Ol) was found (Gilman et al 
(1986). In two of the published NONMEM studies of theophylline in neonates (Moore 
et a11989, Lee et a11996) postnatal age was one ofthe two important covariates on CL. 
In comparison with the present study, these other NONMEM studies had a much wider 
range of postnatal ages, namely from 1 to 111 days for the study by Lee et al (1996) and 
3 to 182 days for the study by Moore et al (1989). Both Lee et al (1996) and Moore et al 
(1989) found that CL values increased steadily with age. 
In premature neonates, renal clearance of theophylline is relatively more important than 
metabolic clearance. Approximately 50% of the drug is excreted unchanged compared 
to about 14% in children and adults (Tserng et a11983, Baird-Lambert et a11984, Kraus 
et al 1993). Theophylline clearance and urinary metabolite patterns apparently reach 
adult values at 55 weeks postconceptual age (Kraus et al 1993). Renal function could 
not be assessed in the present study and creatinine clearance could not be included as a 
candidate covariate for theophylline clearance, as it is not normally determined in our 
. population~ 
In any event, creatinine excretion (Sertel and Scopes 1973) and glomerular filtration rate 
(Arant 1978, Robillard et al 1979) can vary considerably in the neonatal period. 
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Although it was at first believed to be a reflection of the mothers serum. creatinine 
(Manzke et al 1980), it is now accepted that the higher plasma creatinine values in the 
neonate are due to the inability of the immature neonatal kidney to get rid of the excess 
creatinine (Bueva and Guignard 1994, van den Anker et al 1995). However, it was 
recently shown that creatinine reabsorption occurs along the renal tubule of the 
premature neonate (Guignard and Drukker 1999). The authors speculate that this 
temporary phenomenon is attributable to back-flow of creatinine across leaky immature 
tubular and vascular structures. Apparently, with time maturational changes will impose 
a barrier to creatinine reabsorption. 
The possibility of renal tubular reabsorption of theophylline cannot be overlooked. It 
was previously shown that if a drug in the kidney is only filtered, then renal clearance 
might be calculated as CLR = fu * GFR (page 16). If, for theophylline, the value for GFR 
is taken as 0.7 mVmin (range 0.6 to 0.8 ml/min), (van den Anker 1996) the fraction 
unbound theophylline as 0.7 (range 0.64 to 0.74), (Aranda et a11976, Butts et aI1991), 
then the CLR should be 0.49 ml/min or 0.0294 Llh. This is greater than the highest CL of 
·0.0104 Llh in this study. Therefore one might speculate that reabsorption of theophylline 
has occurred. This is supported by the finding of Guignard and Drukker (1999) who 
showed that creatinine is reabsorbed along the immature renal tubule of the premature 
neonate. 
Glomerular filtration rate is lower than normal in infants with respiratory distress 
syndrome (Guignard et al 1976). This is a condition that is commonly found in the 
premature neonate during the first week of life due to the immaturity of lung tissue. The 
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low CL of theophylline found in the present study could also be due to the large number 
(92%) of neonates with respiratory distress syndrome at the time of sampling. It was 
previously shown that theophylline administration does not modify the course of 
respiratory distress syndrome (Hegyi et aI1986). 
In the present study it was shown that neonates who received oxygen by headbox, 
cleared theophylline 47% faster than those who did not. Although some of the neonates 
may have been classified as suffering from asphyxia, it was not possible to record this 
accurately in our setting, and therefore asphyxia could not be tested as a covariate. It is 
known that hypoxia may decrease theophylline CL (Letarte and du Souich 1984, 
Kishimoto et al 1989, Richter and Lam 1993), and that CL is lower in asphyxiated 
neonates (Gal et a11982, Gilman et aI1986). Gal et al (1982) originally reported a 46% 
lower CL in asphyxiated compared to non-asphyxiated neonates. In a subsequent study 
Gilman et al (1986) found a 19% lower CL in asphyxiated neonates. Asphyxia in these 
studies was defined as a 1- or 5-minute Apgar score of ~ 3, a cardiac or respiratory arrest 
requiring resuscitation, apnoea longer than 1 minute requiring bag breathing, or an 
arterial oxygen pressure ~ 3 torr. In the population study by Lee et al (1996), CL was 
reduced by about 10% in asphyxiated patients, but asphyxia as a covariate did not reduce 
the objective function value significantly. In the other population study by Moore et al 
(1989) asphyxia had no significant influence. However, it should be noted that in this 
study by Moore et al (1989), less than 10% of the serum samples were collected within 
the first week and any change in theophylline metabolism due to birth asphyxia may not 
have been detected. 
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Although it is now routine practice to administer corticosteroid treatment antenatally 
(Ryan and Finer 1995), only 31% of the mothers in the present study received a 
corticosteroid during labour. It is known that corticosteroids administered antenatally 
activate the hepatic microsomal metabolism of the neonate during the first week of life 
(Baird-Lambert et aI1984). However, theophylline CL value of these neonates was not 
different to those neonates whose mothers did not receive the drug. In children, the 
concomitant corticosteroid administration has also shown to be without influence on the 
clearance of theophylline (Leavengood et a11983, Anderson et aI1984). 
Karlsson and Sheiner (1993) reported that if inter-occasion variability is not recognised it 
may inflate inter-individual variability and/or residual variability. The results of the 
present study support this as the introduction of inter-occasion variability reduced inter-
individual variability on both CL and V, and substantially decreased residual variability. 
The inter-occasion variability on CL and V were 34% and 35% respectively. An 
'occasion' was taken as a day as theophylline sampling was done on consecutive days 
whenever possible. Therefore these values might reflect the changes due to the 
deVelopment of hepatic and renal function and the changes in body composition as well 
as changes in the clinical condition of the premature neonates. 
Even after introduction of inter-occasion variability, the inter-patient variability in CL 
remained high at 56% for the final model, despite testing all the available covariates. 
This value is higher than those obtained in the other NONMEM studies. For example, 
Moore et al (1989), Karlsson et al (1991) and Lee et al (1996) reported inter-patient 
variability in CL of 16%,25% and 30%, respectively. Various factors could account for 
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this large inter-individual variability in CL. The present study was conducted during the 
first few days after birth when the premature neonate undergoes profound changes to 
adapt from foetal to neonatal physiology (Behrman et al1994, Lorenz et al1995, Oliver 
et al 1995). All the other population studies followed the patients for longer periods of 
time thus allowing for maturation of the neonate and stabilisation of neonatal 
physiological processes such as elimination. 
Some of the complicating factors that may contribute to the large inter-patient variability 
during the immediate time after birth, are the reabsorption of lung fluid (Behrman et al 
1994) and the phase of spontaneous diuresis (Oliver et al 1995). The median age of 
onset of this diuresis is 24 hours in 87% of the patients with a cessation of diuresis at 96 
hours median. Moreover, theophylline may also cause a diuresis. In neonates this effect 
will peak at 2 to 4 hours after a loading dose of 6 mg/kg and with the ratio of urinary 
~ 
output to water intake nearly doubled (Mazkereth et at 1997). However, this effect does 
not occur during maintenance therapy with theophylline in neonates. As sixteen percent 
of the theophylline measurements in the present study was made approximately an hour 
after the loading dose, the diuretic effect of theophylline could have affected the CL of 
the drug. Moreover, the second serum concentration measurement (24% of the total 
measurements) was done early the following day, thus during the phase of spontaneous 
diuresis that occurs in most but not all neonates (Oliver et al 1995). Another factor 
contributing to the large inter-patient variability is the possible reabsorption of 
theophylline previously mentioned that would also vary from patient to patient 
depending on the degree of renal maturity. 
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Also, during the immediate time after birth not all neonates are at the same stage of 
change. For example in the present study 20% of the patients had developed neonatal 
jaundice by day two, and another 30% from day three onwards. As lung function may 
also affect CL, the 26% variability of pulmonary mechanisms over the three days after 
birth (Goyal et al 1995) could also contribute to the variability found in CL. Another 
variable factor is respiratory distress syndrome. At entry to the study, the majority of 
patients suffered from respiratory distress syndrome. This usually resolves 
spontaneously, but slowly, after birth and therefore its time to resolution would have 
differed from patient to patient. This could have affected the glomerular filtration rate as 
discussed previously. These changes, as well as the different stages of maturity of the 
physiological and biochemical systems (Tsemg et al 1981, Rylance 1992, Kraus et al 
1993, Mazkereth et aI1997), may be responsible for much of the variation found in the 
estimation of CL. It could also perhaps be explained in part by the fact that the study 
was carried out In a very busy third world hospital where the prevailing circumstances, 
such as individual nursing care, ambient temperature etc, were sometimes variable. 
Despite attempts to ensure constant body temperatures of the patients during the study 
period, this was not always possible. It is known that very modest decreases in body 
temperature can affect the immature kidney causing significant decreases in urine flow, 
glomerular filtration rate and renal plasma flow (Guignard and Gilli6ron 1997). 
With regard to V, weight was found to be the most influential covariate. This supports 
the fact that in the neonate extra-cellular fluid volume is known to correlate better with 
weight than with gestational age (Aranda et aI1992). The inter-patient variability (47%) 
on V was high, but similar to that of 44% obtained by Lee et al (1996). The three phases 
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of fluid and electrolyte homeostasis (Lorenz et al 1995) and the shift of fluid from the 
extra- to the intra-cellular fluid compartments during the fIrst week of life (Heimler et al 
1990, Ramiro-Tolentino et aI1996), could all contribute to the high variability. Another 
possible contributing factor is the 50% increase in binding of theophylline to plasma 
proteins in the neonate from 28 to 40 weeks gestation (Reading et al 1990, Butts et al 
1991). 
The residual variability of 16% in the present study is similar to that of 14% recorded by 
Lee et al (1996) and within the range (9 to 25%, depending on concentration) found by 
Moore et al (1989). 
Several limitations of the study have to be pointed out. Ideally more than one sample per 
patient should be obtained for accurate analysis of data (Jelliffe et a11993, Aarons et al 
1996, Jonsson e~t al 1996). Unfortunately this was not always possible as occasionally 
the neonate was too ill or permission for taking a sample was not granted. Thirty single 
serum samples were obtained out of a total of 263 samples from 105 patients. 
It was assumed that an error free dosing history of theophylline was used for the 
analysis. Unfortunately not all the drug dosing and recording of the dosing times could 
be supervised at all times. However, the serum sampling times in the study were correct, 
as the researcher and assistant were responsible for these. 
Under normal circumstances it IS assumed that the covariate values are 
recorded/measured without error. The weights of the neonates were recorded whenever 
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possible, but we had to rely on the judgement of the clinicians for assessment of certain 
clinical conditions of the neonate such as hypotonia and asphyxia, as well as the Apgar 
1- and Apgar 5 minute scores. 
In the analysis of the data the assumption was made that the structural model was 
adequate and applied to all the subjects at all times. A one compartment first-order 
model was used, but non-linear kinetics have been described for theophylline especially 
at higher doses. Seventeen percent of the theophylline serum concentrations were higher 
than the suggested therapeutic range of 5 to 15 mg/L for the control of apnoea (Aranda et 
at 1992). Four percent of the serum concentrations were above 20 mg/L, which falls in 
the toxic range (Shannon et at 1975, Aranda et al 1992). Although parallel first-and 
zero-order elimination was tested and found deficient, saturation of some of the 
metabolic processes at the higher theophylline serum concentrations could have been 
possible. 
It was assumed that the changes in individual parameter values between study occasions 
are random with a variability that is constant between occasions (Karlsson and Sheiner 
1993, Karlsson et at 1998). However, if this variability is influenced by different 
underlying mechanisms, the variability will not be constant from occasion to occasion. 
This would be the case for premature neonates, with changing hepatic and renal function, 
changing lung function, gradual recovery from RDS, changing oxygen supply, 
developing and also recovery from neonatal jaundice, changing extra-cellular fluid 
volume and so forth. 
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An important feature of the development of pharmacokinetic models is the assessment of 
the model's predictive performance when applied to a separate but similar group of 
patients. Unfortunately we were unsuccessful in recruiting enough patients for a test 
data set. There are several reasons for this. For example, since the election of a 
democratic government, more suburban clinics were established and free medical care 
became available to all pregnant females. This improved prenatal care that resulted in 
more healthy term pregnancies. Therefore the number of patients admitted to the 
neonatal wards decreased. Also theophylline serum concentrations are not routinely 
monitored at the hospital due to lack of funds. Additionally, corticosteroids, which have 
been shown to improve lung function (Ryan and Finer 1995), are now routinely 
administered during labour. Moreover, the trend is to supplement oxygen using nasal 
prongs and prescribe the minimum of drugs. The data set was also not large enough to 
allow splitting into an index and a test set. 
4.2 CONCLUSION 
Clearance of theophylline in the premature neonate in the fIrst few days after birth is low 
resulting in long half-lives. Small peak-to-trough fluctuations would be expected, even 
on once daily dosing. The estimated values of CL and V correlate better with those 
obtained in traditional studies with neonates of comparable postconceptual ages than 
with the results of the population studies that had a larger range of postconceptual ages. 
The study confIrms the high inter-individual variability in theophylline pharmacokinetics 
in the premature neonate, which is only partly explained by the contribution of inter-
occasion variability. This makes it diffIcult to predict concentrations with the same 
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degree of accuracy as in other populations. The inter-occasion variability in CL of 34% 
is an indication of the variability in an individual that cannot be improved by therapeutic 
drug monitoring. The dramatic physiological changes in the neonate during the 
immediate time after birth, contribute to the higher variability recorded. Other 
confounding factors are the diuretic effect and the possibility of theophylline 
reabsorption, as well as the changing clinical condition of the premature neonate. 
Therefore, serum concentration measurements should be used to determine the safety of 
administering additional loading doses of theophylline in the infant who fails to respond 
to initial therapy. 
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SECTIONB 
THE EFFICACY OF THEOPHYLLINE IN APNOEA AND 
HYPOXAEMIA 
SECTION B: CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
"Neonatal apnoea represents the most common and probably most important disorder in 
the control of breathing in the newborn infant" (Aranda et aI1992). This statement aptly 
underlines the findings of the earlier research of Henderson-Smart (1981) who 
established that apnoea incidents of 20 seconds or longer occurred in 78% of infants born 
at 26 to 27 weeks gestation, 75% at 28 to 29 weeks and 54% at 30 to 31 weeks. 
The most important physiological effects of apnoea are a deficiency of oxygen and the 
development of bradycardia. It has been suggested that a lack of oxygen might have 
J 
severe long-term consequences and that it might be associated with poor 
neurodevelopment (Low et al 1993, Cheung et al 1996). Thus effective control of 
apnoea and of prolonged hypoxaemia in the neonate seems essential (Poets et al 1994, 
Poets et aI1995). 
Pharmacological management of apnoea consists primarily of the administration of 
methylxanthines, theophylline or caffeine. Another respiratory stimulant, doxapram, is 
occasionally used as a second-line agent. Although theophylline is the drug that is most 
widely used, some researchers have questioned its efficacy. Moreover, the 
pharmacokinetic/pharmacodynamic relationship for theophylline in this population group 
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has been little studied. Therefore, this study investigated the efficacy and the 
concentration-effect relationship of theophylline in premature neonates with apnoea. 
1.1 APNOEA AND RELATED CONDITIONS 
1.1.1 Definitions of apnoea 
Apnoea is defined as the intermittent absence of breathing, with hypoxaemia and 
bradycardia as major adverse effects (Aranda et aI1992). The definition of apnoea and 
other related and relevant pathophysiological conditions of the neonate have, over the 
years, been subjected to a wide range of interpretations and different researchers have 
used different definitions in their investigations. This may account for some of the 
divergent findings with respect to drug efficacy. Only in 1985 did the American 
Academy of Pediatrics Task Force on Prolonged Infantile Apnea, define pathologic 
apnoea as "a cessation of breathing for at least 20 seconds, or as a briefer episode of 
apnoea associated with bradycardia, cyanosis, or pallor" (American Academy of 
Pediatrics 1985). Two years later the American Academy of Pediatrics published a 
statement on the various definitions of infantile apnoea (Consensus Statement 1987). 
The definitions that have been used in this study are given in Table B.l.l in summarised 
fonn. 
1.1.2 Aetiology of apnoea 
The aetiology of apnoea is unclear. A variety of factors and pathophysiological 
disorders are associated with the genesis of neonatal apnoea. Examples of such factors 











Clinical definitions used in this study 
Definition Reference 
A respiratory pause is abnormal if it is Consensus 
prolonged (2::20 seconds), or associated with Statement, 
cyanosis, abrupt, marked pallor or hypotonia, 1987 
or bradycardia. 
A cessation of respiratory airflow. The Consensus 
respiratory pause may be central or Statement, 
diaphragmatic (i.e., no respiratory effort), 1987 
obstructive (usually due to upper airway 
obstruction), or mixed. Short central apnoea 
«15 seconds) can be normal at all ages. 
A breathing pattern in which there are three 
or more respiratory pauses of >3 seconds 
duration with <20 seconds of respiration 
between pauses. Periodic breathing can be a 
normal event. 
This is periodic breathing with pathologic 
apnoea in a premature infant. Apnoea of 
prematurity usually ceases by 37 weeks 
gestation (menstrual dating) but occasionally 
persists for several weeks past term. 
A fall in peripheral oxygen saturation 2::10 % 
from the previous baseline. 
In premature neonates bradycardia is usually 















The detection of cyanosis (or pallor) in Samuels 
premature neonates relies on the subjective and 
assessment of the change in skin colour of Southall, 
the infant from pink or rosy to pale or pale- 1993 
blue. _ 
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input, airway obstruction, impaired central nervous system metabolism, low respiratory 
muscle function and hyperactive reflexes (Aranda et al 1992). Conditions such as 
infections, necrotising enterocolitis, hyper- or hypothermia, hypoxia, metabolic 
disorders, gastro-oesophageal reflux and the use of certain drugs by the mother, are also 
associated with apnoea (Eichenwald and Stark 1993). Factors associated with the 
development of neonatal apnoea are depicted in Figure B.l.l. 
Hypoxaemia: 
Low lung volume 
Lung pathology 
Anoxia 
Con cardiac failure 
Autonomic instability 
-----. APNOEA 




Depressed medullar centre 
Drugs 





....---- muscle function 






Fig. B.1.1 Factors associated with the development of neonatal apnoea 
(References: Aranda et a11992, Eichenwald and Stark 1993). 
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At the molecular level it is known that the peripheral chemoreceptors playa major role in 
apnoea, as these are the only organs signalling hypoxia (Lahiri et at 1978). Thus failure 
of the satisfactory development of the chemoreceptors could contribute to respiratory 
disorders in the neonate (Lahiri 1994). This failure may reside in any of the steps 
involved in chemoreceptor regulation and response. This could be the initiation of 
oxygen-chemoreception involving respiratory and non-respiratory pigments (Duchen and 
Biscoe 1992, Buerk et al 1997), ion balance including hydrogen ions and calcium ions 
(Lahiri et al 1997), neurotransmitter mechanisms (Marchal et al1992) and transduction 
(Higbee et al1982). 
In premature neonates,speUs of apnoea usually begin during the first two days of life. If 
such spells do not occur in the first week of life, apnoea is unlikely to evolve later unless 
illness develops (Henderson-Smart 1981). Although apnoea attacks may persist after 
~ 
birth, for variable periods of time, they generally cease when the neonate has reached the 
postconceptual age of 37 weeks (Consensus Statement 1987, Eichenwald and Stark 
1993). 
1.1.3 Definition of a hypoxaemic episode 
No consensus regarding the definition of a hypoxaemic episode has yet been reached. 
Arterial oxygen saturation of <80% (lenni et aI1997), or <85% (Bolivar et alI995), or 
:S;80% for ~4 seconds (Poets et a11993, Richard et aI1993), as well as a 5% (Finer et al 
1992) or a 20% (Bucher and Duc 1988) fall in peripheral oxygen saturation from 
baseline, have been used. The limitations of the available equipment (giving a printout 
of the average value of the peripheral oxygen saturation over the previous ten seconds) 
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influenced the definition of a hypoxaemic episode as a fall in peripheral oxygen 
saturation of ~1O% from baseline, used in this study. The value of ;:::10% fall in 
peripheral oxygen saturation is in accordance with the alann limits for apnoea monitors 
suggested by Upton et al (1991). 
1.1.4 Aetiology of bypoxaemia 
Very little infonnation on the aetiology of hypoxaemic episodes is available. In the 
premature neonate hypoxaemic episodes may occur associated with apnoea, or with 
bradycardia, or with apnoea and bradycardia, or not associated with either apnoea or 
bradycardia. The last-mentioned is referred to as an isolated hypoxaemic episode. Thus, 
isolated hypoxaemic episodes may occur despite both continued breathing movements 
and continuous airflow (Poets et al 1991). It has been shown that an active exhalation 
that produces a decrease in end-expiratory lung volume, which is followed by a decrease 
~ 
in tidal flow and volume, precedes episodes of hypoxaemia (Bolivar et al 1995). This 
reduction in lung volume, probably leading to the closure of small airways and the 
development of intra-pulmonary shunts, would explain the rapid development of 
hypoxaemia (Poets et al 1992, Samuels et al 1992, Southall et al 1993, Bolivar et al 
1995). Intrapulmonary shunts is a collective term for all conditions in which 
deoxygenated venous blood passes through the pulmonary circulation into the systemic 
circulation without taking up oxygen. This could be due to ventilation-perfusion 
inequalities, anatomic right-to-Ieft shunting in the lung, or blood flow through 
unventilated areas of the lung, or when gas diffusion is impaired (Poets et al 1992, 
Bolivar et al 1995). Another common cause of hypoxaemia in the neonate is periodic 
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breathing, which leads to low peripheral oxygen concentrations, causmg alveolar 
hypoxia (Hunt et aI1996). 
Many other factors, such as respiratory distress syndrome, local or central autonomic 
reflexes and others, are implicated in intrapulmonary shunting (Poets et al 1993). Only 
some of these causes can be prevented by clinical intervention or treated 
pharmacologically with drugs. See Figure B.l.2 for an illustration of the relationship 





...--Upper airway obstruction 
Airway hypoxia 
~ + 
~ Atelectasis --.. Ventilation-perfusion inequality 
1 ~ IntrapJmonary shunt 
shunts 
Anatomic ~ 1 
Hypoxaemic episode 
Fig. B 1.2. The relationship between apnoea and intrapulmonary shunts that may lead to 
hypoxaemic episodes (references: Poets et a11992, Samuels et al1992, 
Southall et a11993, Bolivar et aI1995). 
86 
l.1.5. Physiological and other consequences of apnoea and hypoxaemia 
The ventilatory consequences of apnoea are hypoxia and hypercarbia. These may 
produce derangement of central respiratory control, increased broncho-motor tone, 
depressed cardiac function and disturbed acid-base balance, which may all adversely 
affect the neonate (Miller and Martin 1992). 
Finer et al (1992) showed that, regardless of the type of apnoea or treatment, oxygen 
saturation values decrease with an increase in duration of apnoea. A strong and very 
important relationship exists between apnoea and oxygenation (Samuels et al 1992, 
Southall et aI1993). Normally apnoea monitors detect most pathologic apnoea incidents 
by sounding an alarm after the neonate has stopped breathing for a number of seconds. 
These alarms are usually set at 20 seconds. However, depending on the type of 
equipment used and the availability of nursing staff, isolated hypoxaemic episodes may 
go unnoticed (IHchard et a11993, Poets et a11995, Poets et a11995a) and cause hypoxic 
injuries such as those described above by Miller and Martin (1992). 
Additionally, hypoxaemia may have potentially harmful effects on early development 
(Poets et al1993a, Poets et al 1994) and may even be associated with an increased risk 
of sudden death in premature neonates (Samuels et al 1992, Poets et al 1993a). 
Moderate grade hypoxaemia may also harm the function of the neonatal kidney that may 
affect the neonate adversely (Talosi et al 1996). The growing concern with hypoxaemia 
and its consequences is highlighted by the fact that some recent researchers tend to 
ignore the actual duration of the apnoea and rather concentrate on the duration and fall in 
oxygen saturation (Upton et al 1991, Bhandari et al 1992). Upton et al (1991) aptly 
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stated that "the degree of hypoxaemia is more important than the cessation of breathing 
per se" . Other researchers who indicated that it would be more appropriate to measure 
oxygen saturation than count apnoea incidents in infants at risk also supported this view 
(Samuels et al 1992, Poets and Southal1 ] 994). 
The reflex effects of apnoea include changes in heart rate, blood pressure and pulse 
pressure. In the neonate, bradycardia usually occurs during apnoea as a response to 
decreasing oxygen saturation levels (Upton et aI1992). Bradycardia may result in a fall 
of anterior cerebral artery blood flow velocity that may lead to the development of 
periventricular leucomalacia (Perlman and Volpe 1985, Livera et al 1991). A close 
relationship between bradycardia, apnoeic pauses and oxygen desaturations has been 
demonstrated. For instance, 83% of bradycardia incidents are associated with apnoeic 
pauses and 86% of bradycardia incidents with oxygen de saturations (Poets et al 1993). 
~ 
Usually most bradycardia incidents commence after onset of fall in oxygen saturation 
(Poets et aI1993). 
1.1.6 Determination of apnoea and hypoxaemic episodes in the premature neonate 
The development since the 1970' s of new techniques and tools to investigate breathing, 
contributed greatly to an understanding of the effects of apnoea on premature neonates. 
At first devices to pick up body movements associated with respiration were developed. 
These included apnoea mattresses, pressure sensitive devices that lie underneath the 
baby, pressure sensitive capsules attached to the abdominal skin and devices that 
measure change in the abdominal circumference. These devices had many disadvantages 
such as false positive alarms if the sensitivity is set too low, or failure to alarm if the 
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sensitivity is set too high and inability to distinguish between breathing and other body 
movements (Milner 1996). 
With the development of electrodes to monitor transcutaneous oxygen pressure, 
researchers became aware of the previously unnoticed hypoxaemic episodes associated 
and not associated with apnoea. Development of the pulse oximeter refined the 
measurement of the oxygen concentration in the blood. These values could be recorded 
with electrodes attached to the finger or earlobe of an adult, or foot of a premature 
neonate. The continuous recording of plethysmographic pulse waveforms, peripheral 
oxygen saturation and breathing movements followed. This, in turn, led to the study of 
isolated hypoxaemic episodes in relation to apnoea (Poets et al 1991, Stebbens et at 
1991), periodic breathing (Poets and Southall 1991), and bradycardia in the neonate 
(Poets et aI1993). 
A number of monitors to record peripheral oxygen saturation, nasal airflow and heart rate 
in the neonate, are available. Examples are the Dinamap Oxytrack (Johnson and 
Johnson), the Spegas Neoset Neonatal Capnograph (Brittan Healthcare) and the Criticare 
Poet Te plus (Marcus Medical). These monitors differ in ease of operation, initial cost, 
reproducibility of recorded parameters and sensitivity. The Datex Oscar II capnograph 
was regarded as the most suitable for the requirements of the study as it gave a visual 
display of the essential parameters, a continuous plethysmograph, and it could also 
accommodate a data acquisition system. The following measurements could be 
recorded: peripheral oxygen saturation, breathing rate, pulse rate, carbon dioxide and 
nitrous oxide concentrations. 
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1.2 DRUG TREATMENT OF APNOEA AND HYPOXAEMIA 
Only a few drugs are available for the treatment of apnoea of prematurity. They include 
the methylxanthines, theophylline and caffeine and the respiratory stimulant, doxapram 
(Aranda et al 1992). Other drugs being investigated are almitrine (Magny et al 1987) 
and the anti-epileptic, primidone (Miller et al 1992). The pharmacology of theophylline, 
which was used in this study, will be discussed in detail after a brief review of some of 
the other drugs mentioned above. 
1.2.1 Doxapram 
Doxapram, structurally unrelated to the methylxanthines, is an analeptic agent usually 
used as a respiratory stimulant in adults. The first study of doxapram in the treatment of 
apnoea of prematurity, was published in 1978 (Burnar~ et al). A number of studies 
followed, confirming the effectiveness of doxapram (Alpan et al1984, Eyal et al 1985, 
Barrington et al 1986, Barrington et al 1987). Eyal et al (1985), in a double blind 
controlled study of 26 premature neonates, concluded that doxapram is as effective as 
aminophylline in abolishing apnoea spells. Effectiveness was judged by a reduction in 
frequency of apnoea during treatment. A full response was classified as complete 
cessation of apnoea, a partial response as a reduction of apnoea spells by more than 50% 
from pre-treatment frequency and failure as a reduction of less than 50% in apnoea 
frequency. In the doxapram group (n = 9) 66% of the neonates gave a full response and 
22% failed. In the theophylline treated group (n = 7), 57% of the neonates gave a full 
response and 14% failed. The serum theophylline concentration was 16.1 ± 2.9 mgIL. 
90 
Barrington et al (1987), in a dose-finding study, used incremental doses of doxapram in a 
small group of premature neonates with idiopathic apnoea of prematurity refractory to 
therapeutic levels of theophylline. They defined a response as a ~50% reduction in 
apnoea frequency. The optimum serum concentration for doxapram seemed to be about 
2.9 mg/L (Barrington et at 1987). A loading dose of 2.5 to 3 mglkg administered over 
15 to 30 minutes followed by a continuous infusion of 1 mg/kg/h, with careful 
surveillance of blood pressure changes, are recommended (AJanda et aI1992). Adverse 
effects such as consistent increases in blood pressure as well as central nervous system 
irritability are frequent at serum concentrations above 5 mgIL (Barrington et at 1987). 
Another problem associated with doxapram use, is that the commercial preparations 
often contain benzyl-alcohol, a substance that is associated with the gasping syndrome in 
neonates (Jordan et alI986). 
Currently doxapram is used in cases where methylxanthines are not effective and before 
more aggressive fonus of treatment such as mechanical ventilation are considered. It is 
also useful in weaning infants from ventilation, particularly if used in addition to 
theophylline (Samuels et a11993). 
1.2.2 Investigational drugs 
1.2.2.1 Primidone 
Recently it was shown that primidone is effective in neonates with apnoea resistant to 
theophylline treatment (Miller et al 1993). The dose used was 10 to 15 mg/kg per day 
and positive results were noticed 24 to 72 hours later. Although no toxic reactions were 
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observed, the authors warned against other possible effects related to the complex 
pharmacological characteristics of primidone. 
1.2.2.2 J\lnoitrine 
Almitrine bismesylate is a triazine derivative that has a munber of effects on respiration 
such as improvement of the hypoxic ventilatory response (Maxwell et at 1985) and 
ventilation-perfusion-matching in adults (Castaing et al 1986). J\lnoitrine was shown to 
improve oxygenation in a small group of infants with bronchopulmonary dysplasia, but the 
response was highly variable, as were the serum concentrations of the drug (Magny et at 
1987). The drug is being investigated for a possible role in bronchopulmonary dysplasia 
but is not yet available commercially. 
1.2.3 The methylxanthines 
The methylxanthines, theophylline, caffeine and theobromine, are naturally occurring 
alkaloids but only the first two are used in therapeutics. Theophylline is 1,3-
dimethyl xanthine and caffeine, 1,3,7-trimethylxanthine. The commonly used parenteral 
preparation of theophylline, aminophylline, is a water-soluble salt containing 
approximately 80% theophylline. The ability of caffeine to stimulate respiration has 
been known for a long time, but the potential role of theophylline to improve breathing 
in adult patients was first described in 1927 (cited by Aranda et at 1992). The role of 
these two drugs to control apnoea in the neonate was only recognised in the late 1970's 
and is discussed in more detail below. 
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1.2.3.1 The phannacological mechanism of action of the methyixanthines 
Several mechanisms have been proposed to account for the range of pharmacological 
effects of the methylxanthines. These include antagonism of adenosine, inhibition of 
phosphodiesterase (thereby increasing intra-cellular cyclic AMP), direct and indirect effects 
on intra-cellular calcium concentrations and interference with the intra-cellular translocation 
of calcium (RaIl 1996). As theophylline was used in this investigation, its mode of action 
will be discussed in more detail. 
Theophylline, at clinically relevant drug concentrations, may non-selectively relax smooth 
muscle in pulmonary arteries and airways by inhibition of phosphodiesterase isoenzymes, 
types III and IV, and thus increase the concentration of cyclic adenosine monophosphate 
(cAMP) (Schudt et a11995, Banner and Page 1996). Apparently this effect is greater in the 
airways of asthmatics than in normal airways. This theory could explain why some of the 
~ 
early in vitro studies performed on non-asthmatic smooth muscle showed only weak 
phosphodiesterase activity (Polson et al 1978). It is not known whether relaxation of 
bronchial smooth muscle plays a role in the control of apnoea in the neonate, but it has been 
shown that theophylline can relax constricted bronchial smooth muscle of foetal lambs 
(Mehta et al 1991). 
The recent [mdings of the anti-inflammatory properties of theophylline have resulted in a 
renewed interest in theophylline as an anti-inflammatory medication rather than as a 
bronchodilator (Vassallo and Lipsky 1998). Theophylline may act as an anti-inflammatory 
agent by numerous mechanisms of which the influence on cytokine production (Finnerty et 
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al 1996) and the late asthmatic response to antigen (Chung 1996) seem to be very 
important. It is not known whether similar effects occur in the neonate. 
Theophylline has been shown to cause a statistically significant increase in adrenaline 
concentrations in healthy non-asthmatic subjects (Krzanowski and Polson 1988). The 
increase in cAMP production from adrenaline release and the decrease in cAMP breakdown 
from phoshodiesterase inhibition might result in a synergistic effect (Vassallo and Lipsky 
1998). It is well known that cAMP acts as a second-messenger regulating many aspects of 
cellular function by activation of various protein kinases. This includes increased activity 
of voltage-activated calcium channels in heart muscle cells thereby increasing the force of 
contraction of the heart and improving circulation and oxygenation. 
Theophylline may also improve the strength of muscle contractility, such as those of the 
diaphragm of neonates (Martin and Miller 1986). It is thought that theophylline acts 
through alterations in the calcium environment in the cells. The increase in muscle 
contractility is inhibited by calcium channel blockers and by removal of extracellular 
. calcium, an indication that theophylline probably produces this effect through alterations 
of transmembrane calcium flux (Kolbeck and Speir 1989). Another possible effect of 
theophylline on calcium homeostasis is an interference with calcium release from the 
sarcoplasmic reticulum (Gayan-Ramirez et aI1995). 
Theophylline blocks adenosine receptors (Lagercrantz et al 1984). Adenosine is a neuro-
regulating substance released during hypoxaemia. It acts through A1- and A2-receptors, 
coupled respectively to inhibition and stimulation of adenylate cyclase (Ongini and 
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Fredholm 1996, Monin 1997). Theophylline's non-specific adenosine antagonism may be 
responsible for the increase in ventilation seen during hypoxia in adults and the decrease in 
diaphragmatic muscle fatigue (Barnes and Pauwels 1994), as well as the significant 
improvement in foetal breathing movements (Bissonnette et aI1990). Theophylline's effect 
on the AI-receptors may be responsible for some of the drug's adverse effects such as the 
increase in psychomotor activity and heart rate (Barnes and Pauwels 1994). 
However, the precise mechanism of action of theophylline in neonatal apnoea is still 
unknown. Gerhardt et al (1979) observed that theophylline decreased the incidence of 
apnoea, normalised minute ventilation and carbon dioxide pressure secondary to a 33% 
increase in oesophageal pressure change per breath. Theophylline administration shifted 
the position of the carbon dioxide curve to the left, but did not change the slope of the 
oxygen curve. The oxygen consumption of the neonates increased by 20% from the basal 
value (Gerhardt Jet a11979). It was then postulated that apnoea in the neonate is related to 
an immature respiratory centre characterised by a decreased output. This was supported 
when it was shown that the ventral brainstem chemosensing function increases with post-
conceptual age, and that a decreased sensitivity to carbon dioxide is found in premature, 
compared to full-term infants (Pan et al 1995). The role of theophylline is most probably to 
lower the threshold of the central chemoreceptors to carbon dioxide and thereby increase 
the output of the respiratory centre (Lahiri 1994). This suggested mechanism was later 
confirmed when it was shown that theophylline may enhance conduction along central 
auditory pathways and stimulate the regulatory effect on the respiratory centre of the brain 
stem (Chen et aI1994). Data from animal models suggest that this effect may be mediated 
through adenosine antagonism (Bissonnette et a11990, Bissonnette et aI1991). Apnoea is 
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often triggered by hypoxaemia and it is possible that adenosine which is released during 
hypoxia, mediates this effect. 
1.2.3.2 The pharmacological effects of met hylx ant hines on neonatal apnoea 
Kuzemko and Paala (1973) first described the use of aminophylline in suppository form 
to treat apnoea in a group of ten neonates. Apnoea was recorded using mattresses with 
the apnoea alarm set at 30 seconds as well as nurses' recording of observed apnoea 
spells. Forty percent of the patients had no apnoea after theophylline treatment and 
another forty percent had 'very occasional' apnoea. One of the patients died due to 
hyaline membrane disease and pulmonary haemorrhage. These results prompted further 
studies of the potential role of theophylline in neonatal apnoea. 
Fortunately recording of apnoea improved by using cardio-respiratory monitors and not 
only mattresses~ with apnoea alarms. The results of these early studies showed varying 
decreases in apnoea incidents after theophylline. Unfortunately comparison of results is 
difficult as no single definition of apnoea was used. Using a group of neonates (n = 7) 
with only apnoea of prematurity, Myers et at (1980) found an overall reduction of 62% 
in apnoea incidents (apnoea was defined as > 15 seconds plus bradycardia). The serum 
theophylline concentration ranged between 2.8 and 3.9 mgIL. In a similar study (n = 11) 
an 81 % reduction in apnoea incidents was recorded with serum theophylline 
concentration ranging from 1.5 to 15.3 mg/L (Milsap et al 1980). All the patients 
responded to therapy and one patient had no more apnoea after 48 hours of theophylline 
therapy. Finer et at (1984) recorded a 72% reduction of apnoea > 10 seconds and only a 
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59% reduction in apnoea <10 seconds, in patients after seven days of theophylline 
treatment. No mention was made of how many patients did not respond to treatment. 
The question arose whether theophylline would be effective in neonates with apnoea plus 
concomitant disorders that are common during the neonatal period. Results in a small 
group of patients (n = 10) with apnoea of prematurity as well as intra-ventricular 
haemorrhage (grade not specified) and/or hyaline membrane disease, found that 20% of 
the patients did not respond to therapy (Roberts et al 1982). The theophylline 
concentration was 7 to 13 mgIL. An overall reduction of only 58% in apnoea incidents 
was recorded. Apnoea was defined as cessation of breathing for 220 seconds or less if 
accompanied by bradycardia. Considerable patient variability was found and no 
correlation could be drawn between degree of response to theophylline, gestational age, 
postconceptual age, clinical diagnosis, or theophylline concentrations. 
Non-responders to theophylline therapy were also observed in a group of neonates with 
apnoea of prematurity but no other disorders (Shannon et al1975). In this study one of 
the eight patients with apnoea, 10 to 19 seconds in duration, showed an increase in 
apnoea incidents; the serum theophylline concentration ranged from 6.6 to 32 mglL. In a 
small dose-effect study by Muttitt et al (1988), twenty-three percent of the patients (n = 
22) were considered non-responders. A non-responder was a patient who had 20.33 
significant apnoea per hour. Five patients did not respond even at the highest 
theophylline concentration (215.3 mgIL). These patients eventually required doxapram 
and/or continuous positive airway pressure (CP AP). Fourteen percent of the patients 
responded at a serum theophylline concentration of 4.2 mg/L, a further 14% at 8.5 mg/L, 
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then a further 45% at 12.7 mgIL and the remaining 4.5%, at 15.3 mglL. These patients 
had apnoea of prematurity and no other disorders. Apnoea was defined as ~20 seconds or 
less if accompanied by bradycardia and a 10% decrease in peripheral oxygen saturation. 
In another study 27% of the patients (n = 60, gestational age 32.7 ± 0.4 weeks), after 
seven days of theophylline therapy, did not respond adequately. The author calculated 
the density of apnoea namely the percentage time spent in apnoea relative to the total 
monitoring time. An inadequate response was a density ~3. These patients were then 
switched to caffeine therapy (Harrison 1992). Of these patients 12% did not respond to 
caffeine either. Serum theophylline concentrations were not given 
Jones (1982) conducted a trial to compare the efficacy of theophylline with CPAP in the 
treatment of apnoea of prematurity. Although theophylline was found to be more 
effective than CP AP the response to both modes of treatment was 'disappointing'. Five 
of the 18 patients given theophylline needed intennittent positive pressure ventilation for 
apnoea compared with 12 of the 14 patients given CPAP, suggesting that theophylline 
treatment was better. 
As it is often considered unethical to have a control group in a population at risk such as 
the premature neonate, only two studies to date used a control group to assess the 
efficacy of theophylline. In a study by Sims et al (1985) a definition of apnoea ~20 
seconds was used. On the first day a significant decrease in apnoea incidents was 
observed in both the control and the treated groups. Within one week 67% of the treated 
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and 33% of the control group, had no apnoea and this was considered as a significant 
difference. However, during the following week only another 17% of the treated but 
33% of the control group registered no apnoea. After four weeks 17% of the treated and 
20% of the control group continued to have apnoea. This difference was considered not 
significant and it was concluded that maturity played a significant role in decreasing the 
frequency of apnoea. Serum theophylline concentrations were between 9 and 13 mgIL. 
A control group was also used by Merchant et al (1992) who administered theophylline 
prophylactically with the aim of preventing apnoea of prematurity. In the treated group 
16% of the patients developed apnoea (defined as > 15 seconds) with theophylline 
concentrations ranging from 5 to 40 mg/L. In the control group, 32% of the patients 
developed apnoea. See Table B.l.2 for a summary of studies oftheophyUine's effect on 
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Gestationa l Postnatal age 
age (weeks) (days) mean or 
mean or range range 
(SD) (SO) 
26 - 34 1- 6 
Not given 7 
30.2 I - 21 
27 - 34 2 - 10 
28 - 34 1-21 
27 - 34 1 - 34 
25 - 32 1 -28 
A SUMMARY OF THE EFFICACY OF THEOPHYLLINE IN NEONATAL APNOEA 
Author's dermition Theophylline dose Serum drug level Outcome of patients 
of apnoea, and route of administration meanandlor 
(range), and (SD) 
mWL 
>30 swith 5mg Not measured. I died due to HMD and pulmonary haemorrhage. 
bradycardia and Rectally 6 hrly 4 had occasional apnoea spells and 4 had none after 
cyanosis theophylline treatment 
Pathological: >20 s 4 mg/kg 14.7 One patient had an increase in apnoea. Apnoea decreased 
Short apnoea 1O-19s NG-tube 6 h1'ly (6.6 - 32) in all the other patients. 
>20 or < 20 with 2mglkg 10.2 Apnoea decreased by 85%. All babies responded. 
bradycardia IV 6 hrly (0.7) No improvement in lung function. 
«100 bpm) 20% increased tidal volume. 
Increased oxygen consumption and alveolar ventilation 
2': IS s Group 1: 8 mglkg 10 - 16 Apnoc<I decreased in all patients. 
12 hrly for 2 doses Total duration ofhypoxaemia decreased. 
Group 2: 8 mglkg 12 hrly No change in duration of apnoea episodes. 
for 2 doses then 4 mg/kg Heart and respiratory rate more regular. 
for 8 doses. Rectal dosing 
I. >15 sanda LD: 2.5 mglkg 2.8 - 3.9 After 1-2 days: 62 ± 9% reduction in incidenceslhour. i 
HR<IOObpm MD:2 mglkgld All neonates responded positively. 
! 2. Also incidences Orally 
>5 s 
I. >15 sanda LD: 2.5 mglkg 3.9 After 1-2 days: 81.4% reduction in incidenceslhour. 
HR <100 bpm. MD:2 mg/kgld (0.2) All neonates responded positively. 
2. Also incidences Orally 
>5 s 
were counted 
2':10 s with Oral choline theophyllinate 2.5 Not recorded 5 of 18 (28%) theophylline treated babies needed 
bradycardia < 100 to 10.9 mglkg or IV 5.1 to 7.8 intermittent positive pressure ventilation compared to 12 
bpm or cyanosis mglkg of 14 CPAP patients. 
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Table B.l.2 continued 
--
Reference Number, Gestational Postnatal age Author's dermition Theophylline dose Serum drug level Outcome of patients 
condition of age (weeks) (days) mean or of apnoea and route of administration mean andior 
patients mean or range range (range), and (SD) 
(SD) (SD) mg/L 
Roberts et al 10 26 - 34 1-30 z20 s or less if LD 6 mglkg 6.6 c I3 No response in 20% of babies. 
1982 Variety of HR = ~ 100 bpm. .MD:2 mglkg 8 hrly 58% reduction in apnoea incidences . 
disorders Orally Total resolution of apnoea in 20% of babies. 
Finer et al 19 36.1 7 - 11 6 z3s 2.3 mglkg 6 hrly 6 - 19 Significant reduction in number of apnoea; no significant 
1984 Apnoea (5.1) reduction in falls of transcutaneous oxygen pressure, or 
number of bradycardia. 
Brouard et al 16 (8 per group) 30.5 8 - 14 >10 s andHR< 80 Theophylline: Tbeophylline: Day I: Frequency decreased with theophylline from 1.02 
1985 Apnoea (0.4) for 30 s, or < 60 for LD: 4.4 mglkg IV 4.5 - 6.8 to 0.12 and with caffeine from 1.42 to 0.13 
15 s MD: 0.64 - 2 mglkg 8 hrly Caffeine: Day 5: Frequency further reduced by theophylline to 
Apnoea frequency = orally or IV 11.5 - 13 0.06, and by caffeine to 0.07. 
number/IOO minutes Caffeine: 
LD: 10 mglkg IM ..... 
o ..... 
.MD: 2.5 mglkgld orally 
Sims et al 43 31.4 2.5 20 s LD: 6.8 mglkg Week I: 10.0 No response in 17% of treated patients, and 21 % of 
1985 Apnoea (0.5) (0.3) .MD: 1.4 mg/kg 8 hrly or 6 hrly (0.4) control patients. 
IV Week 2: 10.3 Total resolution by day 7: 67% in study group and 36% 
(0.3) in control group. 
Week 3: 11.7 
(0.5) 
Bairam et al 20 30 6.2 >15 s and HR < 80 LD: 6 mglkg Tbeophylline Cardio-respiratory abnormalities lowered by 
1987 Apnoea (1.5) (3.4) bpm. Apnoea .MD: 2 mglkg 12 hrly 6 - 12 theophylline: By day 3: From 0.6 to 0.2 
A double-blind incidences IV By day 7: to 0.3 
study. calculated as a 
Comparison of factor of cardio-
theophylline with respiratory Caffeine : Caffeine Caffeine: By day 3: From 0.7 to 0.4 
caffeine. abnormalities/ 100 LD: 10 mglkg 5 - 15 By day 7: 0.2. 
minutes. .MD: 125 mwkg 12 hrly 
Muttitt et al 22 26 - 32 1 - 16.9 z20 s plus 25% LD: 4 mglkg Level 1: 4.2 No response in 23% of patients. 
1988 Apnoea decrease in HR and IV - all four levels Level 2: 8.5 Responded: At level I: 14%. 
10% decrease in Level 3: 12.7 At level 2: A further 14% responded. 
SpOz. .MD: 4 dosage groups Level 4: 15.3 At level 3: A further 45% responded. 
Incidences counted. I ; 1.5; 2; 2.5 mglkg 8 hrly At level4: The remaining 4. 5% responded. I 





Table B. 1.2 continued 
Reference Number, Gestational Postnatal age Author's dermition Theophylline dose Serum drug level Outcome of patients 
condition of age (weeks) (days) mean or of apnoea and route of administration mean and/or 
patients mean or range range (range), and (SD) 
JSD) (SD) mWL 
Harrison 60 32.7 19 ~ 1 9 s ifHR <,go Density <! 5: Theophylline Theophylline: 
1992 Apnoea (0.4) (J I) bpm for >2 s LD: 5 mglkg If density >5 treatment commenced. No response 
Initially on Shorter: 10-1 9 s MD: 1-1.5 mglkg Caffeine: (density <! 3) in 27% of patients. 
theophylline, if not Calculated densities: 8 hrly IV or orally 15 -41.4 73% responded after day 2. 
sufficiently time spent in apnoea A decrease in density from >5 to 0.4. 
improved, caffeine as a percentage of When density still <! 3: Caffeine: 
was started. total monitoring Caffeine started No response in 12% of above 27%. 
time. LD: 10 mglkg orally 88% of above 27% responded; density = 0.8. 
MD: 2.5 -3.75 mglkg per day 
Merchant et al Group A: 56 28 - 34 I >15 s Group A: 0. 16 - 0.3 mg/kg/b 5 - 40 Group A: 16% developed apnoea despite theophylline 
1992 Theophylline infusion Group B: 32% developed apnoea 
prophylactic. 
Group B: 25 Group B: Control Doxapram started in all patients who developed apnoea . 
in control group. 
Various disorders. 
Scanlon et al 36 <3 1 2 - 12 No airflow plus Group A (n =12): Caffeine Group A: Group A: No response at all in 8% of patients 
1992 Apnoea of stimulation of LD: 12.5 mglkg I3 - 20 50% responded by day I . 
prematurity neooa te and a fall in MD: 3 mglkgfd 92% responded by day 2. 
HR of <! 40 bpm. 
Incidences counted. 
Gr<?up B (0 =12): Caffeine GroupB: Group B: 83% responded by day I. 
LD: 25 mglkg 26 - 40 100% responded by day 2. 
MD: 6 mglkg/d 
Group C(n =12): Theophylline GroupC: Group C: 92% responded by day 1. 
ill: 7.5 mg/kg J3 - 20 100% responded by day 2. 
MD: 3 mg/kg 8 hrly 
Orally 
Abbreviations: RDS = respiratory distress syndrome, HMD = hyaline membrane disease, hrly = hourly, s = seconds, NG = naso-gastric, bpm = beats per minute, LD = 
loading dose, MD = maintenance dose, po = orally, IV = intravenous, 1M = intramuscular, Sp02 = peripheral oxygen saturation, CP AP = continuous positive airway 
pressure, PNA = postnatal age. 
Aranda et al (1977) was the first to document the efficacy of caffeine, the other 
methylxanthine, in neonatal apnoea. Decreased incidents of apnoea, regularisation of 
breathing patterns, and an increase in alveolar ventilation was observed. Caffeine is 
usually given orally or intramuscularly but tmfortunately a neonatal dosage form is not 
commercially available. The oral preparation is usually prepared by the resident 
pharmacist and often administered by naso-gastric tube. A loading dose of 10 mg/kg 
followed by daily maintenance doses of 2.5 mg/kg is recommended to prevent or 
decrease apnoea and increase respiratory drive (Aranda et al 1977, Rooklin 1989). No 
undesirable effects have been reported from this regimen and there appear to be no 
apparent adverse effects on the growth and development of infants given caffeine during 
the neonatal period. The target serum concentration of caffeine is 5 to 20 mg/L (Aranda 
et aI1992). 
A number of clirucal trials comparing the efficacy of theophylline with caffeine followed 
the initial research by Aranda et al (1977). No difference between the effects of 
theophylline and caffeine on neonatal respiratory function could be observed but caffeine 
seemed to have an earlier onset of action (Bairam et a11987, Laubscher et a11998). In a 
small group of neonates a 66% and 43% reduction in cardiorespiratory abnormalities 
(defined as apnoea ~ 15 seconds, episodes of bradycardia <80 bpm, apnoea plus 
bradycardia <100 bpm) due to theophylline and caffeine respectively were found 
(Bairam et al 1987). In the study by Scanlon et al (1992) two different dosing regimens 
of caffeine were compared with a single dosing regimen of theophylline. In the 'usually' 
recommended dosing regimen for caffeine (i.e. a loading dose of 12.5 mg/kg and a 
maintenance dose of 3 mg/kg daily), 4 of the 12 patients responded to therapy within 
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eight hours. A response was regarded as a >50% reduction in number of apnoea over 8 
hours. In the higher caffeine dosing regimen (loading dose of 25 mg/kg and maintenance 
dose of 6 mglkg daily), 10 of the 12 patients (83%) responded within the first eight 
hours. In the theophylline group (loading dose 7.5 mg/kg and maintenance dose of 3 
mg/kg three times daily) 11 of the 12 patients (92%) responded within the first eight 
hours. The serum theophylline concentration was 10.87 ± 3.52 mgIL. No failures were 
recorded in the theophylline and the higher caffeine group after 48 hours, whereas one 
patient in the lower caffeine group did not respond after 48 hours. In this study all 
patients with secondary apnoea were excluded. When Larsen et al (1995) compared 
theophylline and caffeine they found that 29% of the theophylline treated and 41 % of the 
caffeine treated patients needed respiratory therapy some times during their ten-day 
treatment with either drug. The serum theophylline concentrations ranged between 4.8 
and 16.8 mg/L and the caffeine concentrations between 9.6 and 23.8 mgIL. 
Side effects such as tachycardia, arousal and gastrointestinal intolerance are more 
frequently observed with theophylline than with caffeine (Bairam et al1987, Fuglsang et 
al 1989, Harrison 1992, Romagnoli et al 1992, Seamon et al 1992, Larsen et al 1995). 
Caffeine seems to have a wider margin of safety than theophylline as no adverse effects 
are usually observed at concentrations as high as 50 mg/L (Aranda et al1977). 
In practice it seems that caffeine is preferred in the treatment of apnoea of prematurity 
(Aranda et aI1992). However, when bronchodilation is required, such as in patients with 
bronchopulmonary dysplasia, theophylline is still the drug of choice (Aranda et alI992). 
Caffeine is not available in South Africa for neonatal use. 
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1.2.3.3 The pharmacological effects of the methylxanthines on hypoxaemic episodes in 
the neonate 
Few studies mention an effect of the methylxanthines, beneficial or otherwise, on 
hypoxaemic episodes. One study with theophylline found a reduction in total duration of 
hypoxaemia and a significant reduction in the number of apnoea incidents after two days 
of drug administration. The number of apnoea as well as the duration of hypoxaemia 
increased forty-eight hours after withdrawal of the drug (Peabody et aI1978). In another 
study, Finer et al (1984) reported a significant reduction in apnoea incidents after 7 days 
of theophylline therapy (serum concentrations 6 to 19 mgIL), but no significant reduction 
in the number of falls of transcutaneous oxygen pressure greater than 3 mm (11.1 versus 
7.2/h). 
In a placebo-controlled trial, Bucher and Duc (1988) studied the preventative effect of 
caffeine by continuously monitoring transcutaneous oxygen tension and heart rate in 
premature neonates for fifty hours. They defined a hypoxaemic episode as a decrease in 
oxygen tension of 20% from the baseline within 20 seconds. They found no significant 
effect of caffeine on hypoxaemic episodes. 
1.2.3.4 Other pharmacological effects of the methylxanthines in the neonate 
Heart rate effects: In the above and other studies of theophylline and caffeine in neonates 
with apnoea, other pharmacological effects were observed. One of the most pronounced 
effects of these drugs is the ability to decrease the incidence of bradycardia that is often 
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associated with apnoea in the neonate (Shannon et at 1975, Aranda et a11977, Howell et at 
1981, Walther et a11986, Bairam et a11987, Nadkarni et a11988). 
Tachycardia is a common side effect of theophylline. Six of the 18 patients in the study by 
Jones (1982) had tachycardia >180 beats per minute (bpm); the serum theophylline 
concentrations were not mentioned. The effect of theophylline on heart rate seems to be 
inconsistent. Most results show an increase in heart rate, but reports of no significant 
effect on heart rate are also found. Finer et al (1984) studied premature neonates with 
gestational ages of 36.1 ± 5.1 weeks and postnatal ages 1 to 16.4 weeks. Theophylline 
was administered in doses of 2.3 mg/kg every six hours. Serum theophylline 
concentrations of 10.7 mIL (range 6 to 19 mg/L) were obtained. A significant decrease in 
the number of apnoea was found but the number of apnoea with bradycardia and 
bradycardia incidents without apnoea did not change significantly. This finding IS 
supported in another study with comparable premature neonates (Muttitt et a11988). 
Respiratory effects: The ability of theophylline to stimulate the respiratory centre might lead 
to effects such as an increase in tidal volume, minute ventilation and respiratory timing 
(Muttitt et aI1988). The drug may also decrease the carbon dioxide threshold and increase 
carbon dioxide sensitivity in the neonate (Davi et a11978). Gerhardt et al (1979) observed 
a parallel shift in the slope of the carbon dioxide response curve after theophylline 
administration. This is most probably due to an increase in ventilation (expired volume per 
minute) and a decrease in end-tidal carbon dioxide pressure, indicating a stimulating effect 
on the respiratory centre output. Theophylline may also cause respiration to become more 
regular in the neonate (Davi et al 1978, Weintraub et al 1992). In the foetus, it was 
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observed that maternal theophylline administration is associated with an increase in the 
incidence of foetal breathing movements (Ishikawa et aI1996). Theophylline and caffeine 
are also effective in apnoea that occurs during weaning from mechanical ventilation (Harris 
et al 1983, Viscardi et al 1985). The effect could be related to the improvement in 
respiratory muscle function and decreased pulmonary resistance (Blanchard et al 1987). 
Other effects in the neonate are the ability of theophylline to accelerate lung maturation 
(Karotkin et a11976) and to influence surfactant production (Barrett et alI978). 
1.3 OBJECTIVES 
As theophylline has been reported to have variable effects in the premature neonate with 
apnoea, and as its effect on hypoxaemic episodes is not at all clear, the objectives of 
Section B of this study were: 
Firstly, to assess~the response of premature neonates with apnoea to theophylline and to 
determine the effect of theophylline on hypoxaemic episodes; if indeed non-responders 
were identified, then predictors of non-response were to be detennined; thirdly, the 
concentration of theophylline producing a response or toxicity was to be investigated. 
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SECTION B: CHAPTER 2 
MATERIALS AND METHODS 
2.1 THE PATIENTS 
2.1.1 Ethics approval and consent 
The study was approved by the Ethics Committee of the Faculty of Medicine, University 
of Natal and was conducted in the Nursery of King Edward VIII Hospital. Informed 
written consent was obtained for each patient entered into the study. (See Appendix A.I 
for ethics approval and Appendix A.2 for the consent form). 
2.1.2 Inclusion and exclusion criteria 
Any prematureJ neonate under two days old, who was not recelvmg mechanical 
ventilation or continuous positive airway pressure support, and for whom theophylline 
was prescribed, was eligible for the study. The neonates were studied irrespective of 
concomitant diagnosis such as respiratory distress syndrome (RDS). Exclusion criteria 
were congenital malformations, intra-ventricular haemorrhage of grade III or greater. 
Intra-ventricular haemorrhage was diagnosed and classified by the attending paediatrician 
and verified after an ultrasound scan. 
Before a patient was entered into the study, all identifiable causes of apnoea such as 
hypo-or hyperglycaemia, and hypothermia were addressed and corrected. Thus all the 
patients suffered from apnoea of prematurity and 96% had RDS. 
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2.1.3 Demographic and clinical data 
The demographic and clinical data collected was similar to that of Section A. A daily 
record was kept of weight, development of neonatal jaundice or sepsis, presence of hypo-
or hyperglycaemia, full blood count, values of urea and electrolytes, other drugs 
prescribed and all clinical interventions. The blood pressure and mean arterial pressure 
were recorded at regular intervals using a DINAMAPTM PLUS Vital Signs Monitor.a All 
data were captured on specially designed data sheets (see Appendix A.9 for an example 
of the data collection sheet). 
2.2 DRUG ADMINISTRATION AND SERUM THEOPHYLLINE 
CONCENTRATION MEASUREMENTS 
2.2.1 Theophylline administration 
Aminophyllineb was administered through an IV -line and flushed in with 2 ml of normal 
saline in over two minutes. The loading doses varied from 4 to 7.7 mg/kg. Maintenance 
doses ranged from 1.4 to 6 mg/kg per day and were given in two to four divided doses. 
All doses were detennined by the physician in charge and not by any requirements of the 
study. 
2.2.2 Sample collection for serum drug concentration measurements 
Accurately timed blood samples were collected approximately one hour after the loading 
dose. Thereafter, a sample was obtained each day if possible in the morning during the 
pre-dose monitoring period. The samples were centrifuged immediately and the serum 
a Critikon, Inc 4110 George Rd Tampa, Florida 33634. 
b Sabax Aminophylline 250 mg/IOmI, Adcock Ingram. Sabax Rd, Isando, South Africa. 
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kept frozen at _700 C until analysis. Total serum theophylline concentrations were 
measured by Emit Assay. C The coefficient of variation of the assay was approximately 
6% for both between (7.5 mgIL) and within-run (10 mgIL) measurements. 
2.3 RECORDING AND ANALYSIS OF CLINICAL EFFECTS 
2.3.1 Recording of clinical effects 
The neonates were monitored using a Datex Oscar II SC-123 Multigas Monitor 
(capnograph) and Pulse Oximeterd linked to a Datex Data Acquisition system. This is a 
combined airway gas monitor and pulse oximeter. It measured inspired and expired 
concentrations of carbon dioxide, nitrous oxide, saturation percent of haemoglobin, and 
respiratory and pulse rates. The monitor continuously pumped a small sample of the 
airway gas for analysis. 
The accuracy of the peripheral oxygen saturation (Sp02) measurement of the Datex 
Oscar II was % Sp02 ± 1 standard deviation (SD), range: 100 to 80% ± 2 digits. 
Resolution was 1 digit (= 1 %) and the measuring range 0 to 100%. The accuracy of the 
pulse rate measurement was ± 1 %, ± 1 beat per minute and the range 30 to 250 beats per 
minute. The respiratory rate range was 4 to 60 breaths per minute with a detection of 1 % 
(7.6 mm Hg) variation in carbon dioxide. 
: Syva ~ompany, P.O. Box 10058,~alo Alto, California 94303 . 
Datex Interface cable from the Senal and Analog connector for data recording with a computer Chicony 
386, programmed to read the serial data output. ' 
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To record the peripheral oxygen saturation, the neonatal pulse oximeter electrodes were 
securely attached to the foot of the neonate and covered with a black sock to eliminate 
ambient light and possible interference with the signal. A neonatal sampling line taped 
in front of the nostrils, monitored airflow and respiratory rate. To obtain maximum 
sensitivity of airflow, a length of 150 cm of sampling line was selected as the most 
appropriate. The monitor drew a continuous gas sample from the sampling line for the 
measurement of carbon dioxide concentration. The respiratory rate was taken as the 
frequency of peak carbon dioxide measurements per minute. The values from the pulse 
oximeter were validated with the oxygen saturation of an arterial blood sample whenever 
such a sample was drawn for clinical purposes. The apnoea alarm setting was twenty 
seconds. 
The neonates were monitored for as long as possible (usually 2 to 4 hours) before the 
loading dose of theophylline was given. These pre-dose recordings formed the baseline 
for analysis. After the loading dose, if possible, the neonates were again monitored for 2 
to 4 hours and this period was termed day 1. The neonates were then monitored before 
the early morning maintenance dose of theophylline on the next two days when possible 
(day 2 and day 3). Monitoring of the neonates after the loading dose de.pended upon the 
clinical condition of the neonate. 
All neonates were positioned to prevent neck flexion (Thach and Stark 1979). Oral 
secretions were removed whenever present (Ruggins and Milner 1991). All neonates 
were kept in the same p~sition throughout the monitoring period, usually in the supine 
position. Handling and disturbance of the babies were kept to a minimum (Long et at 
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1980). If any neonate required oxygen during the monitoring period, then this supply 
was kept constant while monitoring. As a thermoregulated isolette was not always 
available, some of the neonates were monitored in an open cot. Therefore, the neonate's 
body temperature was measured in the morning before monitoring started and if 
necessary measures were taken to normalise the body temperature. As bolus feeding is 
known to cause apnoea, monitoring did not occur during or after a feed. 
The following information was stored in a time ordered fashion on the computer by the 
Datex programme: 
Pulse rate per minute 
Volume percentage of inspired and expired carbon dioxide 
Respiratory rate per minute 
Percentage peripheral oxygen saturation, and 
Clock time in ten second intervals. 
The monitor gave a beat to beat display of the above measures, a phlethysmographic 
pulse waveform, and a respiratory waveform in a breath-by-breath display. The 
instrument was calibrated each day before monitoring started. Monitoring was carried 
out at the same time each day to eliminate possible chronobiological influences. 
In 1991, Ruggins pointed out the inadequacies of apnoea monitors, especially the 
problems of attachment, movement artefact, and the failure to detect obstructive apnoea. 
Therefore, a strict continuous manual record was kept of all incidents of cessation of 
breathing (shown on the video screen of the capnograph), any movements (Abu-Osba et 
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al 1982), mouth breathing, sneezes, yawmng and any other interruptions and 
interventions. These were later used to confirm the computer printout. All apnoea 
events 20 seconds or longer were signalled by the monitoring system. It was possible to 
identify the pathologic apnoea events from the printout, and to confirm them using the 
manual recordings and the alann. The printout only gave a ten second resolution, that is 
an average of the recordings per ten seconds. Thus, it was impossible to identify, from 
the printouts, the absolute length of the apnoea event, the precise change in oxygen 
saturation, pulse rate, and respiratory rate. The disadvantages of this system were 
overcome by using the manual recording as described above. Each patient was also used 
as his/her own control. 
2.3.2 Processing of recorded clinical effects 
A data file containing all the relevant information was constructed (see Appendix B.1 for 
an example of the data collection sheet for clinical effects). 
From the printout and the manual recording the following clinical effects were calculated 
for each monitoring period and then averaged per hour, where appropriate: 
The total number of apnoea ~5 seconds 
The number of pathologic apnoea incidents (cessation of nasal airflow ~o 
seconds) 
The number of pathologic apnoea associated with a hypoxaemic episode and a 
fall in pulse rate, or a fall in pulse rate only, or a hypoxaemic episode onlv 
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The number of times the Sp02 fell 210% for > 1 0 seconds from the average over 
the previous uneventful minute (isolated hypoxaemic episode) 
The number of hypoxaemic episodes associated with movement, or pathologic 
apnoea, or a pathologic apnoea with a 220% fall in pulse rate 
"Associated with" was defined as an event that occurred within 30 seconds of the 
onset of the hypoxaemic episode 
The average Sp02 
The number of times the pulse rate fell below 100 beats per minute (incidents of 
bradycardia) 
The average pulse rate 
Apnoea densities, for pathological and total apnoea, were calculated as the 
percentage of the time spent in apnoea compared with total monitoring time. 
2.3.3 Data analysis 
a) Statistical analysis 
The mean, median and standard error values of all the recorded clinical effects on the 
data file as described above were calculated and tabulated. The Wilcoxon Sign Rank 
Test with a Bonferroni correction was used to compare the differences from baseline to 
days 1, 2, and 3 of all the recorded clinical effects. A probability value ~O. 017 indicated 
significance. All changes were noted with the serum theophylline concentration. 
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b) Exploratory graphical analysis 
A graph of each patient's response of total apnoea per hour (i.e. ~5 seconds) and total 
hypoxaemic episodes per hour (a fall in Sp02 of ~ 10% for > 10 seconds) to theophylline 
therapy from baseline to day three with the measured serum theophylline concentrations 
was constructed. These graphs were visually analysed and compared. 
c) Classification of patients as responders and non-responders 
Each patient's response to pathologic apnoea (~20 seconds), total apnoea and 
hypoxaemic episodes were separately analysed and the patient was then classified as a 
'responder' or a 'non-responder' for that specific clinical effect. A 'responder' was 
classified as a neonate with ~50% reduction in apnoea count (for pathologic as well as 
total apnoea) from baseline to the last recording of apnoea incidents. This is in 
accordance with the definition of a 'response' to theophylline therapy in apnoea used by 
Barrington et al (1987) and Scanlon et al (1992). The author used a similar ~50% 
reduction in hypoxaemic episodes to classify patients as 'responders' and 'non-
responders' to theophylline therapy. 
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SECTION B: CHAPTER 3 
RESULTS 
3.1 THE PATIENTS 
The patients were all Black premature neonates who were prescribed theophylline for 
apnoea of prematurity. The demographic details are shown in Table B.3.1. 
TABLE B.3.1. 
Demographic and clinical data of patients on entry 
Patients = 46 Males = 24 
Median Range Average SD -
Birth weight 1.3 0.8 - 1.8 1.3 0.2 
(kg) 
Gestational age 30 28 - 34 30.6 1.3 
Jweeks) 
Postnatal age 1 1-2 1.1 0.3 
(days) 
Body surface area 0.114 0.08 - 0.15 0.114 0.015 
Jm2) 
Haemoglobin 15.6 11 - 22.5 16.4 2.8 
(g/dL) 
Apgar 1 minute 7 2-9 6 2 
Apgar 5 minutes 9 4 -10 9 1 
Baseline recordings of apnoea, hypoxaemic episodes, pulse rate and other relevant 
clinical signs and symptoms were obtained from 46 neonates before the loading dose of 
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theophylline was given. These 46 patients formed part of the 105 patients used for the 
phannacokinetic analysis described in Section A. Monitoring for baseline recordings 
started within 6.4 (± 5.8) hours after birth as soon as the patient was stabilised, the body 
temperature and other clinical signs satisfactory and informed consent obtained from the 
mother. Accurate time of birth was available for only 35 patients as some were born 
before the mother's arrival at the hospital. 
Forty-four patients had mild-to-moderate respiratory distress syndrome diagnosed 
clinically and verified by X-ray examination. Thirteen neonates were born by caesarean 
section, and 12 were one of a set of twins. Most (96%) of the neonates received 
penicillin and an aminoglycoside for proven or suspected sepsis. Only 2 presented with 
a positive bacterial culture after the third day of the study., The appropriate antibiotics 
were then prescribed. Thirty-three percent of the mothers received antenatal 
corticosteroids. None of the mothers smoked and no caffeine containing beverages were 
ingested shortly before or during labour. 
3.2 PATIENT MONITORING, DRUG ADMINISTRATION AND SERUM 
THEOPHYLLINE CONCENTRATION MEASUREMENTS 
All the patients (46) were monitored before the loading dose of theophylline and this 
recording formed the baseline. Approximately an hour after the loading dose of 
theophylline was given, all the clinical effects were again recorded and this recording 
was termed 'day 1'. Only those patients whose clinical condition (determined by the 
attending physician) was satisfactory were monitored after the loading dose. The 
following day before the early maintenance dose of theophylline was given, recording of 
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the clinical effects for 'day 2' took place. Again only the patients whose clinical 
condition was satisfactory were monitored. Fortunately, all the patients who could not 
be monitored after the loading dose (' day 1' ) were then monitored ('day 2'). Recording 
of the clinical effects for 'day 3' occurred the next day at approximately the same clock 
time as 'day 2' . Figure B.3.1 illustrates when monitoring of the patients took place and 
the number of total apnoea per hour (that is, all apnoea ~5 seconds) recorded at those 
times. The baseline recordings are shown on the y-axis at 0 hours. The recordings for 
'day l' follow within an hour of the baseline recordings, while the recordings for 'day 2' 
and 'day 3' follow about 20 hours and 40 to 49 hours after baseline. (See Appendix B.2 
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Fig.B.3.1 Scatter of number of total apnoea per hour recorded at the different monitoring 
times 
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Thirty-nine of the initial 46 neonates were monitored after the loading dose of 
theophylline was given. Thirty-nine neonates were monitored before the early morning 
maintenance dose of theophylline on the next day, 'day 2' and 29 neonates were 
monitored on day 3. As mentioned above, not all the neonates could be monitored on all 
the days due to deterioration in the condition of the neonate requiring positive 
ventilation. Seven neonates requiring ventilation from day 2 were then excluded from 
the study. Two of these died: one due to laryngomalacia and the other due to 
pneumothorax. Seven other neonates died subsequent to the 3 days of monitoring. 
Causes of death were extreme prematurity (3) and pneumonia (4). 
There were 108 theophylline serum concentration measurements with a median of 2 and 
a range of 1 to 3 per patient. Average (SD) serum theophylline concentrations for days 
~ 
one, two, and three, were 5.8 (± 3.9), 8.8 (± 7.5), and 8.8 (± 5.7) mgIL respectively. The 
average caffeine concentrations on the three days were 0.2 (± 0.3),0.5 (± 1.0) and 0.7 (± 
1.0) mglL respectively. As these concentrations of caffeine were low, the possible effect 
of caffeine was not considered in further analysis. 
3.3 RECORDED CLINICAL EFFECTS 
For clarity the recorded clinical effects are divided and presented in 5 major sections, 
namely total apnoea, pathologic apnoea, hypoxaemic episodes, heart rate and finally 
mean arterial pressure and peripheral oxygen concentration. 
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3.3.1 Total apnoea (~5 seconds) incidents and density 
3.3.1.1 Recorded total apnoea 
Total apnoea included all apnoea ~5 seconds. Baseline total apnoea recordings were 
obtained from 46 patients. Recordings at day 1, day 2 and day 3 were obtained from 39, 
39 and 29 patients respectively. 
A scattergram of the number of total apnoea per hour versus serum theophylline 
concentration recorded from baseline to day 3 is shown in Figure B.3.2. This gives an 
indication of the spread of the number of apnoea counts over the three days measured 
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Fig. B.3.2 Number of total apnoealh versus serum theophylline concentration (mgIL) 
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The results of the total apnoea incidents and density (percent time spent not breathing) 
from baseline to day 3 are given in Table B.3.2. 
TABLE B.3.2 
Incidents and densities of total apnoea (25 sec) per hour: median and (range) and 
average (SD) serum theophylline concentration (mg/L) 
Day Incidents of total Densities of total apnoea Serum theophylline 
apnoea/h (% time in apnoea) concentration mg/L (SD) 
Baseline 16.0 (0.5 - 63) 4.8 (0.3 - 22.7) 0 
(n = 46) 
1 8.0 (1 - 27)* 2.3 (0.1 - 6.6)* 5.8 (3.9) 
(n = 39) 
2 8.8 (0 - 36)* 2.0 (0 -11.4)* 8.8 (7.5) 
(n = 39) 
3 9.5 (0 - 66)* 1.8 (0 - 14.5)* 8.8 (5.7) 
(n = 29) 
* Statistically significant (p <0.017) compared with baseline, n = number of patients. 
The incidents and density of total apnoea decreased significantly from baseline on all 
three days. The serum theophylline concentration increased from day 1 to day 2, but not 
from day 2 to day 3. (See Appendix B.3 for the total apnoea data file from baseline to 
day 3). 
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3.3.1.2 Graphical analysis of total apnoea 
As the aim of the project was to investigate the influence of theophylline on apnoea as 
well as hypoxaemic episodes, both these clinical effects are shown in the individual 
graphs in Fig.B.3.3. However, the results of the effect of theophylline on hypoxaemic 
episodes will be presented in detail in section 3.3.3. 
Although a significant decrease in the overall number of apnoea incidents from baseline 
was found, the response among patients was highly variable as shown in these graphs. 
For ease of graphical analysis, patients were divided into 4 groups according to the 
recorded number of total apnoea at baseline. Thus the scale of the Y-axis, showing the 
number of total apnoeaJh; differs from group to group. The X-axis shows the days of 
momt.oring, the secondary Y-axis the number of hypoxaemic episodeslh, and the 
secondary X-axis the serum theophylline concentration (mglL). It should be noted that 
all the patients had apnoea at baseline, but not all of them had hypoxaemic episodes, thus 
some graphs show no hypoxaemic episodes. 
Patients were classified as responders and non-responders according to the definition of a 
responder as a patient with a decrease equal to or more than 50% in apnoea incidents 
from baseline to the last recorded apnoea. 





percentile of the characteristics or clinical condition of the population 
to determine whether a non-responder belonged to the category or not. For gestational 
age the 25
th 
percentile was 30 weeks; a patient with the characteristic of low gestational 
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age would be one born at less than 30 weeks gestntionnl ngc. (The postconccptunl ngc 
was not used as the patients were monitored during the first three days after birth and the 
gestational age and the postconceptual age did not differ significantly). For total apnoea, 
the baseline 75th percentile was 27.4 total apnoea per hour. The 25th percentile for birth 
weight was 1.1 kg. 
Group 1. Patients with >45 total apnoeaJh at baseline: 
There were four patients in this group with very high baseline counts. All four of them 
showed a decrease of more than 50% in the number of total apnoeaJh from baseline and 
could thus be classified as responders. 
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Fig. B.3.3. Individual graphs of patients, Group 1. 
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Group 2. Patients with between 30 and 45 total apnoea/h at baseline: 
This group of six patients with intennediate baseline counts had 4 responders showing a 
;:0:50% decrease in number of total apnoea/h, the two non-responders being' patient 
nwnbers 5 and 84. 
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Th""ph. cone. 































+-______ ~~------~------~ 0 
o 3 0 I Days 2 1 Days 2 3 
[ ~TN11 ...-e-- Hi%] I ~TAlh ~ tWhJ 
L-______ ~_=_~_=_=========_. ______ ~ ______ ~======~~~~ ____ ~ 












O~------~~------~--------~ · 0 
o I Dnys 2 3 
Patienl91 

















































0 I Davs 2 3 [ . __ .. - - -' - --- ---
-.-.. TAlh .-0- HEll!] 
Fig.B.3.3 (cont.). Individual graphs Group 2, responders. 
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The demographics and clinical conditions of the non-responding patients will be briefly 
noted: 
Patient 5 was a baby girl born at 29 weeks gestational age who weighed 1.1 kg at birth. 
She was born before her mother arrived at the hospital. She was in a poor condition and 
needed oxygen support. The total apnoea counts at first decreased and then increased 
after day 2. The serum theophylline concentration fell from 10 mgIL on day 2, to 7 mglL 
on day 3. The value of the peripheral oxygen saturation remained stable at 98% over the 
three days. 
Patient 84 was a baby boy who weighed only 800g at birth. He was the second of a set 
of twins born at 28 weeks gestational age. The mother suffered premature rupture of the 
membranes. The patient's apnoea incidents decreased after the loading dose of 
theophylline but thereafter increased steadily to day 3. The serum theophylline 
concentration was 5 mg/L on day 3. Despite oxygen support the peripheral oxygen 
concentration fell from 97% at baseline to 91% on day 3. Unfortunately the patient died 
on day 8 due to extreme prematurity. 
If the denotations of markers of non-response are applied, both the patients in this group 
who did not respond, had gestational (postconceptual) ages less than the 25 th percentile 
that is, <30 weeks, of the population and one had birth weight below the 25th percentile 
«1.1 kg) of the population. Both patients had more than the 75 th percentile (>27.4 total 
apnoea/h) of total apnoea at baseline and both patients needed oxygen support. 
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Group 3. Patients with between 15 and 30 total apnoea/h at baseline: 
This group of fourteen patients with lower baseline counts than Group 2 had varying 
degrees of response. According to the definition of a non-responder, 7 patients, numbers 
12, 70, 72, 73, 77, 93 and 124 qualified as non-responders. 
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126 
3 





30 t-------+------+-----; 4 
20 
























.. 'Il.eoph, conc. 6 
0 
I Days 2 












~ 15 '" :r: I-
0 .~----~====~~------4 0 0 ·~--------~--------~--------~· O 
o J Oays 2 3 0 I Days 2 




S 6 5 




. ... .. .... _-... 
o+---------~------~--------_+o 
0.0 1.0 Days 2.0 
~TNl.L___=_~lt- H~LI 
Fig.B.3.3 (cont.). Individual graphs Group 3, responders. 
3.0 
3 
It is interesting to note the sharp decline in apnoea incidents from baseline to day 1, i.e. 
after the first dose of theophylline. This was seen in the responding as well as non-
responding patients. 
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The demographics and clinical conditions of the non-responding patients will be briefly 
noted: 
Patient 12 was a baby boy born at 30 weeks gestational age who weighed 1.3 kg at birth. 
The patient had grade 1 intra-ventricular haemorrhage. From baseline the patient 
received oxygen support but after the monitoring period on day 2 the oxygen support 
-
was stopped as the patient appeared satisfactory. The peripheral oxygen saturation was 
96.8%. Hours later the patient developed tachypnoea and had to be resuscitated. Oxygen 
support was re-instated and on day 3 the peripheral oxygen saturation was 94.5%. The 
apnoea incidents showed a steady decline from day 1, but increased sharply from day 2 
to day 3, reaching baseline values. The serum theophylline concentration was 5 mgIL on 
day 3. Unfortunately the patient died of pneumonia on day 10. 
Patient 70 was a baby girl born at 30 weeks gestational age who weighed 1.25 kg at 
~ 
birth. She did not require oxygen support. A decrease of 46% in apnoea incidents 
occurred from baseline to the last recorded apnoea. Again this percentage is very close to 
a responder. The serum theophylline concentration was 12 mg/L. 
Patient 72 was a baby boy born at 30 weeks gestational age who weighed 1.36 kg at 
birth. The total apnoea counts decreased significantly after theophylline administration 
but unfortunately the patient accidentally received an overdose of the drug on day 2, and 
the serum concentration increased to 32.6 mglL. When noted theophylline 
administration was immediately stopped. The patient was observed and signs of 
jitteriness were recorded. The total apnoea incidents increased from 6/h on day 1 to 19/h 
on day 3. The patient's classification as a non-responder might have been erroneous as 
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he received the incorrect dose of the drug. The patient received oxygen support and the 
peripheral oxygen saturation increased from 92.8% at baseline to 96.4% at the last 
recording. 
Patient 73 was a baby boy who weighed 1.5 kg at birth. He was born at 31 weeks 
gestational age by caesarean section from a teenage mother. The patient did not need 
oxygen support. The apnoea incidents decreased by 6% after baseline. The serum 
theophylline level was 9 mg/L on day 3. 
Patient 77 was a baby boy who weighed 1.1 kg at birth. He was born at 31 weeks 
gestational age as one of a set of twins. The mother suffered premature rupture of 
membranes. A decrease of 48% in apnoea incidents oc~urred from baseline to the last 
recorded apnoea. He did not require oxygen support. The serum theophylline 
~ 
concentration was 6 mglL. 
Patient 93 was a baby boy who weighed 1.1 kg at bilth. He was born at 29 weeks 
. gestational age and was one of a set of twins. The mother suffered premature rupture of 
membranes. From day 2 the patient was ventilated due to poor perfusion and was thus 
excluded from further study. This patient's twin sister (patient 94, see group 4), also a 
non-responder, had less apnoea at baseline but did not require assisted ventilation 
although oxygen support was given. Both babies developed pneumonia after day three. 
Patient 124 was a baby boy who weighed 1.2 kg at birth. He was born by caesarean 
section at 32 weeks gestational age. His mother suffered pregnancy-induced 
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hypertension. The patient's apnoea counts showed a steady decline after theophylline 
administration and was 48% less than baseline on day 3, very close to being a responder. 
The serum theophylline concentration was 10 mg/L. 
Thus in summary, 5 of the seven patients in this group who did not respond, were males. 
One patient had gestational age less than the 25th percentile «30 weeks) of the 
population. Only one patient had more than the 75th percentile (>27.4/h) total apnoea per 
hour at baseline. Two patients had pulse rates less than the 25th percentile «120.5 bpm) 
of the population at baseline. Four patients required oxygen support; two were one of a 
set of twins; two mothers suffered premature rupture of membranes and one patient was 
born by caesarean section. 
Group 4. Patients with equal to or less than 15 total apnoea/h at baseline: 
~ 
Group 4 consisted of 22 patients with low starting baselines depicting varying degrees of 
response. All the patients had less than the 75th percentile total apnoea for the population 
at baseline. Thirteen patients, numbers 1, 10, 15, 16, 18, 76, 78, 80, 81, 87, 88, 94 and 
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The demographics and clinical conditions of the non-responding patients will be briefly 
noted: 
Patient 1 was a baby boy born at 30 weeks gestational age who weighed 1.2 kg at birth. 
The patient received oxygen support. A slight increase in apnoea incidents occurred 
after baseline; the serum theophylline level was 5 mg/L. Unfortunately the patient 
required assisted ventilation from day 1 and was thus excluded from further study. 
Patient 10 was a baby girl who weighed 1.4 kg at birth. She was born by caesarean 
section at 32 weeks gestational age as one of a set of twins. The patient did not need 
oxygen support. The apnoea counts did not decrease after theophylline administration 
and the serum drug levels were 5 mg/L on day 2 and day 3. On day 3 the patient 
presented with grade 2 intra-ventricular haemorrhage. 
Patient 15 was a baby boy born at 32 weeks gestational age who weighed 1.4 kg at birth. 
The patient received oxygen support. The total apnoea incidents decreased from 151h to 
8/h after the loading dose of theophylline. The serum drug concentration was 5 mg/L. 
Unfortunately the patient required assisted ventilation from day 1 and was thus excluded 
from further study. 
Patient 16 was a baby boy born at 30 weeks gestational age who weighed 1.2 kg at birth. 
The patient received oxygen support. The total apnoea COlli,ts decreased by only 24% 
after theophylline administration. The serum theophylline concentration was 8 mg/L. 
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Patient 18 was a baby girl who weighed 0.95 kg at birth. She was born at 30 weeks 
gestational age as one of a set of twins. Her mother suffered premature rupture of 
membranes. After the loading dose of theophylline the total apnoea incidents did not 
decrease. The serum drug level was 5 mglL. Unfortunately the patient's condition 
deteriorated and she died late afternoon on day 2. 
Patient 76 was a baby girl who weighed 1.5 kg at birth. She was born by caesarean 
section at 31 weeks gestational age. At baseline the patient had three total apnoea/h and 
no pathologic apnoea (:2:20 seconds). After the loading dose the serum theophylline 
concentration was 18 mglL and the patient was restless. On day 2 the patient's perfusion 
was erratic. From day 2 the total apnoea incidents increased; the serum theophylline 
level was 5 mglL. The patient received oxygen support. . 
Patient 78 was a baby girl who weighed 1.35 kg at birth. She was born by caesarean 
section at 31 weeks gestational age. Her mother suffered premature rupture of the 
membranes. On day 2 the patient experienced an increase in apnoea counts; the serum 
theophylline concentration was 15 mg/L and oxygen support was given. 
Patient 80 was a baby boy who weighed l.25 kg at birth. He was born at 30 weeks 
gestational age as one of a set of twins. The patient received oxygen support. After the 
loading dose of theophylline a slight drop in apnoea incidents occurred; the serum drug 
concentration was 3 mglL. Unfortunately the patient developed pneumothorax on day 2 
and died. 
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Patient 81 was a baby boy who weighed 1.45 kg at birth. He was born by elective 
caesarean section at 30 weeks gestational age and was in a poor condition after birth. He 
required oxygen support until day 2. On day 2 the patient unfortunately received an 
overdose of theophylline and the serum drug concentration was 42 mgIL. Drug 
administration was immediately stopped. The patient showed signs of jitteriness. On day 
3 an increase in apnoea was experienced. The serum theophylline concentration was 27 
mg/L. This patient was classified as a non-responder in terms of the definition. This 
classification might be erroneous if the patient had received the correct dose. 
Patient 82 was a baby girl who weighed 1.2 kg at birth. She was born by caesarean 
section at 30 weeks gestational age. The patient was in a poor condition after birth and 
received oxygen support. On day 2 the patient experienced an increase in apnoea counts~ 
the serum theophylline concentration was 5 mg/L. On day 3 the apnoea counts decreased 
to approximately baseline counts and the serum drug concentration was 7 mg/L. 
Patient 88 was a baby girl who weighed 1.2 kg at birth. She was born by caesarean 
section at 30 weeks gestational age and was one of a set of twins. The total apnoea 
incidents increased steadily after birth and a sharp increase was experienced on day 3~ 
the serum theophylline concentration was 17 mgIL. The patient received oxygen 
support. 
Patient 94 was a baby girl who weighed 1.1 kg at birth. She was born at 29 weeks 
gestational age as one ofa set of twins (patient 93 was her brother). She received oxygen 
support. Her total apnoea incidents decreased after baseline but increased on day 3. The 
136 
serum theophylline levels were 5 and 8 mg/L respectively. She developed pneumonia 
after day three. 
Patient 99 was a baby boy who weighed 1.7 kg at birth. He was born at 32 weeks 
gestational age and received oxygen support. The patient experienced a slight drop in 
apnoea counts after the loading dose of theophylline and an increase in apnoea counts on 
day 2 and then a slight drop in counts on day 3. The serum theophylline concentration 
was 3 mglL on all three days. 
Thus in summary, 6 of the thirteen patients in this group who were classified as non-
responders, were males: One patient had gestational age less than the 25th percentile «30 
weeks) and one had a birth weight less than the 25th percentile «1.1 kg) of the 
population. Four patients had pulse rates below the 25th percentile «120.5 bpm) of the 
population at birth. Ten patients required oxygen support, three were one of a set of 
twins, two mothers suffered premature rupture of membranes and six babies were born 
by caesarean section. 
In order to identify possible markers of non-response, the characteristics of all the non-
responders of the four groups with total apnoea (as depicted above) were analysed and 
compared with those of the rest of the patients with total apnoea and this is presented in 
Table B.3.3. As shown in the table, 10 (22%) of the patients (n = 46) weighed less than 
the 25
th 
percentile «1.1 kg) at birth; of these 10 patients, 8 (80%) were responders. 
Similarly there was a high percentage of responders in the group with low 5 minute 
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Apgar scores (80%) and in the group with high total apnoea counts at baseline (75%). 
Twelve patients were one of a set of twins and 8 of these (67%) were non-responders. 
Thus, although the numbers are very small, being one of a set of twins might be regarded 
as an indicator of poor response. On the other hand, there is an indication that very low 
birth weight babies «25 th percentile), those with 5 minute Apgar scores less than the 25 th 
percentile and those with high baseline total apnoea counts (>75th percentile) would be 
more likely to respond (at the defined level of 50%) to theophylline therapy. 
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Table B.3.3 
Characteristics of patients with total apnoea (~5 seconds): nwnber and percentage of 
responding and non-responding patients with population characteristic 
Characteristic Number (%) of Responders (n = 24) Non-responders (n = 22) with this 
total with this characteristic characteristic 
population Number As%of Number As%of As%of 
(n= 46) with responders non- population with 
this (n = 24) responders this characteristic 
characteristic (n = 22) 
Birth weight 10 (22%) 8 33% 2 9% 20% 
<1.1 kg (25th (10 out of 46) (8 out of (2 out of (2 out of 10) 
percentile at 24) 22) 
baseline) 
Gestational age 
<30 weeks (25th 
8 (17%) 4 17% 4 18% 50% 
percentile at 
baseline) 
Classified as 'in 28 (61%) 17 71% 11 50% 39% 
poor condition' 
on entry 
Apgar at 5 
minutes <8 (25th 
5 (11%) 4 17% 1 5% 20% 
percentile at 
baseline) 
Received 32 (70%) 18 75% 14 64% 44% 
oxygen support 





Males 24 (52%) 11 46% 13 59% 54% 




Corticosteroid 16 (35%) 8 33% 8 36% 50% 
given to mother 
before or during 
labour 
Patient is one of 12 (26%) 4 17% 8 36% 67% 
a set of twins 
Patient born by 13 (28%) 6 25% 7 32% 54% 
caesarean 
section 
Developed NNJ 25 (54%) 15 63% 10 45% 40% 
NNJ - neonatal Jaundice, bpm = beats per mmute. 
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A frequency distribution graph (see Fig.B.3.4) illustrates the number of responders and 
non-responders with total apnoea at the various serum theophylline concentrations. The 
cumulative number of responders and non-responders at each concentration are also 
shown. It should be noted that 6%, 45%, 26%, 12%, 2% and 8% of serwn theophylline 
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Fig.B.3.4 Frequency distribution of responders and non-responders with total apnoea at 
the various serum theophylline concentrations. Cumulative nwnber of responders and 
non-responders at each concentration are also shown. 
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3.3.2 Pathologic apnoea (~20 seconds) incidents 
It was considered appropriate and of interest to analyse the results of the pathologic 
apnoea incidents separately as a number of studies report on the effect of theophylline on 
the course of longer apnoea (Shannon et al 1975, Gerhardt el al 1978, Roberts et al 1982, 
Sims et al 1985, Muttitt et al 1988, Harrison 1992). Thirty-eight of the initial 46 
neonates monitored had pathologic apnoea at baseline. At the subsequent three 
monitoring times 32, 31 and 24 of these were followed. Figure 8.3 .5 illustrates when 
monitoring or these patients took place and the number of pathologic apnoea per hour 
recorded at those times. (See Appendix B.4 for the pathologic apnoea data file from 
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Fig.B.3.5. Scattergram of the number of pathologic apnoea per hour at the different 
monitoring times. 
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The number of pathologic apnoea per hour measured against serum theophylline 
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Fig.B.3.6 The number of pathologic apnoea per hour versus serum theophylline 
concentration (mg/L). 
The results of the total pathologic apnoea incidents and density (percentage time spent 
not breathing) as well as all the different types of pathologic apnoea recorded are given 
in Table B.3.4. There was a significant decrease (p <0.017) in the incidents and density 
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of the total pathologic apnoea, as well as the pathologic apnoea incidents associated with 
a fall in pulse rate and a hypoxaemic episode, on all 3 days when compared with 
baseline. However, the pathologic apnoea associated with a hypoxaemic episode 
decreased significantly on day I only. Also the pathologic apnoea associated with a fall 





TABLE B.3.4 The per hour recording of the median and (range) of the following apnoea counts at recorded average serum 
theophylline concentrations (SD): Total pathologic apnoea; density of total pathologic apnoea; pathologic apnoea associated with a 
fall in pulse rate and a hypoxaemic episode; pathologic apnoea associated with a hypoxaemic episode only; and pathologic apnoea 
associated with a fall in pulse rate only. 
Total Density of total Pathologic apnoea Pathologic apnoea with Pathologic apnoea Serum 
pathologic pathologic with a fall in pulse a hypoxaemic episode with a fall in theophylline 
apnoea apnoea rate and a pulse rate mg/L (SD) 
hypoxaemic episode 
Baseline 3.0 2.1 0.5 0.2 0 0 
(n = 38) (0.4 - 24) (0.3 - 13.5) (0 - 2.3) (0 - 3.0) (0 - 2) 
Day 1 1.1 0.8 0 0 0 5.8 
(n = 32) (0 - 8.0)* (0 - 4.3) (0 - 1.5)* (0 - 2.0)* (0 - 1.5) (3 .5) 
Day 2 0.5 0.3 0 0 0 8.2 
(n=31) (0 - 6.1)* (0 - 3.4) (0 - 1.1)* (0 - 1.0) (0 - 1) (7) 
Day 3 0 0 0 0 0 8 
. (n = 24) (0 - 3.0)* (0 - 1.6) (0 - 1.0)* (0 - 6.5) (0)* (5) 
- - -- --- -- -~. --
* Statistically significant (p<0.017) compared with baseline, h = hour, n = number of patients. 
As the number of the different types of pathologic apnoea is very small, only the results 
for theophylline on the total number of pathologic apnoea will be reported further. 
Analysis of the results showed that 5 of the 38 patients (numbers 1,81, 93,99 and 124) 
could be classified as non-responders, that is, a decrease of less than 50% in pathologic 
apnoea incidents from baseline to the last recorded apnoea. 
The characteristics of the 5 non-responders were compared with those of the rest of the 
patients in this group and the results are summarised in Table B.3.5. 
However, as the number of non-responders (n = 5) in this group (n = 38) was very small 
no markers of non-response could really be identified. It was noted that all the non-
responders were males. A much better response to theophylline therapy was found for 
pathologic than for total apnoea. 
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Table B.3.5 
Characteristics of patients with pathologic apnoea (~20 seconds): number and percentage 
of responding and non-responding patients with population characteristic 
Characteristic Number (%) of Responders (n = 33) Non-responders (n == 5) with this 
total with this characteristic characteristic 
population Num As%of Num- As%of As%of 
(n == 38) with -ber responders ber non- population with 
this (n = 33) responders this characteristic 
characteristic (n = 5) 
Birth weight <1.1 9 (24%) 9 27% 0 0 0 
kg (25th percentile (9 out of38) (9 out of33) 
at baseline ) 
Gestational age <30 6 (16%) 5 15% 1 20% 17% 
weeks (25th (lout of 6) 
percentile at 
baseline) 
Classified as 'in 24 (63%) 22 67% 2 40% 8% 
poor condition' on 
entry 
Apgar at 5 minutes 4 (11%) 3 9% 1 20% 25% 
<8 (25th percentile 
at baseline) 
Received oxygen 28 (74%) 26 79% 2 40% 7% 
support 
Patients with >4 . 2~ 9 (24%) 8 24% 1 20% 11% 
pathologic apnoea/h 
(75th percentile at 
baseline) 
Patients with >27.4 
total apnoea/h (75th 
10 (26%0 10 30% 0 0 0 
percentile at 
baseline) 
Males 22 (58%) 17 52% 5 100% 23% 
Pulse rate <120.5 8 (21%) 8 
bpm (25 lh percentile 
24% 0 0 0 
at baseline) 
Corticosteroid given 11 (29%) 9 27% 2 40% 18% 
to mother before or 
during labour 
Patient is one of a 12 (32%) 11 33 1 20% 8% 
set of twins 
Patient born by 11 (29%) 9 27% 2 40% 18% 
caesarean section 
Developed NNJ 21 (55%) 20 61 1 20% 5% 
NNJ neonatal JaundIce, bpm - beats per mmute. 
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A frequency distribution graph (see Fig.B.3.?) illustrates the number of responders and 
non-responders with pathologic apnoea at the various serum theophylline concentrations. 
The cumulative number of responders and non-responders at each concentration are also 
shown. 
1-3 3.1-6 6.1-9 9.1-12 12.1-15 >15 
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Fig.B.3.? Frequency distribution of responders and non-responders with pathologic 
apnoea at the various serum theophylline concentrations. Cumulative nwnber of 
responders and non-responders at each concentration are also shown. 
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3.3.3 HYI)OXaemic el)isodes 
Thirty-five of the 46 neonates who were monitored had hypoxaemic episodes ~ 1 0 
seconds at baseline. Thirty-one, 28 and 22 patients were followed at the subsequent 
monitoring times. The nwnber of hypoxaemic episodes recorded per hour and the serum 
theophylline concentration measured at the same time is illustrated in Fig.B.3.8. (see 
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Fig.B.3.8 The distribution of hypoxaemic episodes/h versus serum theophylline 
concentration (mglL). 
The median (and range) of total as well as aU the different types of hypoxaemic 





TABLE B.3.6 The per hour recording of the median and (range) of the following hypoxaemic episodes at recorded average serum theophylline 
concentrations (SD): Total hypoxaemic episodes; isolated hypoxaemic episodes; hypoxaemic episodes associated with a fall in pulse rate; 
hypoxaemic episodes associated with a pathologic apnoea and a fall in pulse rate; hypoxaemic episodes associated with movement. 
Total Isolated Hypoxaemic Hypoxaeinic Hypoxaemic Hypoxaemic Serum 
hypoxaemic hypoxaemic episodes episodes episodes episodes theophylline 
episodes episodes associated with a associated with a associated with a associated with mgIL (SD) 
pathologic apnoea fall in pulse rate pathologic apnoea movement 
and a fall in pulse 
rate 
Baseline 2.0 1.7 0 0 0 0 0 
(n = 35) (0 - 16) (0 - 15) (0 - 2) (0 - 4.9) (0 - 1.3) (0 - 1) 
Day 1 1.0 0.7 0 0 0 0 5.6 
(n = 31) (0 - 10) (0 - 9) (0 - 1) (0 - 1.6) (0 - 1)* (0 - 2) (3.3) 
Day 2 1.0 0.5 0 0 0 0 8.6 
(n = 28) (0 - 8) (0 - 8) (0 - 0.9) (0 - 3.5) (0 - 0.3)* (0 - 1.1) (8.4) 
Day 3 0.9 0.3 0 0 0 0 8.0 
(n = 22) (0 - 23) (0 - 23) (0 - 0.7) (0 - 1.0) (0 - 0.6)* (0 - 1.6) (5 .5) 
* Statistically significant (p<0.017) compared with baseline, h = hour, n = number of patients. 
I 
At baseline 65% of the total hypoxaemic episodes were isolated, that is, not associated 
with a pathologic apnoea or a fall in pulse rate or a fall in pulse rate with a pathologic 
apnoea or with movement. This remained the same for day 1 but changed to 71% and 
75% on day 2 and 3 respectively. The only significant decrease in hypoxaemic episodes 
were those associated with pathologic apnoea and a fall in pulse rate from baseline to the 
subsequent days. As the number of the different types of hypoxaemic episodes was 
small, only the trend of the total number of hypoxaemic episodes was analysed further. 
The influence of theophylline on hypoxaemic episodes (as well as on total apnoea) is 
shown in the individual graphs of Fig.B.3.3. The response is variable; occasionally a 
decrease is seen in the number of hypoxaemic episodes as well as total apnoea and 
occasionally in the number of the one clinical effect but not in the number of the other 
clinical effect. Not all the patients depicted in Fig.B.3 .3 had hypoxaemic episodes; thus 
some of the graphs will not show any hypoxaemic episodes. 
In order to identifY possible markers of non-response the characteristics of all the non-
responders with hypoxaemic episodes were analysed and compared with those of the rest 
of the patients with hypoxaemic episodes and this is presented in Table B.3.7. 
Analysis of results for hypoxaemic episodes showed that 16 of the 35 patients could be 
classified as non-responders. 
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TableB.3.7 
Characteristics of patients with hypoxaemic episodes 2: 1 0 seconds: number and 
percentage of responding and non-responding patients with population characteristic 
Characteristic Number (%) of Responders (n = 19) Non-responders (n = 16) with this 
total population with this characteristic characteristic 
(n = 35) with Num- As%of Num- As%of As%of 
this ber responders ber non- population with 
characteristic (n = 19) responders this characteristic 
(n = 16) 
Birth weight <1.1 7 (20%) 4 21% 3 19% 43% 
kg (25th percentile 
at baseline l 
Gestational age <30 
weeks (25th 
6 (17%) 3 16% 3 19% 50% 
percentile at 
baseline) 
Classified as ' in 19 (52%) 11 58% 8 50% 42% 
poor condition' on 
entry 
Apgar at 5 minutes 4 (11%) 2 11% 2 13% 50% 
<8 (25th percentile 
at baseline ) 
Received oxygen 22 (63%) 10 53% 12 75% 55% 
support 
Patients with >4.2 9 (26%) 3 16% 6 38% 67% 
pathologic apnoea/h 
(75th percentile at J 
baseline) 
Patients with >27.4 12(34%) 7 37% 5 31% 42% 
total apnoea/h (75th 
percentile at 
baseline) 
Males 20 (57%) 10 53% 10 63% 50% 
Pulse rate <120.5 14 (40% 8 42% 6 38% 43% 
bpm (25th percentile 
at baseline) 
Corticosteroid given 10 (29%) 4 21% 6 38% 60% 
to mother before or 
during labour 
Patient is one of a 8 (23%) 1 5% 7 44% 88% 
set of twins 
Patient born by 7 (20%) 2 11% 5 31% 71% 
caesarean section 
Developed NNJ 18 (51%) 10 53% 8 50% 44% 
NNJ - neonatal Jaundlce, bpm - beats per mmute. 
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Because of the non-significant response of hypoxia to theophylline (Table B3.6), it is not 
really relevant to be too concerned about predictors of response. However the results in 
table B3.7 revealed that those least likely to respond were twins (88%), those born by 
caesarean section (71 %) and those with baseline pathologic apnoea per hour above the 
75th percentile (67%). The frequency distributions of the responding and non-responding 
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Fig.B.3.9 Frequency distribution of responders and non-responders with hypoxaemic 
episodes at the various serum theophylline concentrations. Cumulative number of 
responders and non-responders at each concentration are also shown. 
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Thus, in summary, twins seemed more., likely to respond poorly in tenns of both total 
apnoea and hypoxaemic episodes. Other markers of poor response in the hypoxia group 
were more than the 75 th percentile pathologic apnoea at baseline and delivery by 
caesarean section. The babies most likely to respond in tenns of total apnoea were those 
with very low birth weight «25th percentile), those with 5 minute Apgar scores less than 
the 25th percentile at birth and those with high baseline total apnoea counts (>75th 
percentile). 
3.3.4 The effect of theophylline on pulse rate and episodes of bradycardia 
The results of measurements of pulse rate and recording of all incidents of bradycardia 
were obtained from all the 46 patients at baseline. Of these 39, 39 and 29 were followed 
at the other three monitoring times respectively. The results are shown in Table B.3.8. 
The average pulse rate measured at each monitoring time increased significantly from 
baseline to all three days as shown in Table B.3.8. The biggest increase in pulse rate is 
seen after the loading dose of theophylline was given, thus from baseline to day 1. The 
number of incidents of bradycardialh decreased significantly from baseline to all three 
days and on day 3 a median of null incidents was recorded. 
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TABLEB.3.8 
Pulse rate (PR) per monitoring time, and number of episodes of bradycardia per hour: 
median and (range), with serum theophylline concentrations (mglL) 
Day PR(bpm) Episodes of bradycardia Serum theophylline conc 
«100 bpm /h) (mgIL) 
Baseline 133.5 3.0 0 
(n = 46) (99 - 159) (0 - 173) 
1 143.1* 0.7~ 5.8 1 
(n = 39) (110-171) (0 - 59) (3.9) 
2 143.0* 0.5* 8.8 
(n = 39) (117 ~ 188.5) (0 - 19) (7.5) 
3 146.0* O~ 8.8 
(n = 29) (119 - 171.9) (0 - 5.7) (5.7) 
Statistically significant: * p :::;0.017 compared with baseline, n = number of patients, 
bpm = beats per minute, conc = concentration. 
3.3.5 Peripheral oxygen saturation and mean arterial pressure 
The results of the median (range) of the peripheral oxygen saturation (Sp02) and the 




Peripheral oxygen saturation (Sp02) and mean arterial pressure (MAP) per monitoring 
time: median and (range), with serum theophylline concentrations (mgIL) 
Day Sp02(%) MAP Serum theophylline conc 
(mmHg) (mg/L) 
Baseline 96.4 34.5 0 
(n = 46) (83 .6 - 98.5) (29 - 45) 
1 96.5 38.0* 5.8 
(n = 39) (88.0 - 98.3) (32 - 63) (3.9) 
2 96.4 41* 8.8 
(n = 39) (87.6 - 98.3) (33 - 50) (7.5) 
3 96.5 46* 8.8 
(n = 29) (90.3 - 98.5) (30 - 67) (5.7) 
Statistically significant: * p ~ 0.017 compared with baseline, n = nwnber of patients. 
For the whole population (n = 46) there was no significant change in the peripheral 
oxygen saturation (Sp02) per monitoring time from baseline to any of the other days. 
The mean arterial pressure (MAP) showed a steady increase from baseline to the third 
day. 
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SECTION B: CHAPTER 4 
DISCUSSION 
4.1 DISCUSSION 
The results of the study indicate that theophylline reduces apnoea in apnoeic infants with 
mild-to-moderate respiratory distress syndrome. There is, however, variability in 
response. Although hypoxaemic episodes associated with a pathologic apnoea (~20 
seconds) and a fall in heart rate decreased significantly, theophylline appears not to be 
effective in reducing isolated hypoxaemia. 
One of the objectives of the study was to investigate the effect of theophylline during the 
first few days after birth, as this is the time when theophylline is most often used in the 
neonatal wards. In this way the study differs from other published studies as most of the 
patients in the present study were enrolled as soon as possible after birth, whereas the 
patients in most of the published studies had wider ranges of postnatal ages. Also, the 
patients in the present study had RDS, whereas those in most of the published studies 
suffered mostly from apnoea of prematurity only. 
Comparison of the results with other studies is difficult due to the different definitions 
used for apnoea. In the present study, two different definitions of apnoea were used, 
namely total apnoea, which included all the apnoea equal to or longer than 5 seconds, 
and pathologic apnoea, which included all apnoea equal to or longer than 20 seconds. 
The effect of theophylline on shorter apnoea is important as Upton et at (1991) found 
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that apnoea of less than 10 seconds can cause reductions in peripheral oxygen saturation 
of up to 40%. The shorter apnoea (3 to 15 seconds) reflects a disturbance of the 
respiratory control system that may lead on to longer apnoea and to sudden infant death 
syndrome (Kelly and Shannon 1979, Lee et at 1987). The definition of pathologic 
apnoea (220 seconds) corresponded with the definition as determined by the Academy of 
Pediatrics Task Force on Prolonged Infantile Apnea (Consensus Statement 1987). 
Theophylline significantly reduced the incidents of total apnoea from baseline to all three 
days. The biggest effect was seen after the loading dose. No difference was found 
between the average number as well as the densities of total apnoea between day one and 
day two, and day two and day three. As the definition for total apnoea included the 
shorter apnoea, comparison with other studies is difficult. Finer et at (1984) who 
reported on all apnoea 23 seconds, found a significant (p<O. 00 1) decrease in apnoea 5 to 
9.9 seconds and also those 210 seconds. They studied 19 infants with gestational ages 
36.1 (±5.1) weeks at a mean age of7.1 (±4 .3) weeks while asleep, before, and one week 
after theophylline administration. These infants had older gestational and postnatal ages 
than the present study. The dose of theophylline was 2.3 mglkg 6 hourly; the serum 
theophylline concentrations were not reported. 
In the present study, of the group of 46 patients with total apnoea, 22 (48%) could be 
classified as non-responders as they had a less than 50% decrease in total apnoea counts 
from baseline to the last recorded apnoea. An objective was to identify markers of non-
response that could alert the attending physician to the possible problems associated with 
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the management of such a neonate. Such markers of non-response to theophylline 
therapy for apnoea have not been identified in other studies. 
For the group with total apnoea, being one of a set of twins was found to be a 
characteristic of poor response to theophylline, as 67% of twin babies were non-
responders. Greenough et al (1996) have reported that being one of a set of twins is a 
predisposing factor to RDS. This may be due to asphyxia (Arnold et al 1987) or faster 
maturation of the presenting twin (Weller et al 1976). A close relationship between 
RDS, asphyxia or hypoxaemia, and apnoea exists (Poets et al 1994, Greenough et al 
1996), and hypoxaemia is often used to assess the severity of RDS (Greenough et al 
1996). Recently Martin-Ancel et al (1995) analysed the relationship between the 
clinical and biochemical markers of asphyxia and multi-organ involvement and found 
Apgar scores at 1 and 5 minutes to be the only factors related to the number of organs 
involved. In the present study low 5 minute Apgar scores were a marker of favourable 
response (in terms of total apnoea) to theophylline therapy. Other features of babies 
more likely to respond were birth weight less than the 25th percentile and baseline total 
apnoea/hour greater than the 75th percentile. 
The frequency distribution graph of serum theophylline concentrations for total apnoea 
(Fig B.3.4, page 140) shows that most patients in this group responded at concentrations 
of3.1 to 9 mglL. This might give a false impression, as most of the serum theophylline 
measurements in the present study were in the 3.1 to 9 mglL range. The results show that 
22% of the patients have responded at 3.1 to 6 mglL, another 17% at 6.1 to 9 mglL and 
another 7% at 9.1 to 12 mglL. The cumulative values for the responders will be 22% at 
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3.1 to 6 mg/L, 39% at 6.1 to 9 mg/L, 46% at 9.1 to 12 mg/L and 48% at 12.1 to 15 mg/L. 
A maximum of 52% response was reached at > 15 mg/L. Comparison of the results with 
other studies is not possible as the definition of total apnoea included a wider range of 
apnoea than any published study with dose or serum concentration information. 
The results of the present study show that a significant reduction occurred in the number 
of pathologic apnoea (220 seconds) from baseline to all three days following 
theophylline therapy. Of the 38 patients in the group with pathologic apnoea, apnoea was 
completely abolished in 10 (26%) of the patients after the loading dose was 
administered. The results of the pathologic apnoea study may be compared with those 
recorded by Sims et at (1985) who used a definition for apnoea as 20 seconds with or 
without bradycardia. Also the postnatal ages and gestati9nal ages of the patients of this 
study and those used by Sims et at are very similar. However, Sims et al only enrolled 
~ 
patients with apnoea of prematurity, while the patients of the present study also had 
RDS. In the study by Sims et at, theophylline administration was stopped when a 50% 
reduction of the baseline number of apnoea occurred. As in the present study, she found 
an overall significant (p<0.025) decrease in apnoea incidents. However, in her study, 3 
of the 18 patients (17%) treated with theophylline and 3 of the control patients (21 %) 
continued to have apnoea even after three weeks of theophylline administration. These 
six patients were not distinguishable from the other patients in her study in terms of birth 
weight, gestational and postnatal age, or the number of apnoea incidents at baseline. 
Using a definition of apnoea as a cessation of breathing for 220 seconds or less if 
accompanied by bradycardia, Roberts et al (1982) recorded no response in 20% of 
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patients (n = 10) and an overall reduction of 58% in apnoea incidents. These patients 
(postnatal ages 1 to 31 days) had apnoea as well as a variety of other disorders. Apnoea 
was recorded before and then between 40 and 166 hours after theophylline therapy was 
started. Serum concentration levels of between 7 and 13 mg/L were obtained. 
Considerable patient variability was found and no correlation could be drawn between 
degree of response to theophylline, gestational age, postconceptual age, clinical 
diagnoses, or theophylline concentrations. 
In the present study, thirteen percent of the patients with pathologic apnoea did not 
respond. This is lower than the twenty-three percent of the patients in the study by 
Muttitt et al (1988) who did not respond. It should however be noted that Muttitt et al 
used a more stringent definition of apnoea than the present study as well as the studies 
above, namely, z20 seconds plus a 25% decrease in heart rate and a 10% decrease in 
~ 
oxygen saturation. Muttitt et al defined a non-response as zO.33 apnoea per hour. Their 
patients had the same range of gestational ages than the patients of the present study, the 
study by Sims et al and also Roberts et ai, but a wider range of postnatal ages than the 
present study. 
Although the methods for recording of apnoea differed, the percentages of non-response 
for Muttitt et ai, Roberts et al and Sims et al (23, 20 and 17% respectively), were higher 
than the 13% recorded in the present study. Although Muttitt et al used a more 
sophisticated recording system than Roberts or Sims, she agreed that all forms of artefact 
could not be recognised and could have been mistaken for an apnoea. Detection of 
apnoea in the present study was more accurate as computer printouts as well as manual 
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recordings of apnoea incidents were used. We were able to distinguish false apnoea 
recordings due to movement, sighs etc. whereas the above researchers could have 
misinterpreted these incidents. Another drawback in the study by Muttitt et al (1988) is 
the small number of patients, namely 22. 
In the present study, in the group of38 patients with pathologic apnoea, five (13%) were 
non-responders as they did not have a 50% decrease in number of pathologic apnoea 
from baseline to the last recording. These five patients were also non-responders in the 
total apnoea group, as total apnoea included all apnoea ;:::5 seconds. For this population 
with pathologic apnoea, no outstanding characteristic of non-response could be 
identified, but all five non-responders were males. 
It is known that boys are more likely to develop RDS than girls (Farrell and Avery 1975, 
Luerti et al 1993) but, as most of the patients in the study suffered from RDS, it could 
not be considered as a characteristic of non-response. However, RDS is a known and 
common cause of apnoea (Kercsmar 1994, Greenough et aI1996). Male foetuses have a 
delayed appearance of a mature lecithin: sphingomyelin ratio and phosphatidylglycerol 
(Fleisher et al 1985). This seems to be due to an androgen-induced delay in the 
maturation of the surfactant systems in the foetus (Torday 1992). Gender differences in 
lung function (Stocks et a11997) as well as in growth of lung function was shown with 
girls generating greater maximal expiratory flows than boys (Hibbert et aI1995). It is not 
known whether this difference in lung function can be extrapolated to premature 
neonates. 
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The anticipated beneficial effect of corticosteroid administration to the mothers before or 
during labour was difficult to assess, as the numbers were small. Eleven of the mothers 
in the group of neonates with pathologic apnoea received a corticosteroid before or 
during labour and two of these neonates were non-responders. It has been shown that the 
use of antenatal corticosteroids in preterm labour halved the incidence of RDS when 
given between 24 hours and seven days before delivery (Crowley 1995). This may be 
due to an enhanced expression of protein and phospholipids of the surfactant system and 
enzymes of the antioxidant systems (Vyas et al 1997). Most of the clinical trials such as 
the Vermont-Oxford Trials Network (Horbar 1995) concentrated on antenatal 
corticosteroids and neonatal outcome and the emphasis was on the reduction of the 
incidences ofRDS, intra-ventricular haemorrhage and necrotising enterocolotis (Crowley 
et al 1990) and not on apnoea as such. As apnoea and RDS are closely linked, a 
reduction in RDS should mean less apnoea. 
After the loading dose of theophylline (recording of day 1) a sharp drop (50%) in both 
incidents and densities of both pathologic apnoea and total apnoea from baseline was 
observed. Others investigating the effect of theophylline (Peabody et al1978, Brouard et 
a11985, Sims et al1985, Scanlon et a11992) and also caffeine (Turmen et a11981) have 
reported similar findings. The mode of action of theophylline is not clear. It is 
suggested that the peripheral chemoreceptors are inactive during the first 48 hours after 
birth (Barrington and Finer 1990) and are responsible for apnoea and hypoxaemia (Cote 
et al 1996). It was shown that a dopaminergic mechanism suppresses the sensitivity of 
the chemoreceptors and when oxygenation increases after birth the dopamine turnover 
decreases allowing the chemoreceptors to reset (Hertzberg et at 1990, 1993). In term 
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infants these chemoreceptors are more active III the presence of aminophylline 
(Cattarossi et al 1993). One might speculate that this dramatic effect is due to the 
stimulating effect of theophylline on the peripheral chemoreceptors (Cattarossi et al 
1993) allowing them to 'reset' thus increasing their sensitivity to hypoxia (Alvaro et al 
1992, Calder et al 1994). Subsequent beneficial effects on pathologic apnoea might be 
due to antagonism of adenosine that is released during hypoxia (Bissonnette et aI1990). 
Moreover, it could be due to theophylline's enhancement of conduction along the central 
auditory pathways with resultant improved regulatory effect on the respiratory centre of 
the brain stem (Chen et aI1994). 
It is interesting to note that a sharp decline in apnoea incidents (20 seconds) during the 
first 24 hours after birth, has also been reported in neonates receiving no medication 
(Sims et al 1985, Barrington and Finer 1991). However, the apnoea incidents in the 
theophylline treated group in the study by Sims et al (1985), decreased more than in the 
control group of patients. The apnoea incidents of the treated group decreased 
significantly from 11 ± 3 to 4 ± 1, whereas in the control group, apnoea incidents 
dropped from 9 ± 3 to 6 ± 2 per day. Thus the decrease in apnoea incidents cannot with 
certainty only be attributed to theophylline. The profound changes in the first few days 
after birth in the physiology of the chemoreceptors and other systems controlling 
respiration (Hertzberg and Lagercrantz 1987, Hertzberg et a11990, Rylance 1992) could 
play significant roles in regularising breathing. 
The frequency distribution graph of serum theophylline concentrations for pathologic 
apnoea (Fig B.3.7, page 147) showed that most patients responded at concentrations of 
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3. 1 to 9 mg/L. The steepest part of the cumulative response is between 3.1 and 12 mg/L; 
thereafter the curve flattens until an 87% cumulative response is reached. The results 
showed that 39% of the patients have responded at 3.1 to 6 mg/L, another 29% at 6.1 to 9 
mg/L, and another 13% at 9.1 to 12 mg/L. It should be kept in mind that 48% of the 
serum theophylline concentration were between 3.1 to 6 mg/L and 25% between 6.1 to 9 
mg/L. Comparison of these results with other studies is difficult, as most of the serum 
theophylline concentrations in the present study were below 9 mg/L. It should be noted 
that the dose of the drug was detennined by the physician in charge and not by any 
requirements of the study. Muttitt et al (1988), in a dose-finding study, recorded a 14% 
response at a serum theophylline concentration of 4.2 mg/L, a further 14% response at 
8.5 mgIL and a further 45% response at 12.7 mg/L. The postnatal ages of the patients in 
her study were older than the present study but the gestational ages overlapped. Sixty 
percent (6 of 10) of the patients in the study by Roberts et al (1982) had >50% decrease 
in apnoea incidents at serum theophylline concentrations of 6 to 10 mg/L. The other 
patients in the study responded at higher serum concentrations (13 mg/L), and 20% of 
the patients did not respond at all. These patients had similar gestational ages but older 
postnatal ages than the present study. Most of the other published studies, using a 
variety of definitions for apnoea, had responses at higher serum theophylline 
concentrations. For example, Scanlon et al (1992) obtained a 92% response by day 1 
with serum theophylline concentrations of 13 to 20 mg/L, using a definition of no airflow 
plus stimulation of the neonate and a fall in heart rate of :2:40 beats per minute. A flaw in 
the present study (as in some of the others) is that, unlike Muttitt's study, there was a 
lack of titration of the dose within individual patients. 
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As yet no agreement regarding the definition of a hypoxaemic episode has been reached. 
The definition used in the present study was influenced by the limitations of the 
recording instruments used in the study and the alann limits for apnoea monitors as 
suggested by Upton et al (1991). The study demonstrated a reduction in total 
hypoxaemic episodes although this was not significant. The only significant decrease 
was seen in the hypoxaemic episodes associated with a pathologic apnoea and a fall in 
pulse rate. This could be due to the effect of the drug on apnoea and heart rate as such. 
Comparison of the results with other studies is difficult due to experimental differences 
as well as differences in the definition of an episode. Finer et al (1984) reported a 
significant reduction in apnoea incidents after 7 days of theophylline therapy (serum 
concentrations 6 to 19 mglL), but no significant reduction in the number of falls of 
transcutaneous oxygen pressure greater than 3 mm (11.1 versus 7.2/h). Peabody et al 
(1978), who also used transcutaneous oxygen pressure as a parameter, observed a 
significant decrease in the total duration of hypoxaemia after two days of theophylline 
treatment (n = 10, serum concentrations 10 to 16 mglL). However, 48 hours after 
withdrawal of the drug, five of the six neonates who received theophylline for only two 
days, experienced an increase in apnoea incidents and hypoxaemia. It was also shown 
that caffeine the other methylxanthine used for apnoea of prematurity did not protect the 
neonate against the development ofhypoxaemic episodes (Bucher and Duc 1988). 
As reported in other studies many hypoxaemic episodes occurred without apnoea (Poets 
et at 1991, Poets et al 1992, Richard et al 1993). It has been suggested that isolated 
hypoxaemia could be due to intrapulmonary shunts (Poets et al 1992, Samuels et al 
1992, Southall et al 1993). This topic has been extensively reviewed by Poets et al 
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(1992) who suggested that any change in ventilation-perfusion-ratio could lead to 
intrapulmonary shunting. Bolivar et al (1995) have shown that most hypoxaemic 
episodes in mechanically ventilated infants were triggered by an expiratory effort that 
produced a large decrease in lung volume. They suggested that this could lead to closure 
of small airways and the development of intrapulmonary shunts. Many factors are 
implicated in intrapulmonary shunting (Poets et al 1992) and theophylline, through its 
wide range of pharmacological effects, could possibly influence ventilation and/or 
perfusion. Theophylline could improve ventilation since it increases tidal volume (Davi 
et a11978) and therefore enhances alveolar ventilation (Gerhardt et a11979, Cordoba et 
al1994). It also improves respiratory muscle function (Sherman et al1996), and reduces 
diaphragmatic fatigue (Aubier 1986, Heyman et aI1989). During hypoxia, theophylline 
may prevent a fall in minute ventilation and respiratory rate (Bruce et al1986). The drug 
may also improve the regulation of breathing through its stimulatory effect on the 
respiratory centre of the brain stem (Chen et al 1994). Theophylline might improve 
perfusion through its positive inotropic and chronotropic effects (Walther et a11986). A 
lack of surfactant, as found in respiratory distress syndrome, can also lead to 
ventilation/perfusion inequalities (Poets et al 1992). Antenatal administration of 
theophylline has been shown to have a beneficial effect on surfactant production in foetal 
rabbits (Hegyi et al1986) and lung maturation in humans (Granati et al1984). However, 
post-natally the drug had no appreciable effect on respiratory distress syndrome (Hegyi 
et al1986). Regardless of all the potential effects of theophylline to improve ventilation-
perfusion, the results of the present study suggest that theophylline does not have a 
significant beneficial effect on hypoxaemia. Both increasing hypoxia and hypercarbia 
accompany prolonged apnoea and may produce derangement of central respiratory 
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control, increased bronchomotor tone, and depressed cardiac function (Miller and Martin 
1992). Recently it was shown that even moderate grade hypoxaemia could harm the 
function of the neonatal kidney (Talosi et aI1996). 
In the group of 35 patients who had hypoxaemic episodes at baseline, 16 (46%) did not 
respond to theophylline therapy. Possible markers of poor response for this population 
were being one of a set of twins, being born by caesarean section, and more than 4.2 
pathologic apnoea per hour at baseline. However, detennination of markers is not really 
important as hypoxaemia (unrelated to apnoea) was found to respond poorly to 
theophylline. 
The frequency distribution graph of serum theophylline concentrations for hypoxaemic 
episodes (Fig B.3.9, page 152) shows that most patients responded at concentrations of 
3. 1 to 9 mg/L, but again, most of the serum theophylline concentrations were in this 
range. The cumulative response was 55% at > 15 mg/L. Comparison of the results of the 
study with other studies is difficult. Finer et al (1984) found no significant reduction in 
the number of falls of transcutaneous oxygen pressure at serum theophylline 
concentrations 6 to 19 mg/L. Also, Peabody et at (1978) observed a significant decrease 
in the total duration ofhypoxaemia at serum concentrations of 10 to 16 mg/L. 
In the present study theophylline significantly increased the average pulse rate from 
baseline to all three days. Shannon et al (1975), in a study of 17 premature infants, noted 
a similar increase in heart rate (from 155 ± 11. 3 to 173 ± 15.7 bpm) and noted tachycardia 
(>180 bpm) with serum theophylline concentration >13 mg/L. Tachycardia is a well-
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known side effect of theophylline administration (Rall 1996), but in the present study the 
patients who accidentally received overdoses of theophylline did not develop heart rates 
above 180 bpm. This phenomenon was also observed by Nadkarni et al (1988) who 
conducted a study to investigate the relationship between theophylline, caffeine and heart 
rate in neonates; tachycardia did not occur even at theophylline concentrations >20 
mglL. In the present study only one patient presented with an average of 188 bpm on 
day 2 of monitoring, but the serum theophylline concentration was only 11 mglL. The 
reason for this patient's tachycardia was unknown. Thus the practice of using 
tachycardia as an indicator of effective theophylline therapeutic concentrations by some 
clinicians (Samuels and Southall 1993) would be impractical and unsafe in the premature 
neonate during the first few days after birth. In the present study the relationship 
between pulse rate and serum theophylline concentration was weak with a correlation 
coefficient (r) of 0.14. This could be due to the changing dynamics of the neonate during 
the first few days after birth. Nadkarni et al (1988), in a small study with 12 neonates, 
found a good relationship of 0.56 for theophylline concentrations below 10 mglL, but for 
concentrations above 10 mglL, a poor one, namely 0.12. When all the serum 
theophylline concentrations above 10 mgIL were omitted from the data of the present 
study, the correlation coefficient changed from 0.14 to 0.15. 
Sudden episodes of bradycardia are common in the neonate (Hodgman et a11993) and if 
recurrent, may constitute a considerable problem in the clinical management of the 
neonate. In the present study theophylline significantly decreased the episodes of 
bradycardia from baseline to all three days. The episodes of bradycardia associated with 
a pathologic apnoea and a hypoxaemic episode also decreased with theophylline 
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administration. Using very stringent definitions for bradycardia, apnoea and 
de saturations, Poets et al (1993) showed a close relationship between episodes of 
bradycardia, apnoea and desaturations. The mechanism of action of theophylline is not 
clear but might be due to the drug's effect on AI-receptors (Barnes and Pauwels 1994). 
The mean arterial pressure showed a consistent increase from baseline to all three days. 
After treatment it remained above 30 rom Hg in all cases, which should ensure sufficient 
cerebral blood flow (Miall-Allen et al1987). The average peripheral oxygen saturation 
over the three days showed no statistically significant change. These findings were 
consistent with those obtained by Peabody et al (1978) using transcutaneous oxygen 
pressure. 
4.2 CONCLUSION 
This study has~ shown that theophylline, in the doses used, appeared to significantly 
reduce total and pathologic apnoea. A reduction in hypoxaemic episodes occurred but 
this was not statistically significant. The most dramatic effect on apnoea and 
hypoxaemia was seen on the first day of treatment after the loading dose. 
Twins were identified as being poor responders with regard to both total apnoea and 
hypoxaemic episodes. Other markers of non-response for hypoxaemic episodes were 
being born by caesarean section and more than the 75th percentile pathologic apnoea at 
baseline. For the population with total apnoea, there was a high percentage of 
responders in the group with low 5 minute Apgar scores, in the group with high total 
apnoea counts at baseline and in the group that weighed less than the 25th percentile 
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«l.1 kg) at birth. No markers could be identified for pathologic apnoea, but all non-
responders were boys. 
A careful analysis of these results, as well as those of other researchers, highlights the 
uncertainty surrounding the mechanism of action of theophylline and the effect that other 
physiological factors have on the breathing pattern of the neonate. Increasing maturity 
cannot easily be separated from theophylline's effects. The inclusion of an untreated 
control group would have been ideal, but ethical considerations precluded this. Although 
any conclusions drawn from the study are confounded by the lack of a control group, the 
significant decrease in apnoea incidents and densities over the three days suggests that 
theophylline, in the concentrations used, is effective in reducing pathologic apnoea in 
most neonates with respiratory distress syndrome. 
Although the results show that most of the patients responded at serum theophylline 
concentrations of 3.1 to 9 mg/L, no absolute conclusion regarding the effective dose 
range of theophylline could be drawn as most of the serum concentrations fell in this 
range. Information regarding toxic doses/serum concentrations is lacking as the three 
patients who accidentally received overdoses of theophylline only showed signs of 
jitteriness; the serum concentrations were >27 mglL. 
Assessments of concentration-effect relationships in this section were simplistic as they 
involved comparison of a baseline with other time-points in the patient. A more 
appropriate method of analysing repeated measures and using all the data, including that 
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for patients where some values are mlssmg, would be a population analysis. 
Accordingly this was done in Section C. 
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SECTION C 
POPULATION CONCENTRATION-EFFECT MODELLING OF 
THEOPHYLLINE IN PREMATURE NEONATES SUFFERING 
FROM APNOEA DURING THE FIRST FEW DAYS AFTER BIRTH 
SECTION C: CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
The tenn pharmacodynamics relates to the study of the physiological and biochemical 
effects of drugs and their mechanism of action. Towards this end, use may be made of 
either the overall detectable effect, such as a decrease in the number of apnoea, or the 
physiological effect, such as blocking of adenosine receptors. As in pharmacokinetics, 
mathematical models are used to describe the phannacodynamics of a drug. Presently 
the trend is to combine the phannacokinetics and phannacodynamics of a drug and 
report on 'the PKlPD modelling' of a drug. The link between the pharmacodynamics 
and phannacokinetics is the concentration of the drug as this forms a fundamental part of 
both studies. As it is not always possible to measure the concentration at the site of 
action, whether Intra- or extra-cellular, the serum concentration of the drug is nonnally 
used. The correct measurement of the concentration of the drug is thus as important as 
the description of the effect. 
Although the pharmacokinetics of theophylline in premature neonates have been studied 
using both traditional methods and population methods such as NONMEM (see Section 
A), very little has been published on the linked phannacodynamics and pharmacokinetics 
of theophylline especially in the premature neonate with apnoea. In this section, the 
literature pertaining to receptor theory, PKlPD modelling and the proposed mechanism 
of drug action of theophylline and possible factors affecting this will be reviewed prior to 
the presentation of the experimental work. 
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The aim of this section of the study was thus to investigate the PK-PD relationship of 
theophylline in the treatment of apnoea in the premature neonate during the first few 
days after birth. 
1.1 MECHANISMS OF DRUG ACTION 
Drugs exert their pharmacological effects by interacting with macromolecular 
components of the organism. Thus the phannacological effect may result through the 
activating or inhibiting action of a drug on these sites. The concept of a ' receptive 
system', based upon a drug-cell combination was first suggested by Langley in the late 
eighteenth century (Ross 1996). In the 1920' s A. J. Clark developed this view further 
and the concept of a 'receptor' in the biological cell with which the drug may combine to 
trigger a response was born. It is now known that receptors are protein molecules 
usually located in the cell membrane. Many receptors have been cloned and their amino 
acid sequences determined (Ross 1996). Recently the International Union of 
Phannacological Sciences (IUPHAR) published a compendium of receptor 
characterisation and classification (IUPHAR Media, London, 1998). 
As the resultant effect of a drug-receptor interaction seldom equals the proportion of 
receptors occupied, Ariens in 1954 introduced the tenn ' intrinsic activity' (0) to describe 
the relationship between the effect, E, elicited by a drug, D, and the concentration of 
drug-receptor complexes: 
E = a[D] 
173 
In 1956 Stephenson further advanced the concept of concentration-response relationships 
by introducing the concept of 'efficacy' to offer an explanation for non-linear 
relationships between receptor occupancy and drug response. Today the terms 'intrinsic 
activity' and 'efficacy' are commonly used interchangeably and are operationally 
synonymous (Ross 1996). 
1.2 QUANTITATION OF DRUG-RECEPTOR INTERACTIONS 
To understand drug-receptor interactions, it is necessary to quantify the relationship that 
exists between the drug and the biological effect it produces. As the degree of the effect 
produced by a drug is usually a function of the amount of drug administered, this 
relationship can eventually be expressed in terms of dose-response curves (or 
concentration-response curves). 
The above concept may be illustrated as follows: 
kl 
Drug (D) + Receptor (R) B DR ~ Effect 
kz 
This reaction sequence is similar to the interaction of substrate with enzyme and is 
identical in mathematical form with the Michaelis-Menten equation: 
Maximal Effect (D) 
Effect 
KD + (D) 
Where (D) = free drug concentration and KD (= kZ/kI) = the dissociation constant for the 
drug-receptor complex. The fraction of receptors occupied by the drug is [D] / (KD + 
[D]). 
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The scheme defines the drug's 'potency', that is, the dependency of effect on the drug's 
concentration. The equation describes a simple rectangular hyperbola. There is no effect 
if (D) = 0 and the effect is half-maximal when (D) = KD. that is when half of the receptors 
are occupied. The maximal effect is approached asymptotically as (D) increases above 
KD. If the effect is plotted against log (D), the familiar sigmoidal dose-effect curve is 
obtained (Ross 1996). A linear form of this relationship is obtained by taking the 
reciprocal of both sides · of the expression and constructing the equivalent of a 
Lineweaver-Burk plot for enzyme kinetics. When a linear relationship exists between 
concentration and effect, the ECso of the drug can be calculated. This is the 
concentration where it is half-maximally effective and is equal to the drug's KD in many 
but not in all cases. 
In certain situations receptor occupancy IS not related to response and signal 
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amplification may occur between receptor occupancy, effector activation and response. 
Thus the dose-response curve will be to the left of the receptor-occupancy curve. From 
these basic concepts drug-receptor theories have evolved that are widely applied to 
illustrate the drug's agonistic or antagonistic effects on receptors (Ross 1996). 
1.3 PHARMACOKlNETICIPHARMACODYNAMlC MODELLING 
The relationship between the dose of the drug and its eventual pharmacological effect 
can be summarised in the following diagram: 
Dose - PK - Cp - PKlPD - CE - PD - E - PE - Effect 
Where PK = pharmacokinetics, Cp = serum concentration of drug, 
PKlPD = pharmacokinetic-dynamic relationship, CE = effect site concentration, 
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PD = pharmacodynamics, E = the observable effects, 
PE = physiological effect at tissue concentration (Holford and Sheiner 1981). 
A variety of mathematical models have been developed to describe the relationship 
between the pharmacological effect of a drug and its concentration. A brief description 
of these models follows. 
l.3.1 Types ofPK-PD models 
1.3.1.1 Quantal dose response model (Categorical Data) 
This is the simplest model to explain drug-effect relationships. The observed effect is 
either present or absent, or is defined by some criterion, such as a greater than 50% 
reduction in apnoea incidents. Thus the effect is 'fixed', but remains either present or 
absent; this model is thus applicable to dichotomous data. 
With only two observations, the data is called dichotomous, and m = 2. Categories can 
be ordered, for example the drug effect can be classified into none, little, moderate or 
much, Thus, an observation, which can be one of m labels, is called an m-categorical 
observation. Analysis of categorical data uses logistic regression and gives a quantal 
dose-response curve. A number of observations can be in category one, category two 
etc. Thus, with each frequency observation, there are N underlying m-categorical 
observations, but they are not separately recorded. This is referred to as m-categorical 
frequency observations (Beal and Sheiner 1996). 
No assumptions need to be made regarding the form of the relationship between the 
176 
concentration of the drug such as theophylline and the 50% reduction in apnoea counts. 
This is because only one degree of effect is considered, and the effect model has only 
one parameter, namely the concentration at which the 50% reduction occurs. The serum 
concentration, at which the desired effect appears, will vary among the patients. The 
degree of the effect is not important, but only whether it occurs or not (Holford and 
Sheiner, 1981 and 1982). 
This model has been successfully applied in determining serum concentrations of 
alfentanil required to supplement nitrous oxide anaesthesia (Ausems et al 1986). Muttitt 
et al (1988) in a study of the dose concentration-effect relationship of theophylline in 
premature neonates determined whether a decrease in apnoea incidents occurred at a 
given concentration of theophylline. (The definition of response in Muttitt's study was a 
fall in number of apnoea to below 0.33 episodes per hour.) Although the authors did not 
~ 
analyse the phannacodynamics of the drug, the results showed a cumulative frequency 
response curve with a sigmoidal shape. Most of the patients responded at a serum 
theophylline concentration of 12.7 mgIL. 
1.3.1.2 Linear model 
This model describes a continuous effect of the drug over the observed concentrations. 
Thus the data would be continuous variable data such as the measurement of blood 
pressure. When the drug concentrations are low in relation to ECso, the effect becomes 
proportional to concentration and the slope of the line relates the effect to the 
concentration: 
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Where E = the intensity of the effect, S = slope of the curve, C = drug concentration. 
The parameters can be estimated by linear regression. This model is derived from the 
Emax model and it predicts no effect when the drug is absent. The model cannot describe 
maximum effect, and is thus used to study effects in the range below 50% of the 
maximum effect. If however, the effect has some value when the drug is absent, such as 
blood pressure, the equation becomes: 
E = S * C+ EO 
Where EO = the effect without the drug, or the baseline effect. 
Thus this model is applicable when it is not practicable to achieve maximum effect and 
when effects are studied in the range below 50% of the maximum effect (Oosterhuis and 
van BoxteI1988). 
This model was applied to the theophylline data collected by Falhers (1975). A linear 
relationship was found between forced expiratory volume (FEV 1), expressed as a 
percentage of predicted 'normal'. The theophylline concentrations ranged from 2 to 18 
mg/L. The intercept value (EO) was estimated at 58.2%, which was close to the pre-drug 
mean FEV1 of 55.2%. The slope of the line was estimated from pooled data of all the 
patients and was 1.23% per mglL. This value was much lower than the 3.4% per mg/L 
estimated in a single patient. This difference occurred because the data was pooled and 
the intra-individual correlations were ignored (Holford and Sheiner 1982). It is possible 
that a population analysis approach may have been better in this case. 
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l.3 .l.3 Log-linear model 
This model is derived from the linear model and is often used to describe the relationship 
between concentration and effect; thus it may be applied to continuous variable data. As 
many drugs act over a wide concentration range, the concentration axis of the effect-
concentration relationship is often converted to a log-scale, compressing the scale. 
Thus: 
E = S log (C) + I 
Where I is intercept and an arbitrary constant with no physical meaning. 
This model cannot predict the effect when no drug is present, and cannot determine the 
maximum effect (Holford and Sheiner, 1981 and 1982). This is an important drawback 
and may obscure the existence of a maximal effect (Holford and Sheiner 1982). 
The log-linear model has often been used to explain drug action, as the relationship 
between log concentration and effect, in the effect range 20% to 80%, is frequently 
linear. This effect range is also highly relevant under clinical conditions (Oosterhuis and 
van Boxtel 1988). 
Singh et al (1980) used the log-linear model to describe the effects of timolol on heart 
rate during exercise and found only a weak correlation. However, when the same data 
was fitted to an inhibitory Emax model the existence of a maximal effect was shown 
(Holford and Sheiner 1982). (See 1.3.1.4 below.) This was one of the manipulations 
that highlighted the limitations of the log-linear model. 
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This model was used to describe the relationship between the decreasing plasma 
theophylline concentration and number of apnoea in 6 premature infants (Lagercrantz et 
aZI980). The apnoea frequency was monitored after cessation of theophylline treatment 
and plotted against the log plasma concentration of theophylline. The regression line 
crossed an arbitrarily chosen cut-off level of 2 apnoea per 12 hours at a mean 
theophylline concentration of 7 mg/L. Based on these results the authors recommended 
a plasma theophylline concentration >7 mg/L for effective control of apnoea. They 
defined apnoea as cessation of breathing for longer than 30 seconds or less, if 
accompanied by a decrease in heart rate below 100 beats per minute 
1.3.1.4 Emax model 
The Emax model is generally the most appropriate model to adequately describe the effect 
of a drug over the whole range of drug concentrations and the maximum effect a drug 
can achieve. It may be applied to continuous variable data as the log-linear model 
described above. It is based on a hyperbolic relationship: 
E = Emax * C I (ECso + C) 
Where Emax = the maximum effect ascribed to the drug and ECso = the concentration at 
half-maximal effect. 
According to this equation, when the concentration is zero, there is no effect. This 
model can also accommodate a baseline effect as follows: 
E = EO + Emax * C I (ECso + C) 
Where EO = baseline effect. 
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This model also includes the 'law of diminishing returns'; thus ever-higher 
concentrations are needed to increase the effect by a given amount (Holford and Sheiner 
1981, 1982). 
When the drug effect is measured as inhibition of a certain observation, for example 
disappearance of some effect (such as apnoea) from a baseline level, the formula can be 
written as follows: 
E = EO - (Ernax * C) / (IC50 + C) 
Where ICso = the concentration producing half-maximal effect. 
If a drug is able to completely abolish an effect, the value of Emax is equal to EO, which 
then becomes: 
E = EO * {1- C / (ICso + C)} 
The expression C / (ICso + C) describes the relationship between the concentration and 
the fraction of maximal effect that can be attributed to the drug. This is the fractional 
Emax model (Holford and Sheiner 1981, 1982). 
Mitenko and Ogilvie (1973) used the Emax model to illustrate the effects of theophylline 
on airway obstruction in six asthmatic patients. They detennined the change in FEV 1 
over a range of theophylline concentrations and expressed the effect as a percentage of 
the expected FEVl in a normal patient. The maximum effect predicted by the model was 
63% and the ECso of theophylline was 10 mgIL. 
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The Emax model is considered the basic pharmacodynamic model and is widely applied to 
describe concentration-effect relationships, using continuous variable data. When a 
particular effect is studied in the range below 50% of the Emax or where no maximum 
effect can be obtained, the linear model will provide a good approximation of the 
concentration-effect relationship. 
1.3.1.5 Sigmoid Emax model 
The Sigmoid Emax model is based on the Emax model with the addition of a parameter that 
changes the simple hyperbolic form of the Emax model: 
E = Emax * CN I (ECSON + CN) 
Where N = a number influencing the slope of the curve. 
If N equals 1 the equation describes a hyperbolic function, and if N is greater than 1 the 
curve will be sigmoid-shaped (Holford and Sheiner 1981, 1982). The sigmoid Emax 
model has been used by a number of investigators such as Stanski et al (1979) who used 
the model to describe the effect of d-tubocurarine on muscle strength. 
1.3.1.6 Count Model 
The count model is based on the Emax model (Beal and Sheiner 1996) but is applied to 
'count' data (discrete events) whereas the Emax model is normally applied to continuous 
variables. By a 'count' is meant the number of events occurring in a given volume of 
time or space, for example the number of apnoea per hour. The model describing the 
relationship when a baseline count is present, will be: 
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E = A + B {I - C I (D + Cn 
Where B = the effect due to the drug, A + B = the typical baseline count, C = the 
concentration of the drug, and 1 - C I (D + C) = the fractional reduction due to the 
presence of the drug. 
For this count model the Poisson distribution is deemed suitable. The Poisson 
distribution is used to model discrete events that occur infrequently in time or space; thus 
it is sometimes called the distribution of rare events (Pagano and Gauvreau 1993). The 
underlying assumptions for the Poisson Distribution are: 
1. The probability that a single event occurs is proportional to the length of the interval. 
2. Theoretically within an interval an infinite number of events are possible. 
3. The events occur independently both within the same interval and between 
consecutive intervals. 
This Poisson distribution describes the probability (P) that the number K assumes the 
value k and is given by 
P (K =k) ~exp (-II.{) A/lk! 
In this count model adapted for popUlation modelling within NONMEM, the parameter 
AI is related to concentration (or time) as' follows: 
AI= 8 j - 82 (CONCI)+ 111 
Where AI = the mean number of events, given 111. 
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Thus with this model (where the drug reduces the number of events from some baseline 
(91))~ 9 j - 92 (CONCI) is also the populatien mean for individuals with CONCI. AI is also 
the variance of the number of events, given '11r. With this additive model, the population 
variance is 9 1 - 92 (CONCr ) + co
2 (Beal and Sheiner 1996). 
In this area of very topical research, count models are being used in population analysis 
to describe various drug effects such as reduction in apnoea or seizure frequency, as well 
as for drugs that promote the occurrence of a positive event. 
1.3.1.7 Models for indirect phannacodynamic response (based on Dayneka et a11993, 
and .Tusko and Ko 1994) 
Many drug responses, (R), may be considered indirect in nature. Four basic models to 
represent drug responses that are characterised by indirect mechanisms have been 
developed. Factors controlling the production or input (kin) of the response variable may 
be either inhibited or stimulated; similarly, the determinants of loss, (kout), of the 
response variable may also either be inhibited or stimulated. 
The rate of change of the response over time with no drug present can be described as 
follows: 
dR / dt = kin - kout * R 
Where kin = the zero-order constant for production of the response and kout = the first-
order constant for loss of the response, R = the measured response variable. 
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The effect site represents a separate site of drug action where the mode of action controls 
either stimulation or inhibition of the designated controlling process (kin or kout). 
Model 1 and Model 2 represent inhibitory processes that operate according to the 
inhibitory function, I (t) : 
I (t) = 1- Cp I (Cp - IC5o) 
Accordingly, the rate of change of drug response in Modell can be described as follows: 
dR Idt = kin * I(t) - kout * R 
Model 2 describes drug response that results from inhibition of the factors controlling the 
dissipation of the response variable: 
dR Idt = kin - kout * I(t) * R 
Model 3 and Model 4 represent processes that stimulate the factors controlling dmg 
response and operate according to the stimulation function 8 (t): 
8 (t) = 1 + Emax * Cp I (EC50 + Cp) 
Thus Model 3 describes drug response that occurs from stimulation of factors that 
control the production of the response: 
dR Idt = kin * 8(t) - kout * R 
and Model 4 the dissipation of the stimulating drug response: 
dR Idt = kin - kout * Set) * R 
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The development of these models emphasised the importance of mechanism based 
pharmacokineticlpharmacodynamic modelling. Therefore an understanding of the 
biochemical events involved in the phannacological action of the drug should be a 
prerequisite for the development of appropriate drug-effect models. These models have 
been extensively discussed and applied to diverse drugs when time lags exist between 
plasma or biophase drug concentrations and the time course of pharmacodynamic 
responses (Jusko and Ko 1994). 
It is not clear whether these indirect models might apply to theophylline and its effect on 
apnoea in the neonate and it appears as yet that none of them has been used. It is known 
that theophylline probably has diverse mechanisms of action for the relief of apnoea of 
prematurity. For example, the stimulating effect of theophylline on the medullar centre 
and the resultant increase in its sensitivity is most probably mediated through 
~ 
theophylline's blocking effect on adenosine receptors (Bissonnette et al 1991, Barnes 
and Pauwels 1994, Griffiths et alI997). This action may be responsible for the increase 
in ventilation, increase in breathing movements and the decrease in diaphragmatic 
muscle fatigue. Theophylline also relaxes constricted bronchial smooth muscle via 
inhibition of phosphodiesterases (Mehta et al1991, Schudt et al 1995, Banner and Page 
1996) and this must certainly be an indirect effect. Furthermore, it has direct and indirect 
effects on intra-cellular calcium (Kolbeck and Speir 1989, Gayan-Ramirez et al 1995) 
which may also contribute to the decrease in the number of apnoea. 
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1.4 CONCENTRATION-EFFECT RELATIONSHIPS OF METHYLXANTHINES 
The magnitude or intensity of a drug's effect is usually dependent on the dose 
administered and the resultant serum drug concentrations. In general, as the dose 
administered increases, the magnitude of the effect will increase in a gradual fashion 
until a maximum is reached. Therefore, quantitative dose-response relationships may be 
constructed and visualised using the pharmacodynamic models described above. This has 
been done for some of the effects of theophylline in certain populations and will be 
discussed briefly in relation to the models that were described in 1.3 above. 
1.4.1 Concentration-effect relationship of theophylline in asthma 
In adult asthmatic patients a significant relationship between the bronchodilating effect 
of theophylline and the serum theophylline concentration has been shown. This 
relationship has been defined as proportional to the logarithm of the serum concentration 
~ 
over the range of 5 to 20 mg/L (Levy and Koysooko 1975, Simons et al 1982). This 
range of serum concentrations has been termed the "therapeutic range" for theophylline 
in adults with asthma. 
A similar concentration-effect relationship was obtained in asthmatic children. The 
pharmacological effect, described as an improvement of forced expiratory volume in the 
first second, showed a linear correlation between the intensity of the effect and the 
logarithm of plasma concentration of the drug (Levy and Koysooko 1975). 
The therapeutic range or therapeutic window of a drug indicates the serum drug 
concentration limits between lowest effective and lowest toxic dose in a population of 
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patients (Rowland and Tozer 1995). As the drug concentration must always be 
interpreted in conjunction with the clinical assessment of the patient, the therapeutic 
range might bear little relationship to the effects of the drug at a particular concentration 
in a particular patient. The concept of target drug concentration was created to achieve 
the optimum concentration to produce the optimum effect in a particular patient. This 
concept is based on the target concentration strategy (TCS) for therapeutic drug 
monitoring developed by Sheiner and Tozer (1978). This is achieved by first selecting a 
target concentration for a specific patient and then applying prior detennined population 
pharmacokinetic parameters to calculate the loading and maintenance doses as well as 
the rate of administration to achieve the target concentration. Using the measured serum 
concentrations of the drug, the individual values for volume of distribution and clearance 
may then be calculated. The selected target concentration might be revised, if necessary 
~ 
based on the clinical assessment of the patient. The frequency of concentration 
measurements depends on the clinical assessment of the patient and the drug's 
phannacokinetic parameters. For example, the asthmatic patient with altered 
theophylline clearance due to congestive cardiac failure or pneumonia may require daily 
or more frequent serum concentration monitoring than the stable asthmatic patient. 
Target concentration strategy is important for drugs with a narrow therapeutic range such 
as theophylline. Therapeutic drug monitoring of theophylline has been successfully used 
in the treatment of asthmatic patients. 
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1.4.2. Concentration-effect relationships of theophylline in neonates 
1.4.2.1 The concentration-effect of theophylline on auditory evoked potentials m 
neonates 
No linear correlation could be found between the effects of theophylline, the dose and 
also the serum drug concentrations when the neuro-physiological effects of 
aminophylline on apnoea and brain stem auditory evoked potentials were evaluated 
(Chen et al1994). 
1.4.2.2 Concentration-effect of theophylline on cardiac function 
The effect of theophylline on cardiac function in premature neonates was investigated by 
Walther et al (1986). A theophylline loading dose of 6.8 mg/kg and maintenance doses 
of 2 mg/kg every eight hours were administered. A mean theophylline concentration of 
7.3 ± 0.8 mg/L was obtained. Stroke volume increased initially but returned to pre-
treatment values after a few days of treatment. Mean arterial pressure did not change but 
cardiac output and heart rates were increased. No linear relationship between cardiac 
output changes and theophylline concentrations was observed. 
In contrast Nadkarni et al (1988) in a study with premature neonates of comparable 
gestational and postnatal ages, found a good relationship between the increase in heart 
rate and serum theophylline concentrations up to 10 mg/L. No linear relationship was 
found at higher serum theophylline concentrations. No tachycardia (defined as >180 
beats per minute) was observed at theophylline concentration greater than 20 mg/L, 
although it has been associated with serum concentrations above 15 mg/L in other 
studies (Shannon et al1975, Jones and Baillie 1979, Aranda et al 1992). The effect of 
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theophylline on heart rate seems to be inconsistent. Most studies show an increase in 
heart rate (Aranda et al 1992), but reports of no significant effect on heart rate are also 
found (Finer et a11984, Muttitt et aI1988). 
1.4.2.3 The concentration-effect of theophylline on apnoea 
The relationship between serum concentration and efficacy of theophylline in abolishing 
idiopathic apnoea in premature infants appears to be not well defined. Only a few 
publications are available, as it is difficult to perform such studies on patients as small 
and as frail as the premature neonate. 
One of the most frequently quoted study was that of Muttitt et al (1988) who studied the 
effect of theophylline in 22 premature neonates with mean (range) gestational age of 30 
(26 to 32) weeks and postnatal age 4 (1 to 17) days. Apnoea was defined as 220 seconds 
or less if accompanied by bradycardia and a 10% decrease in peripheral oxygen 
saturation. A loading dose of 4 mg!kg and maintenance doses of 1 to 1.5 mg!kg eight 
hourly were used to attain four different levels of serum concentrations namely 4.2, 8.5, 
12.7 or 15.3 mg/L, depending on response in each individual. A non-response was 
defined as 20.33 apnoea per hour. Fourteen percent of the patients responded at a serum 
theophylline concentration of 4.2 mg/L, a further 14% at 8.5 mg/L, then a further 45% at 
12.7 mg/L and the remaining 4.5%, at 15.3 mg/L. Twenty-three percent of the patients (n 
= 22) were considered non-responders and they eventually required doxapram and/or 
continuous positive airway pressure. Characteristics of these non-responders were not 
given. Respiratory function as well as apnoea incidents were recorded. No significant 
change was detected in measures of ventilation across the four levels of theophylline. 
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There was a significant increase in inspiratory pressure, tidal volume, and minute 
ventilation at the maximum dose. However, the significant improvement in ventilation 
measures did not ensure a concomitant decrease in apnoea frequency, nor did a decrease 
in apnoea frequency reflect an increase in ventilation. A cumulative response graph was 
constructed to show that most of the patients responded at a serum theophylline 
concentration of 12.7 mg/L. 
Lagercrantz et al (1980) in a study of six premature neonates used the log-linear model 
to describe the relationship between plasma theophylline concentration and number of 
apnoea after cessation of theophylline treatment. The regression line crossed an 
arbitrarily chosen cut-off level of2 apnoea per 12 hours (0.16 apnoea per hour) at a mean 
theophylline concentration of 7 mgIL. 
Two other studies of theophylline in premature neonates with apnoea showed no linear 
correlation between effect and senun theophylline concentrations (Milsap et at 1980, 
Roberts et alI982). 
The theophylline concentration- response relationship is complicated by the fact that 
theophylline is converted to caffeine and both may stimulate the central nervous system 
(Bada et al 1979, Bory et al 1979, Boutroy et al 1979) which may cause a decrease in 
apnoea. Serum caffeine concentrations may be detected in the neonate from the first day 
of theophylline administration and as caffeine has a longer half-life than theophylline 
(Aranda et al 1992) these concentrations may increase gradually. Premature neonates 
treated with theophylline may achieve mean caffeine concentrations of 4.4 mglL by the 
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eleventh day of treatment (Brazier et al 1979, Brazier et al 1981). A further factor 
influencing the concentration of caffeine is the consumption of caffeine-containing 
beverages by the neonate's mother immediately before or during birth as this could be 
transferred to the neonate. In the present study, however, none of the mothers took any 
caffeine containing substances (for example coffee or cola) before or during birth. In 
long-term investigations of more than three days the total methylxanthine concentration 
should be measured to determine the concentration-effect relationships on apnoea of 
prematurity. It has been shown in Section B that the concentrations of caffeine in these 
first three days after birth were very small and therefore the possible influence of this 
metabolite was not investigated further. 
In the treatment of neonatal apnoea, many people are attempting to employ target 
concentration strategies as used successfully in the treatment of asthma. Some of the 
~ 
earlier investigators observed that apnoea could only be controlled with serum 
theophylline concentrations greater than 5 mg/L but cardiovascular side effects were 
associated with serum concentrations greater than 13 mglL (Shannon et at 1975, Jones 
and Baillie 1979). On the contrary, in other studies with neonates of comparable 
postconceptual ages, theophylline concentrations as low as 2 to 4 mgIL appeared to 
control apnoea and also bradycardia (Milsap et at 1980, Myers et aI1980). However, a 
poor response (3 out of 22 neonates responded) was demonstrated in neonates with 
serum theophylline concentrations between 4 to 8 mg/L by Muttitt et at (1988). After 
increasing mean serum concentrations to 12.7 mglL, an additional 63% response rate 
was noted. (a response was defined as <0.33 apnoea per hour). Based on these and other 
studies, Aranda et at (1992), in a subsequent review, stated that the desired serum 
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concentration of theophylline should range from 5 to 15 mg/L. To achieve and maintain 
these serum concentrations, a loading dose of 5 to 6 mglkg of theophylline followed by 
maintenance doses of 2 to 4 mg/kg daily in two to four divided doses were proposed. 
Table C.1 .1 below is a summary of t~e diverse therapeutic ranges and dosing guidelines 
for the treatment of neonatal apnoea. 
TABLE C.1.1 
Recommended dosages and target serum concentrations for theophylline in neonates for 
the treatment of apnoea 
Theophylline base 
Loading dose Maintenance dose Therapeutic range Reference 
IV or orally N or orally mg/L 
5 - 6 mglkg 1 - 2 mg/kg, 8 or 12 hrly 5 - 15 Halliday 1998 
5 mg/k~ 2 mglkg, 12 or 24 hrly 5 - 15 Rall1996 
Premature <24 d 1.0 mglkg 12 hrly 5 - 10 Hendeles et at 
1.0 1995 
5 - 6 mg/kg 1 mglkg 8 hrly 5 - 15 Aranda et at 1992 
5.5 mglkg 3.3 - 4, 8, 12 or 24 hrly - Besunder et al 
1988 
5 mglkg 1.5 mglkg 12 hrly 6 mg/L (target Gal and Gilman 
conc) 1986 
2.5 mg/kg 0.66 mg/kg 8 hrly 3-5 Milsap et al1980 
2.5 mg/kg 0.66 mg/kg 8 hrly 3-4 Myers et al1980 
5 mglkg 1.2 8hrly 2 - 10 Dietrich et al1978 
AbbreVIatIOns. d - days postnatal age, IV = mtravenous, hrly = hourly, 
cone = concentration. 
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These disparate recommendations confirm that the concentration-effect relationship and 
hence the therapeutic targets are, as yet, not well defined in the treatment of neonatal 
apnoea. 
1.5 OBJECTIVES 
Accordingly the objective of this section of the study was to use NONMEM to do a 
much more sophisticated concentration-effect analysis of theophylline, in premature 
neonates with apnoea, during the first few days after birth. 
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SECTION C: CHAPTER 2 
METHODS 
2.1 THE DATA 
Total apnoea (that is, all apnoea 25 seconds) incidents were used for the phannacodynamic 
modelling. Patient data, theophylline administration and serum theophylline concentration 
measurements are the same as those described in Section A, Chapter 2. Recording and 
analysis of clinical effects are also as described in Section B, Chapter 2. 
A data-file was constructed with the following parameters (abbreviation in parenthesis): 
Patient number (ill) 
Gender (o-EN) with males = 1 and females = 2 
Weight in kg (WT) 
Gestational age in weeks (GA) 
Density of all apnoea 25 seconds in observation time (F APT) 
Number of all apnoea 25 seconds in observation time (NAPN=DV) 
The serum theophylline concentration mgIL (CONC) 
Duration of observation time e.g. 4 hours on that day (DOBS) 
The time the sample was taken (TIME) in hours 
The day, that is day 0, 1, etc (DAY) 
The condition of the patients (COND) 
Whether the neonate received respiratory support (OXY) yes = 1 and no = 2 
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The postconceptual age (PCA) in weeks. 
(See Appendix C.l for an example of the data file). 
2.2 CONCENTRATION-EFFECT MODELLING 
Modelling of the data to determine the relevant pharmacodynamic parameters was 
performed using the computer package NONMEM (version V Level 1.0, double 
, 
precision. See Section A, Chapter 2). Estimates of the following were obtained: (i) the 
objective function value for each model (OFV), (ii) population means of the 
pharmacodynamic parameters Emax, ECso, baseline number of apnoea and other relevant 
parameters as specified in the model and (iii) variances of estimated parameters. 
Criteria used for selecting a model included: a change in OFV of 6.8 (p<O.Ol) or greater, 
visual inspection of scatter plots of predicted versus recorded number of apnoea, and a 
decrease in unexplained variability. 
As the data dealt with a number of events occurring in a given volume of time, it was 
classified as count data where the intra-individual distributions of the data are discreet 
and/or very asymmetrical (Beal and Sheiner 1996). Therefore, all analyses were 
performed using the LaPlacian estimation method. In all cases the concentration used 
was the actual concentration measured during the period of apnoea recordings. 
Consequently no pharmacokinetic models were used to predict concentrations. A number 
of pharmacodynamic models (structural models) were tested as detailed below. 
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The inter-patient variability was modelled usmg an exponential model. For each 
structural model, various numbers and placements of inter-individual variability 
parameters on the PD parameters were tested. 
2.2.1 The fractional Emax count model using theophylline concentration as the 
independent variable 
A control stream was written based on the fractional Emax-model using concentration of 
theophylline as independent variable. As a decrease in apnoea is expected with the use of 
theophylline, the inhibitory model was used. 
The base model was therefore built upon the following equation: 
APNOEA COUNTS per hour = BASELINE COUNT per hour * (1 - maxImum 
fractional reduction * concentration of drug / (concentration of drug that will 
cause 50% inhibition of apnoea counts + concentration of drug». 
Using abbreviations for the parameters, the above equation was re-written as: 
HAPN = EO * (l-FEMX * CONC) I (ICso + CONC) 
Where HAPN = the number of apnoea counts per hour, EO = baseline apnoea count per 
hour, FEMX = maximum fractional reduction of apnoea counts due to the drug, ICso = 
concentration of theophylline (mglL) that will cause a 50% inhibition of apnoea and 
CONC = concentration of the drug (mglL). (See Appendix C.2 for an example of the 
NONMEM control stream). 
All available covariates were tested by adding them to the base model as follows: 
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HAPN = EO * P * (1 - FEMX * CONC I (ICso + CONC)) 
Where P was a covariate such as weight, or PCA etc. 
The following covariates were screened: weight (kg), gestational age (weeks), 
postconceptual age (weeks), respiratory support (oxygen supplied per head-box), and 
condition of the neonate. 'Condition' was noted as = 1 on the data sheet if any of the 
following was present at birth: hypoxia, hypothennia, hypo/hyperglycaemia, hypotonia, 
congenital infection, prolonged rupture of membranes. The attending physician recorded 
these findings in the clinical notes of the neonate. These conditions may contribute to an 
overall poor condition of the neonate. (See Appendix C.3 for the distribution of the 
available covariates). . 
2.2 .2 The sigmoid Emax count model using theophylline concentration as 
independent variable 
The sigmoid Emax model, has an additional parameter, N, which allows for differences in 
the shape of the relationship of Emax and ECso. Therefore the basic structure of the model 
was as follows: 
HAPN = EO * (1- FEMX * CONCN I (ICsoN + CONCN) 
Where N is the number influencing the slope of the curve. 
All the other parameters are as described in the model above. 
(See Appendix C.4 for an example of the NONMEM control stream). 
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2.2.3 Time count models using time as independent variable 
It is acknowledged that the lapse of time from birth may have an effect on the number of 
apnoea counts due to physiological changes and maturation of the premature neonate, as 
described in the literature review part of Section B (see page 99). Therefore, models were 
written where time instead of concentration was the independent variable. In order to 
cancel the influence of the drug, it was assumed that the theophylline concentration was 
equal to zero. Three different types of time models were tested: an exponential, an Emax, 
and a sigmoid Emax model. 
The exponential time model was based upon the following equation: 
HAPN = EO * (1- FEMX * EXP KD) 
Where KD is an exponential change in time. 
All the other parameters are as described above. 
Therefore: 
HAPN = EO * (l-FEMX * EXP (-Log (2) / T50 + TIME)) 
The Emax time model was written using the Emax model described earlier but substituting 
'CONe' with 'TIME': 
HAPN = EO * (I-FEMX * TIME / (ET 50 + TIME)) 
The sigmoid Emax time model was also tested. This equation was based on that described 
in paragraph 2.2.2: 
HAPN = Baseline * (l-FEMX * TIMEN / (ET50N + TIME)) 
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(See Appendix C.5 for an example of the NONMEM control stream for the Emax time 
model). 
2.2.4 Time and concentration count models 
The influence of both concentrations of theophylline and time was modelled together 
based on disease progression models proposed by Holford et al (1993). In these models 
a hypothetical respiratory depression factor (RDF) was used to describe the effect of time 
on the apnoea counts. It was assumed that RDF is present at birth at a certain 
concentration. This RDF has to be removed over time - this concept could be compared 
with, for example maturation of receptor sites, or resetting of chemoreceptors to improve 
breathing control in the neonate. As the removal of RDF could be associated with an 
improvement, a decrease in the number of apnoea counts is expected to occur. It was 
assumed that the concentration ofRDF = 1 at birth. 
Thus the basic model was written as follows: 
HAPN = EO + EFFECT OF RESPIRATORY DEPRESSION FACTOR * (1-
EFFECT OF THEOPHYLLINE) 
Using abbreviations as above, this was again re-written as: 
HAPN =EO + (ERDF at time = Time * (l-ETHEO at CONC = CONC» 
Where ERDF = effect ofRDF, and ETHEO = effect of theophylline. 
The Emax models for RDF and drug effect were then combined as follows: 
HAPN = EO + ERDF * (1 - ETHEO), thus 
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HAPN = EO + ((RMAX * RDFT / (RDFT + RC50)) * (1- CONC / (CONC + TCso)) 
Where RMAX = the maximum increase in apnoea due to RDF, RDFT = concentration of 
RDF at time = Time, RC50 = ECso ofRDF, CONC = concentration of theophylline and 
TCso = ICso of theophylline. (See Appendix C.6 for an example of the NONMEM 
control stream). 
A control stream was written to do simulation of the time-concentration model. (See 
Appendix C.7 for an example of the NONMEM control stream). Estimates of the model 
parameters are used to simulate the offset model to enable visualisation of predictions 
from the proposed model. For the application of the simulation results, specific data files 
were constructed. (See Appendix C.8 for an example of this data sheet). 
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SECTION C: CHAPTER 3 
RESULTS 
3.1 THE DATA 
The patients, drug administration and serum theophylline concentration measurements, 
are the same as those in Section B. Results of the recording and f-nalysis of clinical 
effects are identical to those described in Section B (3.1). The data set available for 
pharmacodynamic modelling comprised of 46 subjects with 154 concentration-effect 
data points. The total apnoea/h (that is all apnoea ~5 seconds) incidents were selected as 
the effect measurement to be modelled with the actual serum theophylline 
concentrations. The number of these apnoea events changed significantly from baseline 
over the three days of monitoring and a larger number of these events compared to 
pathologic apnoeas, were available for modelling. 
3.2 MODELLING 
3.2.1 Results of modelling the fractional Emax count model and the sigmoid Emax 
model with theophylline concentration as the independent variable 
The results are given in Table C.3 .1. For the base model (model 1) inter-individual 
variability, 11, was estimated for each pharmacodynamic parameter viz. for the baseline 
counts, the fractional Emax, and EC50. The estimated value for 113 on ECso was very small 
and estimation of 113 was thus omitted from the next model, model 2. The resultant OFV 
did not change neither did the estimated values of the other parameters. Another 
possibility was that the small 113 for model 1 was the result of a correlation between Emax 
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and ECso .. This was tested by using a covariance (block2) matrix, on the FEMAX and 
ECso parameters (model 3). This resulted in a drop of 7.6 in the OFV compared with 
model 1. However when the initial estimates of parameters were changed (model 4), a 
further reduction of the OFV was obtained (change in OFV of 12 compared with model 
1), suggesting instability possibly due to overparameterisation of the model. 
Similar variations to the above were tried with the Hill equation (Sigmoid Emax model) in 
models 5, 6 and 7 (Table C.3.l). None of these models proved better than the simple 
Emaxmodel (model 1) with respect to OFV. 
Due to the sensitivity to initial estimates of models 3 and 4, model 1 was selected as the 
most appropriate model in this series. In addition visual inspection of the scatter plots of 
predicted versus recorded number of apnoea of the base model (Fig C.3.1), showed no 
obvious difference from model 4 (Fig C.3.2). For modell, estimated population 
parameter values for baseline, ECso and Emax fraction were 16.4 apnoea per hour, 0.37 
mglL and 0.47 respectively. The estimate of the population value for baseline of 16.4 
was very similar to the simple average of 16.0 apnoea/hour (Table B.3.2) and was very 
stable across the various models. 
The available covariates were tested on the base model (model 1) and only on their 
influence on the variability in baseline counts. The results given in Table C.3.2 showed 
no significant improvement in the fit of the data. See Appendix C.3 for plots of the 
distributions of the covariates. 
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TABLEC.3.1 
Results of the Emax and sigmoid Emax count models 
~odelnumberand OFV Baseline FEMAX EC50 N 
properties counts (11%) (11%) 
(11%) 
1 1283.563 16.4 0.474 0.371 -
(311'S) (71) (136) (0.00003) 
2 1283.563 16.4 0.473 0.371 -
(211'S) (71) (136) -
3 1275.918 16.5 0.471 0.099 -
(Omega block2) (70) (126) (289) 
(112,3 = -30) 
4 1271.191 17.5 0.587 0.478 -
(Omega block2) (71) (63) (406) 
(112,3 = -90) 
5 1284.634 16.4 0.438 0.061 6.09 · 
(311'S) (71) (121) (49) 
6 1284.634 16.4 0.438 0.105 5.9 
-
(211's) (71) (121) -
7 1284.634 16.4 0.438 0.072 6.16 
(3 11' s and Omega (71) (121) (48) 
block(2) on FEMAX (112,3=4.1) 
and EC50) 
OFV = Objective function value, 11 = inter-individual variability, FEMAX = the 
fractional Emax, EC50 = the concentration of theophylline (mglL) that decreases the 
apnoea counts by 50% of Emax, N = the Hill coefficient. 
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TABLE C.3.2 
Testing of covariates on fractional Emax count model 
~odelnumberand OFV Baseline Counts FEMAX ECso 
( covariate) tested [covariate estimate] 
(11%) (11%) (11%) 
8 1279.017 18.0 0.566 0.47 
(Postconceptual age) [pCA = 0.043] 
(81) . (131) (149) 
9 1283.562 16.4 0.474 0.37 
(Oxygen support) [OXY = 0.994] 
(71) (137) 
10 1289.913 13.1 0.824 5.29 
(Weight) [WT on baseline] 
(81) (224) 
11 1279.864 17.8 0.493 0.10 
(Gender) [~ales = 0.9] 
(71) (122) (192) 
12 1280.040 17.3 0.770 3.13 
(Condition) 
~ 
[COND = 0.923] 
(71) (249) 
OFV = Objective function value, FEMAX = the fractional Emax, ECso = the concentration 
of theophylline (mglL) that will decrease the apnoea counts by 50%,11 = inter-individual 
variability, PCA = postconceptual age (weeks), OXY = oxygen support at time of 
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Fig.C.3.1 Predictions vs dependent variable, base model (Model 1) Fig.C.3.2 Predictions vs dependent variable, Model 4 
3.2.2 Results of time count models and time plus concentration count models 
Variations of the time model as described in Section C 2.2.3 were tested and the results 
are given in Table C.3.3 . 
TABLEC.3.3 
Results of the time count model 
~odelnumberand OFV Baseline FEMAX ETso (hour) N 
properties (11%) (11%) (11%) (11%) 
13 1298.782 40.3 10 0.105 38.3 
Exponential time - - -
model 
14 1276.863 17 0.565 0.0476 1 
Emax time model (68) (l05) (237) (Fixed) 
15 1274.679 16.6 0.495 0.053 0.969 
Sigmoid Emax time (67) (109) (169) -
model 
J 
16 1272.472 16.5 0.453 0.0206 1 
Emax time model (71) (133) (198) (Fixed) 
with N fixed to 1 (112,3 = 240) 
and 
Omega block(2) 
OFV = Objective function value, 11 = inter-individual variability, 
FEMAX = the fractional Emax of time, ET 50 = the time that will decrease the apnoea 
counts by 50%, N = the Hill equation, a number influencing the slope of the curve. 
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A successful minimisation could not be obtained with the exponential time model, model 
13. The values of the estimated parameters of the Emax and sigmoid Emax time models did 
not differ significantly. The Emax time model with inter-individual covariance between 
FEMAX and ETso (model 16) did not significantly improve the fit of the data and hence 
model 14 was the best of this series. The baseline counts were 17 per hour, the Emax 
fraction was 0.565 and the ETso was 0.0476 hours. The value ofETso, that is the time 
required to decrease the apnoea counts by 50%, was very small. 
3.2.3 Results of the time-concentration count model 
The results of the time-concentration models are given in Table C.3.4. 
F or the base model in this series (model 17) some of the parameter values (including the 
TCso of97.3 mgIL) appear to be unrealistically high. (The TCso is the estimated value of 
the serum theophylline concentration that would decrease the apnoea counts by half in 
the presence of the hypothetical respiratory depressant factor (RDF).) Subsequent 
modelling revealed that the initial estimates of the parameters and the number and 
position of the llS again influenced the estimated values of the parameters. However in 
all these subsequent models the baseline counts plus RMAX (the maximum increase in 
apnoea due to RDF) was about 16. This is the same value as that of the baseline counts 
in the previous series. Covariance between the different parameters was tested by 
implementing Omega block (2), (3), (4) and (5). With the first two mentioned, 
minimisation was successful. However, successful termination could not be obtained 
with Omega block (4) and (5). The model selected as most appropriate from this series 




Results of the time-concentration models 
Model nmnber and OFV Nonnal RMAX RCso Rthalf TCso 
properties (11%) (11%) (11%) (11%) (11%) 
17 1278.673 6.39 33.9 0.723 0.053 97.3 
Base model with 4 11 ' s (70) (0) (225) (94) (99) 
18 1263.968 8.08 7.8 0.037 0.007 2.82 
3 11' s and Omega (66) (104) (241) (0) 
block(2) between (112,3:-
RMAX and RCso 150) 
19 1267.860 7.84 8.5 0.306 0.080 2.97 
As model 18 but with (66) (90) (183) (83) 0 
Omega block(3) between (112,3 = (113,4 = fixed 
RMAX, RCso and Rthalf 27) 17, 10) 
20 1269.595 7.38 8.43 0.235 0.069 2.36 
As model 18 but with (65) (96) (153) (76) (71) 
Omega block(4) between (112,3 = .(113,4 = (114,5 = 
RMAX, RCso, Rthalf, -29) 18,10) 19,11, 
and TC so 20) 
21 1262.894 7.66 7.53 0.223 0.053 2.66 
As model 18 but with (70) (108) (170) (83) (72) 
Omega block(5) between (11 1,2= (112,3 = 9, (11 3,4 = (114,5= 
Nonnal, RMAX, RCso, 16) -28) 18, 16, 21, 18, 
Rthalf and TC so 9) 11, 19) 
OFV = Objective function value, 11 = inter-individual variability, Nonnal = the baseline 
count without the influence ofRDF (respiratory depressant factor), RMAX = maximum 
increase in apnoea due to RDF, RCso = the concentration ofRDF that will have a 50% 
influence, Rthalf= half-life ofRDT, TCso = the concentration of theophylline Cmg/L) 
that will decrease the apnoea counts by 50%. 
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Visual inspection of the scatter plots of predicted versus recorded number of apnoea of 
model 18 as depicted in Figure C.3.3 showed only marginal differences when compared 
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Fig.C.3.3 Predictions versus dependent variable for Model 18. 
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3.2.4 Results of simulation of time-concentration model 
The result of a simulation of the time-concentration model is depicted in Figure C.3.4. 
The figure shows the ERDF (Emux model) of the respiratory depressant factor (RDF) 
when Rmax is taken as 20 and the half-time concentration of RDF (RDFCsu) ~s 1. The 
rapid fall of the respiratory depressant factor over time CROFT) is clearly demonstrated. 
In this simulation the hourly apnoea counts (HAPNO) of the patient at baseline is the sum 
of the normal apnoea counts plus the influence of the respiratory factor, therefore 
HAPNO = Normal + ERDF. When theophylline is administered, the effect of a serum 
concentration of 3 mglL on the hourly apnoea (HAPN+ T) becomes apparent and the 
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Fig. C.3.4 Simulation of the time-concentration model with serum theophylline 
concentration of 3 mglL. 
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Figure C.3 .5 is as above, but the 50% inhibitory concentration of theophylline (TC.'i\)) 








~10 - Conc ______ ~~ __ ~~ _________________________________________ 1 
=' ~ 
~ ~ HAPN+T 
' .. 
~ ..... ...... . .. -. " 
Fig. C.3.5 Simulation of the time-concentration model with serum theophylline 
concentration of 10 mglL. 
3.2.5 Model selection 
There were 3 different series of models and within each series a best model could be 
selected (namely models 1, 14 and 18). However it was difficult to compare these best 
models across the three series and it is probably not appropriate to consider OFV 
di fferences. 
Visual inspection of the graphs, of predictions versus dependent variables, showed no 
obvious difference between the models. With these types of models suitable diagnostic 
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graphs are not possible (Prof S Beal personal communication). 
The inter-individual variabilities of the estimated parameters cannot easily be compared 
between models because the models are highly sensitive to the placement of variabilities 
as well as, in some cases, the value of the initial estimates. All the models tested are 
non-linear and therefore parameters are correlated and difficult to discriminate from one 
another. With the exception of the estimate of the baseline value, confidence in the 
parameter estimates is uncertain. With all models tested the covariance step aborted 
possibly due to instability of the models. 
If we assume that theophylline has some pharmacological effect in apnoea, and that 
measurable concentrations are required for this, then Model 18 gives the only realistic 
ECsovalue at 2.8 mgIL. 
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SECTION C: CHAPTER 4 
DISCUSSION 
4.1 DISCUSSION 
One way of analysing the data in this section would have been to do a population 
analysis using the quantal dose response model as an extension of the assessment carried 
out in section B. However, Prof S Beal advised (personal communication) that a more 
appropriate analysis, which would not involve manipulation of the data, would be the 
count model. 
Accordingly variations on the Emax model adapted for count data were tested on the data 
set involving total apnoeas. In fact, none of the models tested proved to be satisfactory 
either as descriptors, and certainly not for predictions and dosage recommendations. The 
models that considered only theophylline concentrations and took no account of the 
baseline improvement of apnoea, with maturation, all yielded unrealistically small values 
for ECso for theophylline. 
It has been shown that maturity could playa role in the disappearance of apnoea (Sims et 
aI1985). In the third series, which incorporated the possibility of a changing baseline, a 
more realistic value of 2.8 mg/L was obtained. Milsap et at (1980) and Myers et at 
(1980) suggested concentrations of3 to 5 mglL and 3 to 4 mglL respectively to decrease 
apnoea. 
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Modelling drug concentration together with time, as in series 3, resembled a disease-
progression model as described by Holford et at (1993). In this series a hypothetical 
respiratory depressant factor that is removed over time, as the neonate improves, was 
used. In the premature neonate respiratory symptoms are often the result of a complex 
interplay between RDS, intra-cranial haemorrhage, central hypoventilation and infection 
(Hegyi et a11986) as well as low oxygen levels (Poets et at 1993). Thus, the respiratory 
depressant factor could be influenced by any condition that may contribute to the 
development of apnoea such as a lack of proper oxygenation, hypo- or hyper -thermia, 
fever, cardiac malfunction etc. The success of this model series would have been greatly 
facilitated by the inclusion of a control group that would have allowed for discrimination 
between the maturation and the theophylline effect. 
Population concentration-effect modelling of theophylline in the treatment of neonatal 
apnoea proved io be very complex. As mentioned in the results-section, comparison 
between models was not really possible. Population modelling as applied to count data 
is in its infancy and techniques are still developing. Population count models were first 
described by Beal in the mid-l 990s. The methodologies for assessing goodness of fit 
and model discrimination are currently still very unclear. 
With all models tested, the number and position of the inter-individual variability 
parameter, 11, influenced the estimated values of ECso and the OFV, suggesting an 
unstable model (Prof S Beal, personal communication). Although the size of 11 on the 
estimated baseline apnoea counts model remained fairly consistent, it varied significantly 
on the estimated ECso and on the fractional Emax of theophylline as well as on other 
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parameters. One possible explanation for this is that it involves overparameterisation of 
non-linear models and that the data set had relatively few repeated levels per individual. 
Covariate modelling was not carried further because of difficulties in identifying an 
appropriate structural model. 
The analysis in section B clearly showed that, when considering total apnoeas, there 
were distinct groups in terms of response to theophylline (when defined as 50% 
reduction from baseline). A very recent development in analysing count data is the 
recognition that patients may fall into groups with different distributions i.e. responders 
and non-responders. Although it is understood that categorical and count data are 
different, the analysis of data in section B of the present study shows that patients could 
be categorised into responders and non-responders. Likewise the recognition of a group 
of non-responders to theophylline in apnoea appears frequently in the literature (Shannon 
et a11975, Jones 1982, Roberts et a11982, Sims et al 1985, Muttitt et a11988, Harrison 
et al 1992). It is very likely that not taking this into account, in the present study, may 
have contributed to the poor modelling results when total apnoea was chosen. A few 
researchers are currently applying the mixture model feature in NONMEM to apply two 
distributions and to estimate the proportion of individuals falling into each (Piotrovsky 
and Van Peer 2000, Dr R Miller personal communication). This is one way in which this 
data could be further analysed. Modelling using the pathological apnoeas may have been 
more successful using only one distribution because in this group there were only 13% 
non-responders. In the light of the poor results of the modelling using the count model it 
might have been worthwhile to model the data using logistic regression, particularly 
since patients have already been categorised as responders or non-responders. Although 
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this approach is theoretically not as appropriate as the count model, it could have 
provided some indication of a concentration response relationship. 
4.2 CONCLUSION 
Modelling with count data is in its infancy and as a result the findings in this section 
were not conclusive. Possible future directions would be to do even more sophisticated 
modelling. This could involve using the mixture modelling facility in NONMEM with 
multiple distributions. Incorporation of a control group, as well as the option to increase 
dose in non-responders, would greatly improve study design. 
217 
CONCLUSION 
This study has focussed on the pharmacokinetics, the clinical effects and the 
concentration-effect relationship of theophylline in apnoea during the first few days of 
life. 
The results have shown that theophylline has a lower clearance and volume of 
distribution in the premature neonate than in older babies. The clearance is also 
influenced by oxygenation, as clearance is faster in neonates who receive oxygen 
support. The findings are comparable with pharmacokinetic results obtained from 
traditional phannacokinetic studies in premature neonates with postnatal ages similar, or 
close to, those of the present study. The low clearance results in a long half-life thus 
small peak to trough fluctuations would be expected. Therefore, a once daily dosing is 
recommended lor this population. This will ease the burden of the nursing staff and also 
improve compliance and accuracy. 
The results also confinned the high degree of variability in this population group as large 
inter- and intra-patient, as well as inter-occasion, variability were found. This may be 
explained by the changing physiology of the neonate after birth. Unfortunately this high 
variability makes it difficult to predict drug concentrations with the same degree of 
accuracy as in other populations. The inter-occasion variability in clearance of 34% is an 
indication of the size of variability that may be expected during the first few days. 
Because of this variability it is advised that serum drug levels should be determined and 
the dose adjusted accordingly. 
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The effect of theophylline on total apnoea (all apnoea ~5 seconds) was not as dramatic as 
on pathologic apnoea (~20 seconds). Although a statistically significant decrease was 
seen from baseline to all three days for both types of apnoea, only a 52% cumulative 
response was obtained in total apnoea compared to the 87% in pathologic apnoea. 
Approximate EC50 values were in the region of 3 to 9 mg/L. The most dramatic effect 
was seen after the loading dose (day 1) when a sharp drop in both incidents and densities 
of both pathologic and total apnoea, from baseline, was observed. 
Regardless of all the potential beneficial effects of the drug on ventilation/perfusion 
inequalities, theophylline did not decrease hypoxaemic episodes significantly. A 
cumulative response of 56% was seen at serum theophylline concentration > 15 mg/L. 
Only the hypoxaemic episodes associated with a pathologic apnoea (~20 seconds) and a 
fall in heart rate decreased significantly. 
Analysis of possible markers for non-response «50% improvement from baseline) 
indicated that being one of a set of twins was indicative of a poor response for both total 
apnoea and hypoxaemic episodes. Other possible markers of poor response for hypoxia 
were being born by caesarean section and having more than the 75th percentile pathologic 
apnoea at baseline. As there was such a good response to theophylline for pathological 
apnoea (only 13% non-response), no markers of poor response were identified for this 
group. It was noted however that all five of the babies who did not respond were boys. 
It was interesting that, with regard to total apnoeas, there were some features that seemed 
to predict a favourable response to theophylline. These were a birth weight and a 5 
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minute Apgar score below the 25th percentile, and a baseline total apnoea count above 
the 75th percentile. 
The cumulative graphs of the responders and non-responders resembled the fixed effect 
model, which is the" simplest model to explain drug-effect relationships. 
The more sophisticated exploration of the concentration-effect relationship of 
theophylline in neonatal apnoea using the count model was complex. Although none of 
the models tested proved to be satisfactory, that which incorporated the influence of a 
hypothetical respiratory depressant factor gave the most realistic value ofEC5o. 
A control group (which was not possible in this study on ethical grounds) would be 
needed to distinguish the role of theophylline from the effect of maturation. 
Population modelling as applied to count data is still undergoing development and it has 
only recently been recognised that, where patients fall into two distributions (e. g. 
responders and non-responders), the mixture model feature in NONMEM could be 
applied to the data. It is possible that, in future, such modelling could further define the 
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11. IlI70EMED CO!SElIT roa IlICLOSIO~ III .I. ct.IlIIC&!. ntLU.. 
I. I f/!U!t: 
hereby eonse!1~ to the fQlloYinc proeedu.re iUld/or t:eU"ent beinc 
eoodueted 00 the person 1ncUeated in (4) bolau. 
A serum sample to be taken for theophylline concentration measurements 
when necessary. 
2. . I acknculed..:e tha.t I ha.ve been in!or-ed by : 
! Mrs M. du Preez • Professor Adhikari 1 \ 
ccnee:'1li:'1: the possible: ad.".n:a&es and :possl.ble ad '/c!'se e!!ec':3 
uh.lcb :Day result from the a.bove::ent::'oned proe~du:-e and/or 
treat~lI!nt and of the ~ays in o:.:h.ie!\ !': is d:'!!er'!::: f:-o:l ':he 
c!lnve.nt:'cn.a.l i'rocedure and / or trea t :e:lt . The in.!:lr-:l&:icn ~h.;. e !'l 
I I.:U :i'/ c:1 a.nd: wh.ich r ac:bouLed.:e ! t1:lde:-st.a:.c. :.s sho~"'Q ac t:"1e 
reverse side of th::..s !or.:!.. 
J. I a,r~~ ':.~a.t the above procedure ."t! / or tr!a::::Je nt ' .. :' 1. 1 t»e c!.!':-:.!-: 
cut and/or super"'lised by: 
Professor Adhikari 
4. I ack:2ouledle tha.t I understand the c::ntents of :.~s (0:"":1. 
includ!n: the 1ntor:u.t!.on proVided on 1tl reVers! .led a.s the 
r SUBJECT I PAP.!.~T I GUARDIAII I om!? (SP~CI;Y) 
freely consent to the .. bo'/lI: procedure and / or t:"!!.1t::ent bein; 
c::lnducted on: 
1!Wi!: 
S. ! aJD a\l&re tha.t I :nay Yitl:dr~Y my COD.5ent a.t any t:.=e '-lithout 
prejudice to further care. 
srGlItD I SUBJECT: II DA.r! I - I 
SIGlIC IIIImzss: II DA.T! I . I 
SIGlI!'!) I nF.OII!WIT: II OAT!!; I I 
SIGRtD IRtS~CHD\: II DAr! I I 
• il1th tho ox.option of the names and shnaturu in p&neraph.s I. 4 
iUld 5. pltuo provide tho above 1D!onut!on. 
11. OI'lll!MAnC'! GIV!:! TO ~..cT3 
~ltl..5e indiC3.te '-Iba.e. U111 be told. to subject., ,..in sbp!e la.a,ua:!. The 
;7rOc!dure or e.:eat::sene. '-Ihic!\ \1111 be Ipplied. saouJd be ducr:.!:ed. uti 
:-e i e:rer.c: snoule! be :uc!e to poss!bh Side e!!tetj, d.i.sc'Om!or!. 
cor.:pl::!.cat!o1U andlor benefit.t. It::use. be ude c!aAr to the ;a.t!e.:lC 
!~at :-t: / ,he 15 !ree at any ti:e to IJ"ic!':drlY I.l1.chauc sutt!'r:':1& l l':Y 
d:'Ja.r! ·/al1t.l:~. . 
Your baby is being given a medIcine to help it breath. We are trying to find out more 
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Pharmacokinctic data file 
wur l:lSA UA PNA peA UEN AP AQ OXY TIME AMT l)V DEX 
21 1.2 0.112 33 1 33 . 1 
21 1.2 0. 112 33 1 33. i 
21 1.2 0.112 
21 1.2 0.112 
21 1.2 0.112 
21 1.2 0.112 
21 1.2 0.112 







21 1.20.112 33 
21 1.2 0.112 33 
21 1.2 0.112 33 
21 1.2 0.112 33 
21 1.2 0.112 33 
21 1.2 0.112 33 
21 1.1 0.107 33 
21 1.1 0.107 33 
21 1.1 0 .107 33 
21 1.1 0. 107 33 
21 l.l 0.107 33 
21 1.2 0.112 33 
21 1.25 0.114 33 
23 1.95 0.164 32 
23 1.95 0.164 32 
23 1.95 0.164 32 
23 1.95 0.164 32 
23 1.95 0.164 32 
23 1.95 0.164' 32 
23 1.95 0.164 32 
23 1.95 0.164 32 
23 1.95 0.164 32 
24 1 0. 1 30 
24 1 0.1 
25 1.05 0. 102 
25 1.05 0.102 
25 1.05 0.102 
25 1.05 0.102 
25 1.05 0.102 
25 1.05 0.102 

















25 0.9 0.095 
25 0.9 0.095 
25 0.9 0.095 
25 0 .9 0.095 

































































































































































































8 2 0 
8 2 9.83 
8 2 19.1.0 
8 2 25.83 
8 2 33 .83 
8 2 41.08 
8 2 51.33 
8 2 57.83 
8 2 64.83 
8 2 73.33 
8 2 81.83 
8 2 89.16 
8 2 97.33 
8 2 105.83 
8 2 115.08 
8 2 12UB 
8 2 129.83 
8 2 137.83 
8 2 145.33 
8 2 153.83 
8 2 162.16 
820 
824 
8 2 lUG 
8 2 12.21 
8 2 27.96 
8 2 35.13 
8 2 43.46 
8 2 51.96 













































































































































































































































































































27 1.25 0.116 Jl 4 
27 1.25 0.116 31 5 
27 1.25 0.116 31 5 
27 1.25 0.116 31 6 
27 1.3 0.118 31 6 
27 \.3 0.118 31 7 
27 1.3 O. I 18 31 7 
27 1.3 0.118 31 8 
27 1.4 O. 123 3 1 8 
29 1.9 0.154 34 2 
29 1.9 0.154 34 3 
29 1.9 0.154 34 3 
29 1.9 0.154 34 . 3 
29 1.9 0.154 34 4 
29 1.9 0.154 34 4 
29 1.9 0.154 34 4 
29 1.9 0.154 34 4 
29 1.9 0.154 34 5 
29 1.9 0.154 34 5 
29 1.9 0.154- 34 5 
29 1.9 0.154 34 6 
29 1.72 0.146 34 6 
30 1.41 0.128 31 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.41 0.128 
30 1.4 0.128 
31 0.85 0.082 
31 .0.85 0.082 
31 0.85 0.082 


































































































































































































































































































































































































































































































35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.5 0.132 
35 1.3 0.123 
35 1.3 0.123 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.65 0.135 
36 1.6 0.133 
37 1.9 0 .149 
37 1.9 0.149 
37 1.9 0.149 
37 1.9 0.149 
37 1.9 0.149 









































































0 .145 34 













41 1.7 0.143 
41 1.7 0.143 
41 1.7 0.143 
41 J.7 0.143 
41 1.7 0.143 
41 .1.7 0.143 
41 1.7 0.143 
41 1.6' 0.14 
41 1.6 0.14 
41 1.6 0.14 
41 1.6 0.14 































































































































































































































































































































































































































































































































































41 1.6 0.14 32 
41 1.6 0.14 32 
41 1.6 0.14 32 
41 1.6 0.14 32 
41 1.56 0.139 32 
41 1.56 0.139 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.65 0.155 32 
45 1.5 0.148 32 
45 1.5 0.148 32 
46 1.35 0.125 31 
46 1.35 0.125 31 
46 1.35 0.125 31 
46 1.35 0 .125 31 
46 1.35 0.125 31 
46 1.35 0.125 31 
46 1.35 0.125 31 
47 1.1 0.107 30 
47 1.1 0.107 30 





































50 1 0.098 
52 . 0.9 0.098 
52 0.9 0.098 
52 0.9. 0.098 
52 0.9 0.098 
52 0.9 0.098 
52 0.9 0.098 

























































































































































































































































































































































































































































































































































































































































































































66 0.9 0.101 30 2 
66 0.9 0.101 
66 0.9 0.101 
66 0.9 0.101 
66 0.9 0.101 
66 0.9 0.101 
66 0.9 0.101 
66 0.9.0.101 
66 0.9 0.101 
66 0.9 0.101 
66 0.9 0.101 































































































































































































































































































































































































2 78.8 0.86 
2 88.8 0.86 
2 98.8 0.86 
2 160.55 0 



















































































































































































70 1.25 0.116 
70 1.25 0.116 
70 1.25 0.116 
70 1.25 0.116 
70 1.3 0.118 
70 1.25 0.116 
70 1.25 0.116 
70 1.24 0.116 
71 1.1 0.108 
71 1.1 0.108 
71 1.1 0.108 
71 1.1 0.108 
71 1.1 0.108 
71 1.1 0.108 







72 1.36 0.121 
72 1.36 0.121 
74 1.5 0.\29 
74 1.5 0.129 
74 1.5 0.129 
74 1.5 0.129 
74 1.5 O. \29 
75 1.7 0.141 
75 1.7 0.141 
75 1.7 0.141 
75 1.7 0.141 
75 1.6 0.136 
75 1.6 0.136 
75 1.6 0.136 
75 1.6 0.136 
75 1.6 0.136 
75 1.6 0.136 








































76 1.5 0.131 3 I 
76 1.5 0.13 I 3 I 
76 1.5 0.131 31 
76 1.5 0.131 31 
76 1.5 0.131 31 
76 1.5 0. \31 31 
76 1.5 O. \3 I 3 I 
77 1.1 0.108 31 
77 1.1 0.10R 31 
77 1. I O. lOR 31 
77 0.103 31 
77 0.103 31 
77 0.103 31 
77 0.103 31 
77 • O. 103 31 
77 0.103 31 
77 0.103 31 
77 0.103 3 I 
























































































































































































































































































































7.87 0.86 o 

















11.7 0 .86 
19.8 0 

























































































































































































78 1.35 0.124 
78 1.35 0.124 
78 1.3 0.121 
78 I.3 0.121 
78 1.3 0.121 
78 1.3 0.121 
78 1.3 0.121 
78 1.3 0.121 
78 1.3 0.121 
79 1.15 0.112 
79 1.15 0.112 
79 1.15 0.11 
79 1.15 0.11 
79 1.15 0.11 
79 1.15 0.11 
79 1.15 0.11 
80 1.25 0.116 
80 1.25 0.116 
80 1.25 0.1 16 
80 1.25 0.116 
80 1.25 0.116 
81 1.45 0.13 
81 1.45 0.13 
82 1.51 0.131 
82 1.51 0.131 
82 1.51 0.131 
82 1.51 0.131 
82 1.51 0.131 
82 1.51 O.DI 
82 1.51 0. \31 
82 1.51 0. \31 
82 1.51 0.\31 
82 1.51 0.131 
82 1.51 0.131 
83 1.06 0.104 
83 1.06 O. \04 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.8 0.087 
84 0.77 0.085 
84 .0.77 0.085 
&4 0.77 0.085 
84 0.77' 0.085 
85 1.03 O. \05 
85 1.03 0.105 
85 1.03 O. \05 





































































































































































































































































































































































































































































































































































85 1.03 0.105 
85 1.03 0.105 
85 1.03 0.1 05 
85 1.03 0.105 
85 1.03 0.105 
85 1.03 0.105 
85 1 0.103 
85 0.103 
86 0.68 0.082 
86 0.68 0.082 
86 0.68 0.082 
86 0.68 0.082 
87 1.2 0.115 
87 1.2 0.115 








































































0.081 ~ 30 
89 0.8 0.081 
89 0.8 0.081 
89 0.8 0.081 
89 0.8 0.081 
89 0.8 0.081 
89 0.8 0.081 
89 0.8 0.081 
90 1.5 0.126 
90 1.5 0.126 
90 1.5 0.126 
90 1.5 0.126 
90 1.40.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4 0.121 
90 1.4.0.121 
90 1.4 0.121 
90 1.4 0.121 
91 1.25 0.113 







































































































































































































































































































































































































































































































































91 1.25 0.1 \3 30 
91 1.25 0.113 30 
91 1.25 0.113 30 
91 1.25 0.113 30 
91 1.25 0.1 \3 30 
92 1.45 0.115 33 













95 0 .85 































































98 1.3 0.11 
98 1.3 0.11 
98 1.3 0.11 











































98 1.3 0.11 32 
98 1.3 0.11 J2 
98 1.3 0.11 32 
98 1.3 0. 11 n 
98 I • 0.097 32 
98 0.96 0.095 31 
98 0.96 0.095 32 
99 1.7 0.146 32 









































































































































































































































































































































































































































































































































































99 1.7 0.146 32 
99 1.7 0.146 32 
99 1.7 0.146 32 
99 1.7 0.146 32 
99 1.7 0.146 32 






























































































11 1.14 O. \09 30 
12 1.3 0.12 30 
12 1.3 0.12 30 
12 1.3 0.12 30 
12 1.3 0.12 30 
12 I.3 0.12 30 
12 1.3 0.12 30 
12 1.1 0.111 30 
12 1.1 0.111 30 
12 1.1 0.111 30 
12 1.2 0.115 30 
12 \.24 0.117 30 
D 1.25 0.117 31 
B 1.25 0.117 31 
B ,1.25 0.117 31 
IJ 1.16 0.113 31 
13 1.16 .0.113 31 
13 1.16 0.113 31 
\3 1. 16 0.113 31 
13 1.16 0.113 31 






















































































































































































































































































































































2 43 .91 1.29 
2 55.66 1.29 
2 66.33 1.29 
2 114. 18 0 
2 0 43 
2 0.5 0 
2 5.98 0.86 
2 16.54 0 
2 19.16 0.86 
2 30.81 0.86 
2 40.44 0 
2 42.66 0.86 


























































































































































































































































































































17 0. 101 
17 0.101 
17 0.101 
18 0.95 0.099 
18 0.95 0.099 
18 0.95 0 .099 
18 0.95 0.099 
18 0.95 0.099 
19 1.75 0.141 
19 1.75 0.141 
1.2 0. 114 
J.2 0.114 
2 .1.15 0.109 
2 1.15 0.109 
2 1.05, 0.109 
2 1.05 0.104 











































































































































































































































































2 64.98 0.86 0 
2 89.21 o 16.5 
2 161.71 o 3.6 
2 0 5.16 0 































































































































































































































































































3 1.3 0.12 32 
3 1.3 0.12 32 














3 1.3 0.12 32 
3 1.3 0.12 32 
3 1.3 0.12 32 
3 1.18 0.115 
3 1.18 0.115 
3 1.18 0.115 
3 1.18 0.115 
3 \.18 0.115 





















4 0.65 0.08 




























7 1.55 0. 129 
7 1.55 0.129 
7 1.55 0.129 
7 1.55 0.129 
7 1.55 0.129 
7 1.55 0.129 
7 1.55 0.129 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 \.I 0.108 
8 1.1. 0.108 
8 1.1 0.108 
8 1.1 0.108 
8 1.1 0.108 












































































































































































































































































































































































































16.76 0 4.5 





































































































































































































































































































0. \08 31 
0.108 31 
0 .\08 31 
0.108 31 
0 .108 31 
0.108 31 
0. \08 31 
0.108 31 
















0 .113 32 








0 .113 ~ 32 
0.113 32 















III 1.26 0.115 30 
30 III .1.26 0.115 
III 1.26 0.115 30 
I I I 1.26, 0.115 30 
III 1.26 0.115 30 
I I I 1.26 0.11 5 30 
I II 1.16 0. 115 30 








































































































































































































































































































































































































































































































































































III 1.26 0.115 
III 1.26 0.11 5 
III 1.26 0.115 
III 1.26 0.115 
III 1.26 0.115 
111 1.26 0.115 
112 0.75 0.083 
112 0.75 0.083 
112 0.75 0.Otl3 
112 0.75 0.083 
112 0.75 0.083 
112 0.75 0.083 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
112 0.66 0.08 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.114 
113 1.2 0.1 (4 



























115 0.85 0.09 
115 0.85 0.09 
115 0.85 0.09 
115 0.85 0.09 
I IS 0.85 0.09 
I IS 0.85 0.09 
115 0.85 0.09 
115 0.85 0.09 
115 0.85 0.09 
115 0.85 0.09 









































































































































































































































































































































































































































































































































































































116 1.05 0.104 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 0.143 
117 1.75 
117 1.75 






















118 1.3 0.119 
118 1.3 0 .119 
118 1.3 0.119 
I 18 1.3 O. I 19 
118 1.3 0.119 
118 1.3 0.119 
11!l 1.11 0.119 
118 1.11 0.119 
9 1.95 0.154 
9 1.95 0.154 
9 1.95 0.154 
9 1.95 0.154 
















































9 1.95 0.154 33 
9 1.44 0.14 33 
9 1.44 0.14 3~ 
9 1.44 0.14 :U 
9.1.44 0.14 33 
9 1.44 0.14 33 
9 1.44. 0.14 33 
9 1.76 0.15 33 
9 1.76 0.15 33 
9 1.76 0.15 33 































































































































































































































































































































































2 44.86 0.86 0 
2 55.79 0.86 0 
2 73.29 0.86 0 
2 79.R7 0.R6 0 
2 90.79 0.86 0 
2 97.29 O.R6 0 
2 103.51 0.86 0 
















84 .73 1.72 





















































































































































































9 1.76 0.15 33 6 33.9 
'J 1.76 0. 15 3.1 7 .14 
9 1.76 0.15 33 8 34.1 
9 I. 76 0.15 33 9 34.3 
1191.350.124 32 32.1 
119 1.35 0.124 32 32.1 
119 1.35 0.124 32 32.1 
119 1.35 0.124 32 32.1 
119 1.35 0.124 32 2 32.3 
119 1.35 0.124 32 2 32.3 
119 1.35 0.124 32 2 32.3 
119 1.35 0.124 32 3 32.4 
119 1.35 0.124 32 3 32.4 
119 1.35 0.124 32 3 32.4 
119 1.35 0.124 32 4 32.6 
119 1.35 0.124 32 4 32.6 
119 1.35 0.124 32 5 32.7 
119 1.24 0.12 32 5 32.7 
119 1.24 0.12 
119 1.24 0.12 
119 1.24 0.12 









119 1.24 0.12 32 6 
119 1.18 0.12 32 7 
120 0.9 0.093 31 1 
120 0.9 0.093 31 . 1 
120 0.9 0.093 31 2 
120 0.9 0.093 31 2 
120 0.9 0.093 31 3 
120 0.9 0.093 31 3 
120 0.9 0.093 .31 4 
120 0.9 0.093 31 4 
120 0.9 0.09f 31 5 
120 0.78 0.09 31 5 
121 1.1 0.106 31 
121 1.1 0.106 31 2 
121 1.1 0.106 31 2 
121 \.06 0.104 31 3 
121 1.06 0.104 31 3 
121 \.06 0.104 31 4 
121 1.06 O. \04 31 4 
121 1.06 O. \04 31 5 
121 1.06 0.104 31 5 
121 \.02 0.103 31 6 
121 1.02 0.103 31 6 
121 1.02 0.103 31 7 
121 0.88 0.096 31 7 
122 \,4 0.124 30 
122 1.4 0.124 30 
122 1.4 0. 124 30 
122 1.4 0.124 30 
122 1.4 0.124 30 
122 1.4 0. 124 30 
122 1.4 0.124 30 
122 1.4 0.124 30 
122 1.4 0.124 30 
122 1.4 0.124 30 
































































































































































2 126.54 0 6.3 
2 150.6 0 3.2 
2 174.47 0 1.9 
2 198.23 0 II 
o 5.6 0 
5.8 0.86 0 
8.52 0 2.1 
13.02 0.86 0 
23.25 0.86 0 
29.03 0.86 0 
2 37.16 0.86 0 
2 46.98 0.86 0 
2 53.5 0.86 0 
2 63 0.86 0 
2 71.17 0.86 0 
2 77.5 0.86 0 
2 95 0.86 0 
2 101.13 0.86 0 
2 110.75 0.86 
2 118.97 0.86 
2 125.34 0.86 
2 127.42 0 
2 131.4 0 
2 152.71 0 
2 0 4.3 
2 15.5 0.86 
2 27.5 0.86 
2 39.5 0.86 
2 51.5 0.86 
2 63.5 0.86 
2 74 0.86 
2 87.85 0.86 
2 97.9 0.86 
2 101.13 0 
2 0 4.3 
2 9.92 0.86 
2 21 0.86 
2 33 0.86 
2 45 0.86 
2 57 0.86 
2 69 0.86 
2 79.42 0.86 
2 91 0.86 
2 105.51 0.86 
2 117.16 0.86 
2 127.13 0.86 



























































































































































































































123 1.2 0.115 
123 1.2 0.115 
123 1.2 0.115 
123 1.2 0.115 
123 1.2 0.115 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
123 1.28 0.119 
124 1.2 0.111 
124 1.2 0.111 
124 1.16 0.\09 
124 1.16 0.\09 
124 1.16 O. \09 
124 1.16 0.\09 
124 1.16 O. \09 
124 1.16 0.109 
124 1.16 0.109 
124 1.16 0.\09 
124 1.16 0.\09 
124 1.16 O. \09 
124 1.16 O. \09 
124 1.16 0.109 
124 1.1 0.107 
124 1.1 O. \07 
124 1.1 0.107 





































124 l.l 0.107 32 
124 I.I 0.\07 32 
J 24 1.1 0.107 32 
124 1.1 O. \07 32 
125 0.9 0.11 28 
1250.90.11 28 
125 0.9 0.11 28 
126 1.4 0.\2 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.1\6 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 1.28 0.116 32 
126 I.I8 0.112 32 
127 1.35 0.118 32 
127 1.35 0.118 32 
127 1.28 0.118 32 
127 1.28 0.118 32 
127 1.28 0.118 32 







































































































































































7.06 0.86 0 
18.03 0.86 0 
21.28 0 4.9 
31.63 0.86 0 
41.83 0.86 0 
44.85 0 8.2 
55.55 0.86 0 
66.15 0.86 0 
69.21 0 6 
72.29 0.86 0 
79.54 0.86 0 
90.29 0.86 0 
93.06 0 11.4 
o 4.3 0 
9.42 0.86 0 
15.92 0 11.4 
18.73 0.86 0 
21.16 0 11.5 
24.91 0.86 0 
33.57 0.86 0 
40.44 0 10.3 
42.44 0.86 0 
46.94 0.86 0 
55.44 0.86 0 
62.27 0.86 0 
69.77 0.86 0 
79.43 0.86 0 
85.83 0.86 0 
88.83 0 14.7 
94.23 0.86 0 
























































































































































































































































130 0.86 0.094 































































































































































































































































































































































































































O ' 3.44 






































































































































































































































































































l32 1.32 0.121 









133 1.84 0.149 
133 1.84 0.149 
l33 1.84 0.149 
133 1.84 0.149 
133 1.76 0 145 
133 1.76 0.145 
133 1.76 0.145 
133 1.76 0.145 
133 1.76 0.145 
133 1.76 0.145 
133 1.76 0.145 
133 1.74 0.145 
133 1.74 0.145 
135 0.9 0.092 
135 0.9 0.092 
135 0.9 0.092 





























































141 1.48 0.133 
141 1.48 0.133 
141 1.34 0.126 
141 1.34 0.126 


















































































































































































































































































































15.67 0.86 0 
26.45 0.86 0 
29.75 0 2.52 
39.67 0.86 0 
50.29 0.86 o 
52.44 0 3.05 
63.59 0.86 0 
74.17 0.86 0 
87.67 0.86 0 


















































































































































































































































































142 1.78 0.146 34 2 34.3 8 9 2 9.02 0.86 0 
., 
2 2 ... 
142 1.78 0.146 34 2 343 8 9 2 17.42 0.86 0 2 2 2 
142 1.78 0.146 34 3 34.4 8 9 2 33.35 0.86 0 2 3 I 2 
142 1.78 0.146 34 3 34.4 8 9 2 35.53 0 2.18 2 3 0 2 
142 1.72 0.143 34 4 34.6 8 9 2 59.76 0 1.91 2 4 0 2 
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APPENDIX A.4 
Control stream for one-compartment, bolus model. 
$PROB Theophylline in Neonates run I 
RunsNMS 
l.Structural model: one compartment 
2. Exponential etas on CL & V 
3. Exp res error 
4. Covariate Models none 
S. Comment Base model 
$lNPUT ID WGT BSA GA PNA PCA SEX AP AQ OXY TIME AMT DV DVC DAY RT NNJ 
$DATA theoiv.prn ;Amino x.86=theop 
$SUBROUTINE ADV ANI TRANS2 
$PK 















$THETA (0,0.0001,10) ;CL 1 
$THETA (0,0.5,2) ;Vss 2 
;$THETA 1 ;FOXYCL 3 
$OMEGAO.S; CVCL 1 
$OMEGA 0.5 ; CVV 2 
$SIGMA .1 ;CVCP 1 
$SIGMA .001 FIX ;SDCP 2 
$EST MAXEV ALS=3000 SIGDIG=3 POSTHOC NOABORT 
$COV ARIANCE 
$T ABLE ID TIME IPRED IWRES MDV NOPRINT ONEHEADER FILE=sdtab 1 
$T ABLE ID AMT TIME IPRED IWRES NOPRINT ONEHEADER FILE=mutah 1 
$T ABLE ID CL V TVCL TVV NOPRINT ONEHEADER FILE=patab I 
$TABLEID GAPNAPCA WGTBSANOPRINT ONEHEADERFILE=cotahl 
$TABLE ID SEXDAYNNJ AP AQ OXYNOPRINT ONEHEADERFILE=catahl 
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APPENDIX A.S 
Control stream for two-compartment model. 
$PROB Theophylline in Neonates runIOO 
RunsNM5 
1. Structural model: Two compartment 
2. EXponential etas on CL & V 
3. Expres error 
4. Covariate Models none 
5. Comment Base model 
$INPUT ID WGT BSA GA PNA PCA SEX AP AQ OXY TIME AMT DV DVC DAY RT NNJ 
$DATA theoiv.pm ;Amino x.86=theop 
$SUBROUT1NE ADV AN3 TRANS4 
$PK 





CL=FSZCL *THET A( I )*EXP(ET A(1» 
VI =FSZVD*THETA(2)*EXP(ETA(2» ;central vol 
Q=THET A(3)*E:xP(ET A(3) );intercomp CL 
V2=THETA(4)*EXP(ETA(4» ;periph V 
K=CLlVl ;rate constant of elimination 
K12=QNl ;rate constant from central to peripheral 






Y =CP*EXP(ERR( 1 » +ERR(2) 
IPRED=Y 
$THETA (0,0.0001,10) ;CL 1 
$THETA (0,0.005,2) ;Vss 2 
$THETA (0,0.001,10) 
$THETA (0,0.6,10) 
$OMEGA 0.5 ; CVCL 1 
$OMEGA 0.5 ; CVV 2 
$OMEGA 0.5 ; CVV 3 
$OMEGA 0.5 ; CVV 4 
278 
$SIGMA .1 ;CVCP 1 
$SIGMA .001 FIX ;SDCP 2 
$EST MAXEV ALS=3000 SIGDIG=3 POSTHOC NOABORT 
$COV ARIANCE 
$TABLE ID TllvIE IPRED IWRES MDV NOPRINT ONEHEADER FILE=sdtablOO 
$TABLE ID AMT TIME IPRED IWRES NOPRINT ONEHEADER FILE=mutab 1 00 
$TABLE ID CL VI V2 Q NOPRINT ONEHEADERFILE=patablOO 
$T ABLE ID GA PNA PCA WGT BSA NOPRINT ONEHEADER FILE=cotab 1 00 
$TABLE ID SEX DAY NNJ AP AQ OXY NOPRINT ONEHEADER FILE=catab 1 00 
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APPENDIX A.6 
Control stream for rate model. 
$PROB Theophylline in Neonates run4 
RunsNMS 
I.Structural model: one compartment 
2. Exponential etas on CL & V 
3. Res Exp 
4. Covariate Models 
5. Comment RATE model 
$INPUT ill WT BSA GA PNA PCA SEX AQ OXY TIME AMT RATE DV DAY RT 
$DATA .. \theoivrt.prn ;Amino x.86=theop 
$SUBROUTINE ADV ANI TRANS2 
$PK 

















Y =CP*EXP(ERR( 1) )+ERR(2) 
IPRED=Y 
$THETA (0,0.0001,10) ;CL 1 
$THETA (0,0.5,2) ;Vss 2 
$THETA (0,0.1,5) ;TKO 3 
$OMEGA 0.5 ; CVCL 1 
$OMEGAO.S; CVV2 
;$OMEGA 0.5 ; CVTKO 3 
$SIGMA .1 ;CVCP 1 
$SIGMA .001 FIX ;SDCP 2 
$EST MAXEV ALS=3000 SIGDIG=3 POSTHOC NOABORT 
$COV ARIANCE 
$T ABLE ill TIME IPRED IWRES MDV NOPRINT ONEHEADER FILE=sdtab4 
$TABLE ill AMT TIME IPRED IWRES NOPRINT ONEHEADER FILE=mutab4 
$T ABLE ID CL V TVCL TVV NOPRINT ONEHEADER FILE=patab4 
$T ABLE ID GA PNA PCA WT BSA NOPRINT ONEHEADER FILE=cotab4 
$TABLE ID SEX DAY AQ OXYNOPRINT ONEHEADERFILE=catab4 
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APPENDIX A.7 
Control stream for parallel first-and zero-order model 
$PROB Theophylline in Neonates run 300 
control-stream parallel 1 st and O-order elimination 
1. Structural model: one compartment 
2. Exponential etas on parameters 
3. Control stream by E Chatelut 
4. No Covariates 
5. Comment: Date 29.9.98 
$INPUT ID WGT BSA GA PNA PCA SEX AP AQ OXY TIME AMT DV DVC DAY RT NNJ 
$DATA THEOIV.prn ;Amino x.86=theop 





















$SIGMA 0.04 .05 
$EST MAXEV ALS=9000 POSTHOC 
$COV ARIANCE 
$T ABLE ID TIME lPRED IWRES NOPRINT ONEHEADER FILE=sdtab300 
$T ABLE ID AMT TIME lPRED IWRES NOPRINT ONEHEADER FILE=mutab300 
$TABLE ID V KlO VM K.M ETA(1)ETA(2)ETA(3)ETA(4) NOPRINT ONEHEADER FILE=patab300 
$T ABLE ID GA PNA PCA WGT BSA NOPRINT ONEHEADER FILE=cotab300 
$T ABLE ID SEX DAY NNJ AP AQ OXY NOPRINT ONEHEADER FILE=catab300 
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APPENDIX A.8 
Control stream for the final model 
$PROB THEOPHYLLINE IN NEONATES RUN31 
1. structural model 
one compartment 
2.Res error Exp 
3.Interindividual variability 
EXP on CL and V 
4. Covariate 
5.Comments:Checking the interoccasion variability on CL and V 
$lNPUT ill WGT BSA GA PNA PCA SEX AP AQ OXY TIME AMT DV DVC DAY RT NNJ 
$DATA THEOIV.prn ;Amino x.86=theop 
$SUBROUTINE ADV ANI TRANS2 
$PK 
IF (DA YEQ.l) IOVCL=ETA(3) 
IF (DAYEQ.2) IOVCL=ETA(4) 
IF (DAYEQ.3) IOVCL=ETA(5) 
IF (DAYGT.3) IOVCL=ETA(6) 
IF (DAYEQ.l) IOVV=ETA(7) 
IF (DA YEQ.2) IOVV=ETA(8) 
IF (DAYEQ.3) IOVV=ETA(9) 
IF (DA YGT.3) IOVV =ETA(10) 










TVCL=FOXY*FSZCL *THET A(I) 
TVV=FSZVD*THET A(2) 








$THETA (0,0.001,10) ;CL 
$THETA(O,.1,iO) ;V 
$THETA (0,1,10) ;OXY 
$OMEGAO.5 
$OMEGAO.5 
$OMEGA BLOCK(I) 0.1 ;IOVCL 
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$OMEGA BLOCK(1) SAME ;IOVCL 
$OMEGABLOCK(l) SAME ;IOVCL 
$OMEGABLOCK(l) SAME ;IOVCL 
$OMEGA BLOCK(l) 0.1 ;IOVV 
$OMEGABLOCK(l) SAME ;IOVV 
$OtvIEGA BLOCK(l) SAME ;lOVV 
$OMEGABLOCK(1) SAME ;IOVV 
$SIGMA 1.0 
$SIGMA 0.001 FIX 
;$SIML (1) 
$EST METHOD=CONDITIONAL MAXEV ALS=3000 SIGDIG=3 POSTHOC 
$COV ARIANCE 
$T ABLE ill TIME IPRED IWRES NOPRINT ONEHEADER FILE=sdtab31 
$T ABLE ID AMT TIME IPRED IWRES NOPRINT ONEHEADER FILE=mutab31 
$TABLE ID CL V ETA(l) ETA(2) NOPRINT ONEHEADER FILE=patab31 
$T ABLE ID GA PNA PCA WGT BSA NOPRINT ONEHEADER FILE=cotab31 
$T ABLE ill SEX DAY NNJ AP AQ OXY NOPRINT ONEHEADER FILE=catab31 
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APPENDIX A.9 . 
Data collection fonn 
NEONAT_~.L !"'.dEGPHYLLINE STJD'l 
NAME: HOSPITAL Nlil1BE..~ 
ADDRESS: TEI.E:?~ONE: 
MOTHER IS NAi'1E: HOSPIT.\!. NC¥.BER: 
DATE OF BIRTH: BRT WEIGHT: GA: SEX: 
APGAR: 1 min .... 5 min .... LENGT:::: 
RESP.APGAR: 1min ..... 5min ..... 
OBSTETRIC COMPLICATIONS: 
DRUGS USED BEFORE & DURING LABOUR: 
BEVER~GES CONSUMED BEFORE OR DURING L~2CUR: 
MATERNAL SMOKING HISTOR::: Y/N/UNIQfCw"N 
ADMISSION DIAGNOSIS: 
EXCLUSION CRITERIA: 1. VSGA 
2. CONGENIT~L ABNOR¥_~ITIES 
INCLUS!ON CRITER!A: 1. APNOEA. DEFINED AS NO BREATHING FOR >205, 
HR<loO/min, Ai~D/OR CY.~OSIS. 
WHAT IS CONSIDE..1U:D THE CAUSE OF T:!:!S .~.?NCV.? 
RESUSCITATION AT BIRTH: YIN, DETAILS: 
ASSISTED VENT~LATION AT BIRTH: YIN: 





Appendix A. 9 continued. Data collection fonn . 
THEOPHYLLINE FLOW CHART 










UP O. C.piUMY Ab T 
Uloud U 0 
• I n 
• • 0 
I P P II I 
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0 • i 0 i lJi.easea ei· 
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Appendix A. 9 continued. Data collection fonn. 
THERAPY 
Name: .............................. -................................... . 
Number: ..... .... : ... '................................................... . 
Route I Dose I Date I Dare I Dise:lSe 
I 
Other I 
St:med Stopped ,. -. I 
, 
I I I I I 
I 
Plasma 
I NaHCOJ I 
Dopamme I I I I I I I 
I Antibiotics 






I I I I I I I I Phenobarb. 
I I I I I , --. i i IV-fluids i 
I Other I I I I I I 
I \lit.K I I I , I I I 
Oiniol Pkrure: 
RDS: y / n Uet:J.ils: 
PDA: y / n Det:ri1s: 
L.'iF: y / n Deuils: 
BId.sugar i / J. De~s: 
:-\.5phy:tiared y / n Details : ........ ......... ........... ............... ... ........... ......................... . ............................................. ... ... ........ 
Other: ......................................................................................................... - ................................... . .. . 
........................................................................................................................................ 
.................................................... ....... .............................. .......................... .. ........................... ...... 
................................................................................................................................................ 
Final Diagnosis: 
I Dare of I Follow-up visit /' Disch3Tge 








































APPENDIX A.l 0 
Distribution of available covariates 
0.12 0. ((, 
Body surface area (m
2
) 
1.0 1..t 1.11 
Weight (kg) 
4- 6 8 
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26 28 311 l2 
Gestational age (weeks) 















Distribution of available covariates. 
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f 40 I 
: ': 1:=1 ...=,. ~~~:: ~: ~ : ::: m~fli:,!!!,i,~~II!ltiliJl! l~: ~llll!l! 
3 5 7 9 
APGAR score at 1 minute 
234 567 8 
Day of study 
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APPRNDIX A.lt 
Frequency distribution graphs of various residual error models 
Additive Error Model 
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APPENDIX A.12 
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APPENDIX A.14 
Demographic details of possible outliers 
Patient Outlier WGT GA PCA PNA GEN- OXY Number of 
: : 
: : 













PNA = postnatal age, OXY = oxygen support, CL = clearance, V = volume, 





A summary of the NONMEM analysis of the possible outliers using the base model 
(Relative standard error) 
Parameter estimates Etaj% Eta2% OFV Res error 
(RSE %) (RSE (RSE%) (RSE %) 
CL V %) 
Full data set 0.0084 0.67 83 49 1035.56 32 
(17) (9) (36) (23) (26) 
Data without 0.00797 0.67 82 49 1010.61 32 
pat 9 (17) (9) (36) (26) (26) 
Data without 0.00829 0.67 83 49 1029.51 32 
pat 21 (17) (9) (37) (23) (26) 
Data without 0.00849 0.68 85 46 1024.14 32 
pat 86 (17) (13) (35) (23) (26) 
Data without 0.00834 0.66 83 32 1031.05 32 
pat 125 (17) (9) (36) (26) (26) 
Data without 0.00827 0.66 82 49 1019.06 32 
pat 140 (17) (10) (37) (24) (26) 
Data without 0.00828 0.66 82 49 1029.61 32 
pat 142 (17) (9) (37) (23) (26) 
Pat = patient, CL = clearance, V = volume, RSE = relative standard error, Eta = inter-
individual error, OFV = objective function value, Res error = residual error. 
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APPENOIX A.16 










DAV. OXY· GA .•. 
NNJ'" GA 
NNJ + OXY· GA 




GA + WGT 
OXY· GA + PCA 
GA - BS" ........ . - .... .. .... ..... . 
oxy· GA' WGT 
PCA 
SEX + GA 
ns(GA. at = 2) .. .. .... ..... ... . .. . 
OXY+GA"'SSA ...... ....... ... ........ .... . .. . .. ......... ... . ..... ...... . 
GA . ..... ..... . .... . ............... ... .. . . 
oXY • ns(GA, dI = 2) ...... 
SEX ... oX"( .. GA 
oX'( • CiA 




Most common covariate combinations for CL 
OAY+BSA 
OAY+OXY ... .... : ............ . ..: .... .... . ..... ; ..... . 
OXY+GA 
~ OAY+GA . _ .. _ .. _ .... . -_ ... ........ ~- . _ .... .. _ .... ~ _ ..... _ .... . --~. 




Akaike plot for V 
NNJ 
DAY 
AP •. -.-... ...• ..... ... -. . . ... . -.. ... .. -...... . .... • .... 
AQ-GA ...... .. • .... 
PCA ............ . ........ . .... .. .. . . . .. ......... .. ... . ... ..... . ... . 
WGT 
ns{GA. tit 'r 2} 
!!SA 





GA'" BSA e·· 




:;;: DAY '" GA .. PCA 
CAY ·GA 
.a-GA·PCA 
NNJ ·GA .... -..... ... .....•... . .... ... ... .. ..... ..... -. -
AP·OA "PeA ..... ...... ....... .. ............ , ..... 
OXY. GA· PCA • .. .. . 
GA'" PNA .. PCA 
CiA ... PCA ·wGT 
GA .. nstPCA. a1 ':; 2) 
ns(GA, ctt:: 2) ... PCA 
SE)( .GA - PCA 
GA ... PCA ... 8SA .•..... .... ... ••.. 
GA, .... PNA .. ..... • • 
NNJ+uA+PCA ... .. • •. 
GA. PCA 
























Correlation matrix of the developmental covariates 
GA PNA WGT BSA peA 
GA 1.000 
PNA -0.1095 1.0000 
WGT 0.7717 -0.0731 1.000 
BSA 0.7531 -0.0615 0.9781 1.000 
PCA 0.9628 0.1594 0.7461 0.7310 1.000 
GA = gestational age (weeks), PNA = postnatal age (days), WGT = weight (kg), 





Appendix 1\2 I Results of the population pharmacokinetic analysis with the Fa estimation method . 
, .-
CL Model Y Model Parameter estimates (RSE %) Etal Eta2 
CL v . 9J 84 
(RSE %) (RSE %) 
8, 82 0.0084 067 - - 83 49 
( 17) (9) , (36) (23) . 
8,*OXY 82 0 .0060 063 1:87 - 74 55 
(22) (9) (22) (41 ) (24) 
8,*GA 82 0.0003 0.66 - - 80 49 
(17) (9) (36) (24) 
8,*WGT 82 0.0074 0.65 - - 78 47 
( 17) (9) I (36) (25) 
8 1*WGT**8) 82 0.0066 0.66 I. 5 I - 79 45 
(27) (9) {46} (37) (30) 
8 1*WGTo
75 
O2 0.0078 0.65 - - 78 47 
( 17) (9) 
I 
, (35) (25) 
8,*WGTln 82 0.0070 0.65 - - 78 46 
( 17) (9) (36) (26) 
O,*OXY 8 2 0.0002 063 J .84 - 72 54 
*GA (22) (9) (2 I) (39) (23) 
8,*UXY O2 . 0 .0063 060 2.36 1.72 72 54 
*DAY (20) ( 10) (38) (21 ) (37) (26) 
8 1*DAY*GA O2 0.0003 0.60 3.49 - 73 48 
(14 ) (10) (34) J)5) (31 ) 
8,*DAY O2 0.0743 0.59 3.7 - 71 46 
"'DSA (14) (10) (34) (35) (35) 
8 1 "'WGTo 75 82 " 0.0057 0.62 1.84 - 68 52 
"'OXY (2 I) (10) (20) (37) (23) 
aFY 60FY Res error 
(RSE %) 
1035 .56 - 32 
(26) 
1019.52 16.1 29 
(231 
1030.83 4 .7 32 
(27) 
J.021.78 13 .8 33 
(27) 
1019.97 15.6 34 
(29) 
1024 .02 11.6 32 
(27) 
1020.33 15 .2 33 
(28) 
1014.58 21.02 30 
(23) 
1015 .02 20.58 30 
(23) 
1021.89 13 .7 33 
(27) 
1014 .22 2138 34 
(28) 





Appendix A21 continued: Results of the population pharmacokinetic analysis with the FO estimation method 
CLModel V Model Parameter estimates (RSE %) Etal Eta2 OFV 
CL V 83 84 
(RSE %) (RSE %) 
8 1 82*PCA 0.0079 0.022 - - 87 47 1019.10 
(I 7) (9) , (36) (24)_ 
8 1 82*GA 0.0080 0.02 - - 85 47 1019.18 
(I6) (9) (36) (24) 
8 1 82*WGT 0.0078 0.58 - - 82 43 1000.62 
(13) (7) (34) (28) 
8 1 82*GA 0.0021 0.14 - - 1600 120 1243 .64 , 
*PNA 
8 1 82*NNJ 0.0067 2 1.15 - 47 81 1274.59 
*BSA (11) (9) (20) 
, 
(19) (12) 
8 1 82*NNJ 1.93e- 0.37 0.72 - ; 67 58 1152.66 
*PNA 011 
8 1 82*PNA 0.0013 2 - - 290 57 1199.23 
*BSA (140) (17) (270) (31) 
81*WGT'·75 82*WGT 0.0052 0.54 1.94 69 49 981.24 
*OXy (20) (8) (21 ) (38) (29) 
-



















Appendix A.21 continued: Results of the population pharmacokinetic analysis with the FOCE method 
CLModel V Parameter estimates (RSE %) Eta I Eta2 OFV ~OFV Res error 
Model CL V 83 . 84 (RSE %) (RSE %) (RSE %) 
82 82* 0.0074 0.75 - - 73 57 1000.86 - 30 
Base model (16) (9) (27) (20) (22) 
8(*WGTo.7S 82* 0.0056 0.58 1.61 - 60 53 962.29 38.57 29 
*OXy WGT (19) (8) (23) (29) (23) (22) 
Full covariate ' 
I model 
8(*WGTo.7S 82* 0.0060 0.633 1.47 - 56 47 927.94 72.92 16 
*OXY WGT (14) (7) (18) (25) (28) (35) 
Final model IOV 34 IOV 35 
with IOV (77) (29) 
CL = clearance, V = volume of distribution, RSE = relative standard error, 8 = parameter, Eta( = inter-individual variability CL, 
Eta2 = inter-individual variability V, OFV = objective function value, .10FV change in OFV, Res error = residual error. 
APPENDIX A.22 
Results of the lack-knife analysis of the final model 
Number 
of OFV 91 92 93 TJ
CL TJv TJIOVCL l1'OVV Res 
patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) ElT 
left out (SE%) 
1 923.4 0.00597 0.631 l.47 56 47 33 35 16 
(14) (7) (8) (24) (28) (77) (29) (35) 
2 918.3 0.00593 0.63 1.49 56 46 34 35 16 
(14) (7) (18) (24) (29) (76) (29) (35) 
3 913.4 0 .0061 0.63 1.44 57 46 32 34 16 
(32) (7) (38) (100) (56) (110) (30) (35) 
4 914.9 0.00598 0.63 1.48 56 47 34 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
5 917.9 0.00595 0.63 1.45 56 47 33 35 16 
(14) (7) (18) (24) (28) (78) (29) (35) 
6 925 .5 0.00596 0.63 1.45 56 47 33 35 16 
(14) (7) (18) (24) (28) (78) (29) (35) 
7 915.7 0 .00595 0.64 1.48 57 47 33 34 16 
(15) (7) (20) (28) (30) (77) (31) (35) 
8 896.9 0 .00595 0.62 1.54 61 48 37 37 14 
(15) (7) (19) (21) (28) (28) (0) (42) 
9 913 .8 0.00575 0.64 1.45 54 47 38 35 16 
(15) (7) (20) (35) (28) (72) (29) (36) 
10 918.9 0.00593 0.63 1.48 57 47 34 35 16 
(15) (7) (19) (25) (29) (78) (29) (35) 
11 919.8 0.00592 0.63 1.45 56 47 34 35 16 
( 14) (7) (18) (24) (28) (78) (29) (35) 
12 916.9 0.00585 0.63 1.45 55 47 35 35 16 
(14) (7) (18) (28) (29) (77) (29) (35) 
13 904.5 0.00607 0.63 1.43 58 48 32 32 16 
(28) (7) (34) (88) (46) (110) (33) (37) 
14 916.4 0.00574 0.63 1.53 55 48 36 35 16 
(15) (7) (19) (33) (28) (76) (29) (36) 
15 925.3 0.00597 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
16 915.3 0.00602 0.63 1.45 57 47 33 35 16 
(14) (7) (18) (26) (29) (78) (29) (35) 
17 918.5 0.00599 0.63 1.49 56 47 33 35 16 
(14) (7) (18) (24) (28) (76) (29) (35) 
18 920.8 0.00596 0.63 1.48 56 47 33 34 16 
(14) (7) (18) (24) (28) (77) (30) (35) 
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Appendix A22 continued. Results of the Jack-knife analysis of the final model 
Nmnber 
of OFV 61 62 93 l1
CL 
l1
V 11 IOVCL 
l1
IOVV Res 
Patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) Err 
left out (SE%) 
19 925.6 0.00597 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
21 921.9 0.00579 0.63 1.51 56 47 34 35 16 
(14) (7) (18) (26) (28) (76) (29) (35) 
23 916.4 0.00586 0.64 1.48 57 47 34 34 16 
(14) (7) (18) (24) (28) (77) (30) (36) 
24 916.4 0.00586 0.64 l.48 57 47 34 34 16 
(14) (7) (18) (24) (28) (77) (30) (36) 
25 913 .0 0 .00589 0.64 l.47 57 47 34 35 16 
(15) (7) (19) (24) (28) (77) (29) (35) 
26 918.0 0.00597 0.64 1.49 56 46 34 35 16 
(14) (7) (18) (24) (29) (75) (29) (35) 
27 911.0 0.00607 0.64 1.43 60 43 32 35 16 
(21) (7) (27) (67) (45) (100) (29) (35) 
29 919.4 0.00602 0.64 1.45 57 46 34 35 16 
(16) (7) . (20) (32) (31) (79) (29) (35) 
30 916.9 0.00626 0.64 1.41 54 46 31 35 16 
(130 (7) (18) (26) (29) (77) (29) (35) 
35 923.3 0.00597 0.63 l.46 57 47 33 35 16 
(14) (7) (19) (26) (29) (78) (29) (35) 
36 920.9 0.00599 0.64 l.49 56 46 34 35 16 
(14) (7) (18) (25) (28) (76) (29) (35) 
37 921.5 0.006 0.64 1.45 57 47 33 35 16 
(14) (7) (18) (25) (29) (78) (29) (35) 
38 923.1 0.00597 0.63 1.47 56 47 33 35 16 . 
(14) (7) (18) (24) (28) (77) (29) (35) 
41 915.9 0.00588 0,64 l.5 58 46 31 34 16 
(18) (7) (23) (40) (32) (90) (29) (35) 
45 920.4 0.00612 0.64 1.43 56 46 33 34 16 
(18) (7( (23) (24) (31) (77) (29) (35) 
46 922.0 0.00604 0.64 1.44 56 46 33 35 16 
(17) (7) (21) (34) (31) (79) (29) I (35) 
47 920.0 0.00596 0.64 l.5 55 46 34 35 16 
914) (7) (18) (25) (28) (75) (29) (35) 
48 917.4 0.00605 0.64 1.44 57 46 33 35 16 
(16) (7) (21) (33) (31) (80) (29) (35) 
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Appendix A22 continued. Results of the Jack-knife analysis of the final model 
Number 
of OFV 8 j 82 83 l1
CL 
l1
V 11 IOVCL 
l1
IOVV Res 
Patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) Err 
left out (SE%) 
50 919.5 0.0062 0.64 l.42 55 46 33 35 16 
(14) (7) (18) (28) (29) (77) (29) (35) 
52 920.7 0.0061 0.64 l.43 56 46 33 35 11 
(16) (7) (20) (34) (31) (79) (29) (35) 
54 924.1 0.00598 0.64 1.46 56 47 "" 35 16 .:>.:> 
(14) (7) (18) (25) (29) (77) (29) (35) 
55 920.9 0.00597 0.64 1.46 57 47 33 35 16 
(14) (7) (18) (24) 28) (77) (29) (35) 
58 92l.4 0.00608 0.64 1.44 56 46 33 35 16 
(16) (7) (20) (31 ) (30) (79) (29) (35) 
62 921.4 0.00607 0.64 l.44 56 46 
,.,,., 
35 16 .:>.:> 
(16) (7) (20) (32) (30) (79) (29) (35) 
65 921.1 0.00595 0.64 l.49 56 46 34 35 16 
(14) (7) (18) (25) (28) (75) (29) (35) 
66 922.1 0.0058 0.64 1.48 56 47 34 35 16 
_ (14) (7) (19) (26) 28) (76) (29) (35) 
70 917.9 0.00609 0.633 1.44 56 47 33 35 16 
7 (15) (7) (19) (28) (29) (79) (29) (34) 
71 919.& 0.00596 0.63 l.47 57 45 34 35 16 
(29) (7) (34) (87) (51) (100) (29) (35) 
72 924.9 0.00596 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
74 923.7 0.00597 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
75 920.1 0.00599 0.63 l.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
76 923.4 0.00596 0.63 1.45 56 47 33 35 16 
(14) (7) (18) (24) (28) (78) (29) (35) 
77 917.6 0.00595 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (78) (29) (35) 
78 921.7 0.00594 0.64 1.47 57 47 34 34 16 
(16) (7) (20) (30) (30) (79) (0) (35) 
79 918.6 0.00604 0.64 1.44 56 47 33 35 16 
(15) (7) (19) (27) (30) (77) (29) (35) 
80 915.6 0.0059 0.63 1.5 56 48 33 33 16 
(14) (7) (18) (24) (26) (77) (31) (36) 
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Appendix A22 continued. Results of the Jack-knife analysis of the final model 
Number 
of OFV 81 82 83 TJ
CL TJV TJIOVCL TJIOVV Res 
Patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) Err 
left out (SE%) 
81 924.7 0.00596 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
82 915.2 0.00596 0.64 1.45 58 45 34 35 16 
(29) (7) (35) (89) (50) (100) (29) (35) 
83 923.0 0.00594 0.64 1.46 56 46 34 35 16 
(14) (7) (18) (24) (29) (77) (29) (35) 
84 916.4 0.0059 0.64 1.44 57 47 36 34 16 
(16) (7) (21) (32) (29) (75) (29) (35) 
85 917.2 0.00596 0.63 1.46 56 46 33 35 16 
(14) (7) (18) (24) (29) (78) (29) (35) 
86 922.7 0.00595 0.64 1.48 56 46 34 35 16 
(14) (7) (18) (24) (29) (76) (29) (35) 
87 923.5 0.00596 0.63 1.47 1.56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
88 910.8 0.00612 0.64 1.45 52 45 40 36 16 
(14) (7) (18) (31) (31) (82) (28) (34) 
89 912.4 0.00594 0.63 1.51 55 48 33 33 16 
(14) (7) (18) (25) (27) (77) (32) (36) 
90 917.t 0.00592 0.64 1.45 57 47 35 35 16 
(14) (7) (19) (25) (28) (74) (29) (35) 
91 914.9 0.00592 0.63 1.51 55 48 34 33 16 
(14) (7) (18) (26) (27) (76) (31) (36) 
92 921.2 0.00596 0.63 1.46 56 47 33 34 16 
(14) (9) (18) (25) (28) (77) (30) (35) 
93 925.1 0.00596 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
94 921.0 0.00599 0.63 1.48 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
95 917.3 0.00594 0.64 1.46 57 47 34 35 16 
(14) (7) (19) (25) (29) (78) (30) (35) 
96 919.2 0.00599 0.63 1.46 57 47 33 35 16 
(15) (7) (19) (27) (29) (78) (29) (35) 
97 922.6 0.00596 0.63 1.47 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
98 914.9 0.00602 0.64 1.49 55 46 34 35 16 
(13) (7) (18) (25) (29) (76) (29) (34) 
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Appendix A22 continued. Results of the Jack-knife analysis of the final model 
Number 






Patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) En 
left out (SE%) 
99 916.9 0.00605 0.63 1.47 56 47 32 34 16 
(14) (7) (18) (25) (28) (77) (30) (35) 
110 898.4 0.00622 0.64 1.33 61 48 34 32 14 
(15) (7) (20) (43) (31) (79) (26) (29) 
111 918.2 0.00593 0.64 1.43 57 47 35 35 16 
(14) (7) (19) (25) (28) (75) (29) (35) 
112 913.1 0.00613 0.63 1.39 58 46 33 36 15 
(34) (7) (43) (13) (64) (120) (29) (41) 
113 919.3 0.00594 0.64 1.41 56 47 33 34 16 
(14) (7) (18) . (25) (28) (80) (29) (36) 
114 921.8 0.00598 0.62 1.47 57 45 
..,.., 
35 16 .:).) 
(39) (8) (45) (130) (73) (12) (29) (35) 
115 915.7 0.00594 0.63 1.46 56 47 35 35 16 
(14) (7) (19) (25) (29) (74) (29) (38) 
116 924.2 0.0059 0.63 1.49 56 46 34 34 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
117 924.2 0.00595 0.63 1.45 56 47 34 35 16 
(14) (7) (19) (26) (29) (77) (29) (35) 
118 919.6~ 0.00596 0.63 1.47 56 46 34 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
119 916.8 0.00586 0.63 1.5 57 46 34 34 16 
(15) (7) (19) (29) (30) (78) (29) (35) 
120 923.9 0.00586 0.63 1.5 56 47 34 34 16 
(14) (7) (18) (24) (28) (76) (29) (35) 
121 921.3 0.00575 0.63 1.52 54 47 33 35 16 
(14) (7) (19) (31) (29) (76) (29) (35) 
122 925.2 0.00596 0.63 1.45 57 47 33 35 16 
(15) (7) (19) (26) (29) (78) (29) (35) 
123 914.3 0.00631 0.63 1.34 64 43 33 36 15 
(15) (7) (21) (42) (36) (77) (29) (39) 
124 909.2 0.00595 0.64 1.46 57 45 36 35 16 
(21) (7) (26) (54) (39) (82) (29) (36) 
125 922.1 0.00598 0.63 1.46 I 57 45 34 35 16 
(27) (7) (32) (81) (47) (98) (29) (35) 
126 919.3 0.00593 0.63 1.46 60 45 33 36 16 
(33) (7) (44) (140) (73) (110) (30) (35) 
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Appendix A.22 continued. Results of the Jack-knife analysis of the final model 
Number 






Patients (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) (SE%) En 
left out (SE%) 
127 921.1 0.00594 0.63 1.42 57 47 33 34 16 
(15) (7) (20) (29) (29) (82) (29) (35) 
128 924,9 0.00596 0.63 1.46 55 47 35 35 16 
(14) (7) (18) (26) (28) (78) (29) (35) 
129 924.4 0.00596 0.63 1.45 56 47 33 35 16 
(14) (7) (18) (25) (28) (78) (29) (35) 
130 911.6 0.00595 0.63 1.47 57 47 33 34 16 
(15) (7) (19) (25) (28) (81) (30) (34) 
131 920.6 0.00591 0.63 1.47 56 47 34 35 16 
(14) (7) (18) (24) 28) (77) (29) (35) 
132 911.8 0.00577 0.64 1.52 57 46 34 34 16 
(14) (7) (18) (23) (28) (78) (30) (36) 
133 921.3 0.00578 0.63 1.57 43 45 48 35 16 
(17) (7) (20) (66) (31) (93) (29) (35) 
135 920.8 0.00597 0.63 1.47 56 47 34 35 16 
(14) (7) (18) (24) (29) (76) (29) (35) 
136 925.4 0.00596 0.63 1.46 56 47 33 35 16 
(14) (7) (18) (24) (28) (77) (29) (35) 
138 924.9 0.00595 0.63 1.47 56 47 33 35 16 
57 (14) (7) (18) (24) (28) (77) (29) (35) 
139 919.6 0.00598 0.64 1.46 56 46 34 35 16 
(14) (7) (18) (25) (29) (77) (29) (34) 
140 916.1 0.00585 0.62 1.51 56 45 34 34 16 
(15) (7) (19) (35) (32) (78) (29) (36) 
141 919.7 0.00595 0.63 1.47 56 46 33 35 16 
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EVENT TYPES .4.ND INCIDENCES ON DAY THREE 
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\.;.l --'" 
II 
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Total apnoea per hour from baseline to day three with serum theophylli~_ cQnc_entrations (mgl1.) , .--- ------- r·-
! ' 
Patient Baseline Day I Day I l Day 2 Day 2 .1'.ay 3 _ 1_ ...Qat} 1 Percentage 
number total apnoea total apnoea I Theop conc l total apnoea Theop conc total apnoea , Theop conc change 
1 0.5! I i 4.92r r1 -100 
2, 17.7 8.4 ----5.8 7.8 4 .91--~fi[ 4.56 76 
3 28 6.5 5.8 6.) 4.39 0.7 i 2.75 98 
. - i , - ~ - I -- - " - I I 4. 4).1: 271 _ 4') 1 20') 1 10.2 b.) , 8.9, 70 
- : .. - ! -! - -.~-:.. ! I -- --- - .. 1 ! -
) ; h) ! 10.5 , ).7 1 13.36 : 9.8 26') 1 7'i- 2) 
6 : 31 : I I 9 i 4.5 I -L-- 71 
10 , 7.7 1 12 1 61 13 1 4.6 11.61 4.~ -51 
11 ; 12.~ ; ~.l i 4.6 1 _3~) 1 ~ . 6 5'~ 1 4.5 : 59 
12 28''' i h2 ! 41 h)4 , ).4 29')1 4~ ____ -_4 
13 2Ui 8"L ill II ! ;8 291 7'll-------~ 
14 ' 10 : 8.5 1 5.1 6.5 1 6.9 42L-----.?:~ 5~ 
15 , 14.1: 7.7, 5.2 ! I.--+- 45 
16 .: 4.6 1. 4.5 1 64= 3; 69 34 ___ 71-----~ 
17 20.3 ; 1.73 1 _ 6.4 [ ~_ __ ~ __ -+ _________ ~ , [ , 
18 10.4 : 11=.5 __ ~ ____ ~ 11 -r--- -- _ _ _ __ ~ 
19 ; 58.8 : 21 461 1 I [ 64 
70 , 24 l 21 --,H III 117 ,=--t ==- 46 
71 Ii '4-- 11 1 1 ====r 67 
72 23 6-+-____ 751---mt- 326 =------J-=== -=== 17 
73 16: 8.71 =:21 lS i 9.3 ~4 1--- ---.!~L------.i 
___ -.2.'L ____ 16_: ----1 --W 08 1 62; -- ----.----L----- --'!2 
_ _ 75 : 14 , 6 5.2 : 34 1 7.) ,-j'- ---- - .J- -------'!!!. 
_ _ _ ~ 3, I I~ ___ ..!.~ 5.3 74t-------'!:~F' _ ___ -150 
____ ~ 22 ; 7.2-l-__ -'4t. ____ 9.)1 4 1l.51 _____ ~~ ___ . ~ 





80 7.7 ; 61 2.7 i 22 
81 : 10: 8.3 1 8;- 42.4 18 j 27.3 1 -80 
82 ; 7';: 21 _-19.31 ---or - 10.4 : 100 
83 : 22 : 5.71' --11~ , 1 74 
84 37 ; 18 1 4: 36 : 4 : 66T 5.11 -78 
85 63 12 ) 6.1 : ls i 8.1 : 76 
87 : 12 : -28.6r 4.6 : 13.3[ 7 j -11 
88 2.4 I I 6: 15.5 14.51 16 .~ -5041 
89 , 60 20 i 4.6 ! 1 i 7.8 13 1 21.95 1 78 
90 ----9;------t I 7.1 8.1 0.6 12 93 
91 32 ; 4.7 1.8 1 12.9 6.5 a 9 100 
92 10 15 1.71 -5: 6.6 -tr=---=---=-=J- 50 
93 , 21 22 __ 7+ ---.L _____ .L- -51 
94 14 11 __ ~ 51 5 , ~ 7.7 : _ __ 2_1 
95 39 12.2 11.271 1245 1 692 9.5 ( 12.86 ; 76 
2§_,__ 25.5 17.2 _-.2:24 8.8 : 5.62 9.1 1 ~~-------64 
97 : 39 81 54 ' 9.4 ; 4.7 10.3 1 3.91 74 
98 13.6 4.1 51 1 4.5 : 7.9 ~I - --8.5:--- 100 
- --- , ~ I 
99 , 9.2 7+-____ 3.11 _ _ _ .!£~ 2.7 ~ 3.4-_ _ ___ -49 




Pathologic apnoea per hour from baseline to day three with serum theophylline concentrations (mgIL) 
Patient Baseline I Day 1 Day 1 Day 2 Day 2 Day 3 Day 3 Percentage 
munber 1 path ap~oea-T path apnoea Theop conc I path apnoea Theop cone path apnoea Theop cone : ehange 
I! 0.5 1 I! 4.92 : ·100 
2: ---42i 06 i ----.-81 - --O-~---- 4-91 ' 06 : 456 ' 86 I . . . I ) . : ·' 1 . : . i . , -
31 2.5 ] - -0 ),-- 5.8i ---- -0-1 4.39 0; 2.75 , 100 
41 7.1 1 41-- 4.5 1 4 j 10.2 3: 8.9 58 
51 -- -31 ---- II 5.71 -------0.91 9.8 1.5 7.4 50 
6, 11 ! 1 0: 4.5 100 
10 1 4.9; 5i 61 4i 4.6 0 4.5 100 
w+ 0.4 1 a: 4.6 1 0.5 [ 4.6 0 4.5 100 
12 1 3.2 i 31 4 ; 6.1 1 5.4 1.6 ' 4.8 50 
gt 3.1 ! 1.~ 1 ~ 0: 5.s: 0 , 7.4 100 
14 [ 1.5 : 2" 1 ,.11 I : 6.9. 0.5: 7.2 66 
I--- 15 i 4.2 'I' 1.71 5.2 1 i 59 
___ 161 2.1 3 1 6.5 j 4- 6.9 0 , 7.~ 100 
118
7
! 71.38 ! 04.4:+--- 6·~ 1 --~0·1t----51·71 · - ----+----+----- 9693 - _ _ _ '-1 . ~ " 1 -~ .' , ' -----------
____ 19+1 0.8 i 0 ' 4 . 61 ~ _ __ : ____ __ ~ 
~ + 2.5 1 ~ Ii 11.7 75 
71 [ 3
1 
O--L-_ __ ~-----J_ · _____ ~,, ___ _ _ _ 1O_0 
73 1 1.5 ' 0.54 1 a' 0; 9.3 O· 8.8 100 
-----7- 4t 2r-------0-r--- - - -i~+-------o!---6.25 -----i--------IOO I----__+__ I -+.t----~--__;i - . ".-. - -----~---- --
_____ 7~+ 4.4 1 ~+-__ 5.8 1 01 4 4 ____ ,, ____ 5.+-_ ___ _ 100 
:0 1 0.4 1 ~0' -----8.1 -+--------! ~----~ __ . ___ 1-+ 31 ____ 8.l.i _ __ J22: 42.4 2, __ .?2 .~ _ ___ _ ~ 
:~ I O'!] L~ ==- ::;I-=-- i 104 j---===-~r-~ . ____ I~: 
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- 241 7.2i ).~ I 
°i 5.4 1 
1.4 I 5.1 1 
2.5 ! 3.1 1 
1.7 i Il.4L _ 
01 6.1: 11 8. I: 95 
01 4.6 ; OJ 7, 100 
01 15.5 O ~ 16.8: 100 I i 
4.7 1 0; 8.1 12 ; 100 
0 , 6.6 i ! 100 . , 
i 
t 33 I ! i 
08.1 . ) 1 6.92 0 ' 12.86 1 100 
1.4 1 
,
5.62 2.1 i 4.9 , 78 
01 , 4.7 O[ 3.9 ; 100, 
o! 7.9 0 ' I 8.5 100 
2.5 1 2.7 1.7 : 3.3 43 
------o.8T 
-
3.6 : 11.5 10.3 30 


















Baseline L Day 1_ Day 1 Day 2 Day 2 Day 3 Day_ 3 Percentage 
hypox epis 1 hypo:'(eIJi~ _J Theop cone - , h:;-pox epis! Theop cone h:-pox epis Theop conc change 








3.21 4.91 01 4.56 1 100 
1.~ : 1.~. ~ . 8 : 1.51 4.39 1.6! 2 . 7~_ ·6 
O·) i d.,. ).7 l 0; 9.8 01 7.4 [ 100 
10.51 1 0.5! 4.5 I _~ 99 
1.2 1 0.5 6T 11 ! 4.6 2.5! 4.5 1 ·200 
6.81 0.5 4.6[ 0: 4.6 0.61 _ __ 4.5 1 _ _ _ _ ~ 
1.61 0_6 4! 0.9 ; . 5.4 11 _ 4.81 37 
13 . 1.5 1· 3.5 _;# 0.5 1 5.8 0.5'1' _ 7 . ~ ! ___ .£ 
14 2. l 3.5 --44+ 0.4
1 
6.9 0.6 7.21 ____ 7_1 
15 1.5
1 
0_9 52 , I I 40 
12 
16 2.1 i ~~ 6:t 1 i 6.9 0.61 7.5-!- .71' 
18 0.7i 01 .Jt 4i 11 ~ t-----.)7~ 
_ ___ ~_ 0.9[ 0 ' 4.61i! ==r ____ .. -+-_ ___ .~ 
70 1:1 ~:~ _ _ :~ " [ 11.7 . =$-'------- :~ 
~---2::.:c. 2=-!i --. ° - 74 01 32.6 --==-- ____ ~ 
1.9 , 0.54 ~_ I , 9.3 4 8.8 ·210 
---'-___ ....:0....:·~+1 --· i- . 'H!= -=:r 6:! ~?-=- :h= ~= =-~~!: 
83, .!-I----ol -= ,:~ O~ I -- 4~! ~ =~l ~ ':~ 




85 : 3i I - II 6.1 21 S.l ! 3 ~ -' 
90 1.5 -J 5.2! 81 23.2 1 12 -15471 
91 1.3 2.4 1.8 ; 0.91 6.5 OJ 9 100 
92 : 3.41 3 ----1.7 ( , 0 6-.6-: -- 100 
; I I , J 93 1 2! 2.8 : 7i _ _ -140 
95 2.2 2.7 11.27 0.3 6.92 0.81 12.86 1 64 
96 5.2 1.6 5.24 OJ 5.62 1.41 4.9 l 73 
97 3.9 1.8 5.4 0.8 4.7 0.75 i 3.91 81 
98 -- ir 2.3 5.1 ~ 7.9 01- 8.5[ 100 
99 4.8! 10 3.1 0 : 2.7 D) 3.3! 100 
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Phannacodynamic data file 
FAPT 
9.24 
6 . 1 
2.85 
3.4 
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1 30. 1 
1 30.3 
1 30.4 
1 2 9 
1 29. 1 
1 29 .3 




1 32. 1 
1 3 2 .3 
1 32 .4 
APPENDIX C.2 
Summary of results and control stream for fractional Emax count model 
THETA: EO FEMAX ECSO 
ETA: CVEO CVEMAX CVECSO 
ERR: 
THPD5.LST 1271.191 eval=394 sig=4.2 sub=46 obs=154 CIL=YNNY NV1.0 
THETA 17.5 0.587 0.478 




ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 






user 0.0 real 0 .0 





. 82 E+OO 
;FAPT=percent of time in observation time (DOBS) that infant was 
apnoeic 
;NAPN=number of apnoea s in observation time (DOBS) 
iDOBS=duration of observation e.g. 2 h on that day (DAY) 
;CONC=theophylline cone (mg/L) 
;TIME=time of sampling for theophylline conc (h) 
;COND=diagnosis 
$INPUT lD GEN~ WT GA E'APT NAPN= DV CONC DOBS TIME DAY COND OXY PCA 
$DATA c:\users\marie\theoivpd.prn IGNORE=# 








$OMEGA 0.25 CVEO 1 
$OMEGA BLOCK (2) 
0.25 CVEMAX 2 
.01 0.25 i CVEC50 3 
$PRED · 
EO =THETA(l) *EXP(ETA(1)) ;baseline 
TVFEMX =THETA(2) 
;Transform Femax into - INF to +INF before adding ETA 
iThis ensures that an individual value of ~emax will be in 0-1 space 
TMP=TVFEMX/ (l-TVFEMX) 
TMP2=LOG(TMP)+ETA(2) 
iTransform Femax into 0-1 space 
.328 
TMP3=EXP(TMP2) 
FEMX =TMP3/(1+TMP3) ;maximum fractional reduction 





iPredict number of apnoeas in the observation period 
iNONMEM needs actual integer number of observations not a nominal rate 
APN=DOBS* HAPN 
;Stirlings formula for log DV factorial 












$TABLE DV CONC HAPN WT GA DAY PCA ETAl ETA2 ETA3 NOPRINT FILE=THPD5.fit 





i$TABLE ID TIME IPRED IWRES 
iHDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=sdtab002 
i$TABLE ID TIME IPRED IWRES 
iHDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=mutab002 
i$TABLE ID FEMX EO EC50 
iHDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=patab002 
i$TABLE ID GA WT PCA 
;HDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=cotab002 
i$TABLE ID GEN OXY COND 

































0.8 1.2 1.6 
Weight (kg) 
poor not poor 




























28 30 32 34 
Postconceptual age (weeks) 















28 30 32 34 


























sig=4.5 sub=46 obs=154 
0.645 Ic 
3 . 6606 
ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 
CIL=YNNY WI . 0 






user 0.0 real 0.0 






;FAPT=percent of time in observation time (DOBS) that infant was 
apnoeic 
;NAPN=nurnber of apnoeas in observation time (DOBS) 
;DOBS=duration of observation e.g. 2 h on that day (DAY) 
;CONC=theophylline cone (mg/L) 
;TIME=time of sampling for theophylline cone (h) 
;COND=diagnosis 
$INPUT ID GEM WT GA FAPT NAPN=DV CONC DOBS TIME DAY COND OXY PCA 
$DATA c:\users\marie\theoivpd.prn IGNORE=# 
$ESTIMATION METH=COND LAPLACE -2LL MAXEVALS=lOOO PRINT=5 
;$COV 
$THETA (0,15) EO 1 
$THETA (0,.4,1) FEMAX 2 
$THETA (0, .1, ) EC50 3 
$THETA 1 FIX HILL 
$OMEGA 0 . 25 ; CVEO 1 
$ OMEGA BLOCK (2) 
0.25 CVEMAX 2 
.01 0.25 ; CVEC50 3 
$PRED 
EO =THETA(1)*EXP(ETA(I)) ;baseline 
TVFEMX =THETA( 2 ) 
;Transform Femax into -INF to +INF before adding ETA 
;This ensures that an individual value of femax will be in 0-1 space 
TMP=TVFEMX/ (l-TVFEMX) 
TMP2=LOG(TMP)+ETA(2) 
;Transform Femax into 0-1 space again 
TMP3=EXP (TMP2) 
331 
FEMX =TMP3/(1+TMP3) ;maximum fractional reduction 




;Predict number of apnoeas in the observation period 
;NONMEM needs actual integer number of observations not a nominal rate 
APN=DOBS*HAPN 
;stirlings formula for log OV factorial 












$ TABLE ID TIME IPRED IWRES 
HDV HAPN REX WREX NOAPPEND 
$ TABLE 10 TIME IPRED IWRES 
HDV HAPN REX WREX NOAPPEND 
$ TABLE ID FEMX EO EC50 
HDV HAPN REX WREX NOAPPEND 
$ TABLE ID GA WT PCA 
HDV HAPN REX WREX NOAPPEND 
$ TABLE ID GEN OXY COND 
















FI LE=cotabO 02 
FILE=catab002 
APPENDIX C.S 
Summary of results and control stream for time model 
THETA: EO FEMAX EC50 HILL 
ETA: CVEO CVEMAX CVEC50 
ERR: 
TEMXOM2.LST 1272.472 eval=303 sig= sub=46 obs=154 CIL=YNNY NVl:0 
THETA 16.5 0.453 0.0206 lc 




DUE TO ROUNDING ERRORS (ERROR=134) 
ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 
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;FAPT=percent of time in observation time (DOBS) that infant was 
apnoeic 
;NAPN=number of apnoeas in observation time (DOBS) 
;DOBS=duration of observation e.g. 2 h on that day (DAY) 
;CONC=theophylline conc (mg/L) 
;TIME=time of sampling for theophylline conc (h) 
;COND=diagnosis 
$INPUT ID GEN WT GA FAPT NAPN=DV CONC DOBS TIME DAY COND OXY PCA 
$DATA c:\users\marie\theoivpd.prn IGNORE=# 
$ESTIMATION METH=COND LAPLACE -2LL MAXEVALS=1000 PRINT=5 
;$COV 
$ THETA (0,15) EO 1 
$ THETA (0,.4,1) FEMAX 2 
$THETA (0, .1, ) EC50 3 
$ THETA 1 FIX HILL 
$ OMEGA 0.25 ; CVEO 1 
$OMEGA BLOCK (2) 
0.25 CVEMAX 2 
.01 0.25 ; CVEC50 3 
$PRED 
EO =THETA(I)*EXP(ETA(I» ibaseline 
TVFEMX =THETA(2) 
iTransform ~'emax into -INt' to +INF before adding ETA 
;This ensures that an individual value of Femax will be in 0-1 space 
TMP=TVFEMX/(I-TVFEMX) 
TMP2=LOG(TMP)+ETA(2) 
;Transform Femax into 0-1 space again 
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TMP3=EXP(TMP2) 
FEMX =TMP3/ (l+TMP3) imaximum fractional reduction 
EC50 =THETA(3)*EXP(ETA(3» iEC50 
CN=TIME**THETA(4) 
E =FEMX*CN/(EC50**THETA(4)+CN) 
HAPN =EO* (l-E) 
iPredict number of apnoeas in the observation period 
iNONMEM needs actual integer number of observations not a nominal rate 
APN=DOBS*HAPN 
iStirlings formula for log DV factorial 












$TABLE ID TIME IPRED IWRES 
HDV HAPN REX WREX NOAPPEND 
$TABLE ID TIME IPRED IWRES 
HDV HAPN REX WREX NOAPPEND 
$TABLE ID FEMX EO EC50 
HDV HAPN REX WREX NOAPPEND 
$TABLE ID GA WT PCA 
HDV HAPN REX WREX NOAPPEND 
$TABLE ID GEN OXY COND 



















Summary of results and control stream for time-concentration model 
THETA: NORMAL RMAX RC50 RTHALF TC50 
RDFO 
ETA: CVNORM CVRMAX CVRC50 CVRTHF CVTC50 
ERR: 
TCEMOM2.LST 1263.968 eval=460 sig=3.4 sub=46 obs=154 CIL=YNNY NV1.0 
THETA 8.08 7.8 0.037 0.00691 2.82 
1c 




ETABAR IS THE ARITHMETIC MEAN OF THE ETA-ESTIMATES, 
AND THE P-VALUE IS GIVEN FOR THE NULL HYPOTHESIS THAT THE TRUE MEAN IS 
O. 
ETABAR: - .12E-01 .18E-01 .26E+00 .OOE+OO 
P VAL.: .90E+OO .89E+OO .82E-01 .10E+01 
R MATRIX ALGORITHMICALLY SINGULAR 
AND ALGORITHMICALLY NON-POSITIVE-SEMIDEFINITE 
COVARIANCE STEP ABORTED 
user 0.0 real 0.0 tcl 0.0 
$PROB POP COUNT DATA 
.OOE+OO 
.10E+Ol 
iFAPT=percent of time in observation time (DOBS) that infant was 
apnoeic 
iNAPN=number~of apnoeas in observation time (DOBS) 
iDOBS=duration of observation e.g. 2 h on that day (DAY) 
;CONC=theophylline cone (mg/L) 
;TIME=time of sampling for theophylline cone (h) 
iCOND=diagnosis 
$INPUT ID GEN WT GA FAPT NAPN=DV CONC DOBS TIME DAY COND OXY PCA 
$DATA c:\users\marie\theoivpd.prn IGNORE=# 
$ESTIMATION METH=COND LAPLACE -2LL MAXEVALS=1000 PRINT=5 
MSFO=TCEMOM2.msf 
$COV 
$THETA (0,7.7,) i NORMAL 
$THETA (l,10,50) i RMAX 
$THETA (0.001,0.209,5) RC50 
$THETA (0.001, .0646,5) RTHALF 
$THETA (.01,2.09,100) TC50 
$THETA 1 FIX RDFO 
$OMEGA 0.431 CVNORM 
$OMEGA BLOCK(2) 
0.537 CVRMAX 
-.309 1.79 CVRC50 
$OMEGA 0 FIX CVRTHF 




RMAX 'l'HE'l'A(2) *EXP (E'l'A(2)) 
RTHF THETA(4)*EXP(ETA(4)) 
TCSO THETA(S)*EXP(ETA(S)) 
RDFO = THETA(6) 
IF (RTHF.LE.O) EXIT 1 1 
KD=I.OG(2)/RTHF 
RCSO=THETA(3)*EXP(ETA(3)) 
;Predict conc of RDF at time=TIME 
RDFT=RDFO*EXP(-KD*TIME) 
;normal 
;max increase in APN due to RDF 
;RDF half-life 
;theo ECSO 
;Predict effect of RDF at time=TIME 
ERDF=RMAX*RDFT/(RDFT+RCSO} 
IF (TCSO.LE.O) EXIT 1 3 
BASE=NORMAL+RMAX*RDFO/(RCSO+RDFO} 
;Predict theophylline effect at conc=CONC 
ETHEO=CONC/(CONC+TCSO} 
;Hourly APN is normal plus effect of RDF reduced by theo 
HAPN=NORMAL + ERDF * (l-ETHEO) 
;Predict number of apnoeas in the observation period 
;NONMEM needs actual integer number of observations not an hourly rate 
APN=DOBS*HAPN 
;Stirlings formula for log DV factorial 












$TABLE ID TIME CONC RDFT ERDF ETHEO ETA(l} ETA(2} HAPN DOBS 
NOPRINT ONEHEADER FILE=TCEMOM2.fit 
$SCAT HAPN VS DV 
;$TABLE ID TIME IPRED IWRES 
;HDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=sdtab3 
;$TABLE ID TIME IPRED IWRES 
;HDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=mutab3 
; $ TABLE ID NORMAL BASE RMAX RCSO RTHF TCSO . 
;HDV HAPN REX WREX NOAPPEND NOPRINT ONEHEADER FILE=patab3 
;$TABLE ID GA WT PCA 
;HDV HAPN REX WREX NOAPPEND NOPRINT ONE HEADER FILE=cotab3 
;$TABLE ID GEN OXY COND 








Control stream of simulation of time-concentration model 
NORMAL RMAX RCSO RTH .. :;LF 'l'C~O 
CVNORM CVRM.,.n.x CVP.C50 CVRTHf CVTC~O 
HAPNSIM. LS'1' 
1.0 
291].144 eval=O sig~O sub=46 obs=154 CIL=YNNY NV 







~!!,er 0.0 rea.l 0.0 








:FAPT-=percent uf time in observation time (DOBS) that infant \~as apnoei 
c 
;NAPN=.:number of apnoeas in observation time (DOBS) 
;DOBS=duration of observation e.g. 2 h on that day (DAY) 
;CONCc:: theophylline cone (mg/I.) 
;Tli"iE=time of sampling for t.heophylline COi;C (11) 
;COND:::;diagnosis 
$IN!?UT ID ..GEN WT GA FAPT NAPN=DV CONC DCDS TH1E DAY COND OXY PCA 
$DATA c:\users\marie\theoivpd.prn IGNORE-"# 




$THE'l'A (1,20; 50} 
; NORHAL 
; RHA..X 









$CMEGA 0 FIX i 
$OMEGA BLOCK(2) fIX 
o ; CVRMAX 
o 0 ; CVRC50 
CVNORM 
$OMEGA 0 FIX 




NORMAL == THETA(l}*EXP(ETA(l));normal 
RMA.X = 'l'HETA (2) *EXP (ETA (2) ) ;max increase in APN due to RDF 
RTHF THETA(4)*EXP(ETA(4» :RDF half-life 
TC50 ~ THETA(5)*EXP(ETA(5)} ;theo EC50 
IF (RTHF.LE.O) EXIT 1 1 
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KO-=T.OC; (2) /R.1'HF 
RC50=THETA(3)*EXP(ETA{3)) 
; Predict cone of RDF ai... L.!.!!lt::=TIME 
?J)PT=T!IETA{6} "'EXP (-KD*'TIME) 
;P!~ l-::di c.; t effec t of RDF dt time=TIMJ::: 
ERD F=RMlI .... X * RDfT I (RD fT+RC':' U} 
IF (TC50.LE.O) EXiT 1 3 
RDFO-:=THE:TA (6 } 
BASF>N01U1AL+P.Ml\. .. '\ * fWFO/ (P.C!)O+RDFO) 
; Predict lhE!Ophyl line l~lfect i'lt r.()nc~-CONC 
E'l'HEO=CONC/(CONC+'l'CSO) 
;Hourl'l APN is normal plus effect. of EDF rodncod by LheG' 
HAPN=NORMAL -t ERDl" * (l-r~THEO) 
;Predict numbe r of apnoeas in the observation period 
; NONMEM needs act ua 1 in r.eger nUf!'ber of observdtions not a n hourly ra t8 
APN=DOBS*HAPN 
;Stirling;; fO.Lliluld. [or. log DV tacLorial 
IF (DV.GT.O) THEN 




"It' (Al:'N. LE .lD-IO) APN=lD-IO 
LOGAPN=LOG(APN) 





IWRES == l 
$'T'ABU: ID TIME CONC RDF1' ERDF ETIlEO !-iAPN 
NOPRINT ONEHEADER 





rdfD = 10 




TEC50 = 1 



















Data sheet for simulation of time-concentration model 
and Time Cone RDFT ERDF ETheo HAPN+T HAPNO 
(h) (mg/L) 
concentration of respiratory depressant factor (RDF) at time = 0 
apnoea COWlt of any patient before theophylline administration 
the maximwn increase in apnoea due to RDF 
concentration of RDF at 50% of maximwn effect of RDF 
time when RDF is half its original value 
concentration oftheophyIIil1c at which half ofRDF effects arc removcd 
serwn theophylline concentration (mgIL) 
dissociation, calculated as LN(2)/RTSO 
time in hours fi-om 1 to 99 to depict changes in relevant parameters over time 
TheocO = serwn theophylline coucentration (mglL) 
concentration ofRDF at time == TIME, calculated as rdfO*EXP(-kd*TlME) 
the Emax model of the RDF factor calculated as = Rmax*RDFT/(RDFT + 
RDFC50) 
Emax model of theophylline calculated as = Concl(Conc + TEC50) 
hourly apnoea counts with effect of theophylline, calculated as = Nonnal + 
ERDF*( 1 - Etheo) 
Hourly apnoea counts before drug is givcn, calculatcd as = Nonnal + ERDF 
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The Pharmacokinetics of Theophylline in Premature Neonates 
During the First Few Days After Birth 
Marie J. du Preez,* Julia H. Both2.,* M. Lynn McFadyen,* and Nick H. G. Holford, 
Departments of Pharmacology, *University of Natal, Durban-Westville, Durban, South Africa; and tUniversity of Auckland, 
New Zealand 
Summary: The aims of the study were to estimate the pharmacokinetic parameters, 
clearance rate (CL), and volume of distribution (V) of theophylline in 'premature 
neonates durin" the first few days after birth, and to identify factors contributing to 
interindividual C"yariability. The ;uthors obtained 263 serum concentrations from 105 
apneic premature neonates receiving intravenous (IV) theophylline. Mean (SD) birth 
weight and postnatal ages were 1.3 (0.3) kg and 1.1 (0.3) days, respectively. The data 
were analyzed using the nonlinear mixed effects model (NONMEM). A one-
compartment model with flfSt order elimination was used. The final models were: 
CL (Uh) = 0.006 * WO'f'l·75 * P 
V (L) = 0.63 * WOT 
WOT = weight (kg) 
P = 1.47 with oxygen suppon and 
1.0 without oxygen support. 
The CL in the study population was low. resulting in long half-lives. After inclusion 
of the above covariates, as well as interoccasion variability. the interindividual vari-
ability in CL was 56% and in V was 47%. lnteroccasion variability in CL and V was 
34'10 and 35'10 respectively. Theophylline pharmacokinetics are variable in the prema-
ture neonate during the first week of life. and this high variability makes it difficult to 
predict drug concentrations with the same degree of accuracy as in other populations. 
Key Words: Theophylline-Premature neonates-Population pharmacokinetics. 
The pharmacokinetics of theophylline in premature 
neonates have been studied using either individual analy-
sis methods (1-8) or population methods such as the 
Nonlinear Mixed Effects Model (NONMEM) (9-11). In 
the NONMEM studies, the postnatal ages of the neonates 
ranged from I to 182 days, and in the individual analysis 
studies from I to 36 days. In our setting, neonates in-
variably receive theophylline for only a few days after 
birth. There has been very little emphasis in the literature 
on pharmacokinetics in these very young babies at a time 
when physiologic parameters are changing rapidly. As a 
Received April 20. 1999; accepted July 26. 1999. 
Address correspondence and reprint requests to Marie 1. du Preez. 
Department of Experimental and Clinical Pharmacology, University of 
Natal, Private Bag 7, Congella 4013. South Africa. 
340 
result, the models derived in the above studies may be 
inappropriate for predicting the doses required in our 
patients. The objective of this study was to investigate 
the population pharmacokinetics of theophylline in pre-
mature, apneic neonates within the first week of life. In 
view of the ethical constraints, a population approach 
was ·deemed appropriate, as few serum samples per pa-
tient would be required. 
METHODS 
The study was conducted in the Nursery of King Ed-
ward VITI Hospital, Durban, South Africa. It was ap-
proved by the Ethics Committee of the Faculty of Medi-
cine, University of Natal and infonned written consent 
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was obtained from the mother for each patiel).t entered 
into the study. 
Any premature neonate under 2 days old, for whom 
theophylline was prescribed to reduce neonatal apnea, 
was eligible for the study. Exclusion criteria were con-
genital malformations and intraventricular hemorrhage 
of grade III or greater. 
All relevant demographic and clinical information was 
recorded. Gestational age. if not available from sonar 
scans or menstrual dates, was estimated using the method 
described by Parkin (12) and verified by comparison of 
birth weight, length, and occipital frontal circumference 
on an anthropometric chart that was developed by Lub-
chenco et al (13). Body surface area was calculated using 
the formula of Mosteller (14). 
Aminophylline (Sabax Aminophylline 250 mg/l0 mL, 
Adcock-Ingram, Isando, South Africa) was administered 
through an IV line and nushed in with 2 mL normal 
saline over 2 minutes. Loading doses varied from 4-7.7 
mglkg. Maintenance doses ranged from 1.4-6 mg/kg per 
day and were given in 2-4 divided doses. All doses were 
determined by the physician in charge and not by any 
requirements of the study. 
Accurately timed blood samples were collected ap-
proximately 1 hour after the loading dose. Thereafter, a 
sample was obtained each day if possible: these samples 
were drawn illlIl1ediately prior to the next dose. The 
samples were centrifuged immediately and the serum 
kept frozen at -70"C until analysis. Total serum theoph-
ylline concentrations were measured by Emit Assay 
(Syva, Palo Alto, CA, USA). The coefficient of variation 
is approximately 6% for both between-run (7.5 mg/L) 
and within-run (10 mg/L) measurements. 
Population Pharmacokinetic Modeling 
Data analysis was performed using the computer pack-
age NONMEM (NONMEM Project Group, University 
of Catifomia, San Francisco, CA. USA) (version V Level 
l.O, double precision) which models fixed and random 
effects to determine which effects innuence the pharma-
cokinetic parameters. 
One- and two-compartment pharmacokinetic models 
were compared using the appropriate subroutines from 
the NONMEM library. In the first phase of the analysis, 
a base model with no covariates on CL or V was used. 
The interpatient variability in CL and V was generated 
from exponential models. Various residual error models 
were t~sted, namely: exponential, log, proportional, ad-
ditive, and a combination model. The following covari-
ates were available for testing: Weight, body surface 
area; gestational age, postnatal age, postconceptual age, 
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Apgar score at 5 minutes, the presence of neonatal jaun-
dice, respiratory support (i.e., oxygen supplied per head-
box at time of sampling), and antenatal corticosteroid 
administration. 
The Xpose program (XPOSE 2.0), was then used for 
model diagnostics and covariate identification (Jonsson 
EN and Karlsson MO. Xpose - an S-PLUS based model-
building aid for popUlation analysis with NONt·.1EM. 
Department of Pharmacy, University of Uppsala, Uppsala, 
Sweden). The GAM (stepwise-generalized additive mod-
eling) function in Xpose was used for the identification 
of covariates of CL and V (15). The bootstrap of the 
GAM was used to test the stability of the covariate in-
clusion. Using NONMEM, the covariates selected by 
GAM analysis were then tested singly and in combina-
tion on CL and V. respectively. In the model-building 
process, criteria used for selecting a model included a 
reduction in objective function value (OFV) of 6.8 (p > 
0.01) or greater. .,-
All covariate model-building was performed using the 
first order estimation method. Thereafter the base and 
final models were run using the first order conditional 
estimation method. The presence of interoccasion vari-
ability in CL and V was tested at the very end (16). An 
"occasion" was a different day, i.e., days I. 2, and 3. All 
days after day 3 were grouped together as occasion 4. 
The predictive performance, in terms of bias (mean pre-
diction error) and precision (root mean square prediction 
error) for the base and final models, was calculated using 
the popUlation values and comparing these with the post 
hoc estimates of the final model parameters (17). 
RESULTS 
The Patients 
All the patients were black premature neonates. De-
mographic and clinical data are summarized in Table 1. 
Of the 105 patients, 97 (92%) had respiratory distress 
syndrome at the time of serum sampling. Oxygen support 
TABLE 1. Demographic and clinical data of the study 
population 
Demographic data at enuy 
Patients = 105 Males = 52 
Mean SD Median Range 
Birth weight (kg) 1.3 0.3 1.3 0.7-1.9 
Gestational age (weeks) 30.8 1.8 31.0 26-34 
Postnatal age (days)" 1.1 0.3 1.0 1-2 
Postconceptua! age (weeks) 31.0 1.8 31.1 26.1-34.1 
Body surface area (m2) 0.117 0.017 0.115 0.081-0.146 
Apgar at 5 min 9 I 9 5-10 
.. Day of birth = day I. 
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bv head box was given to 64%. 59%, and 48% of the 
n~onates on days 1,2, and 3 respectively. The peripheral 
oxygen saturation was measured at intervals of 4 hours 
and was kept above 90%. Oxygen supply was removed 
when the concentration was higher than 97%. Antenatal 
corticosteroids were given to 30% of the mothers. None 
of the mothers smoked or took caffeine-containing bev-
erages during labor. Most of the neonates (96%) received 
beta-Iactam and aminoglycoside antibiotic combinations 
for proven or suspected sepsis. 
Concentration Measurements 
There were 263 concentration measurements taken, 
with a median of 2 samples per patient and a range of 1 
to 7. Of the theophylline measurements, 60% and 94% 
were obtained in the first 3 days and within I week of 
birth respectively. Average (SD) serum theophylline 
concentrations for days 1, 2. and 3 were 5.6 (3.1), 
7.5 (3.9). and 8.8 (5.7) mglL respectively. Because of 
the long half-life of theophylline in neonates. very few 
of these samples could be expected to be steady state 
concentrations. 
Population Analysis 
As there was no- significant difference in OFV be-
tween one- and two-compartment models, the one-
compartment model was selected for further analysis. 
The exponential residual error model was selected be-
cause a frequency distribution of the weighted residuals 
gave a more normal distribution than did the other error 
models. 
The GAM on CL indicated that oxygen support and 
gestational age featured as significant covariates. For V, 
postconceptual age and gestational age were significant 
covariates. The bootstrap of the GAM showed inclusion 
frequencies for all the above covariates of greater than 
30%. 
Weight was also selected for testing on both CL and V 
because. besides being the most accurately and com-
monly measured covariate, it was also highly correlated 
(,.1 = 0.8) with both gestational age and postconceptual 
age. Weight (WGT) was modeled as a continuous func-
tion on V and CL and, in addition. as various exponential 
functions on CL. These exponential functions included 
the general model of WG'fl·75 as propos~d by Holford 
(18) and the specific value of WGTl.28 found by Moore 
et al (9) in a study of theophylline in neonates. In addi-
tion, an attempt was made to estimate an exponent on 
weight. . 
Testing these covariates singly in the NONMEM 
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analysis showed that oxygen support and w~ight (all 
models) on CL; ' and weight, gestational age, and post-
conceptual age on V all significantly (p > 0.01) de-
creased the OFV. With respect to the covariates on V, 
gestational age and postconceptual. age produced the 
same reduction in OFV (15.5) while weight produced a 
larger reduction (35.0). Therefore weight was chosen for 
further model-building on V. The exponential functions 
of weight on CL all gave similar changes in OFV (11.6-
- 15.6). Therefore, various combinations of these models 
on CL were tested together with oxygen support (while 
weight was on V). At this stage the WG'fl·75 combina-
tion was marginally better than the others and, as a result, 
the best covariate models were: 
CL (LIb) = 81 * ~VGr>·7S * 83 
V (L) = 82 * WGT 
WGT = weight (kg) 
83 = with or without 
oxygen support. 
In general. parameter values appeared to be more pre-
cisely estimated when the first order conditional estima-
tion method was used. As a result of the relatively high 
values obtained for interindividual and residual variabil-
ity, it was thought important to check for interoccasion 
variability. This resulted in the final model. Parameter 
values are presented in Table 2. Before testing for inter-
occasion variability, interindividual variability for CL, 
V, and residual variability were 60%, 53%. and 29% 
respectively. On the introduction of interoccasion vari-
ability, these decreased to 56%, 47%, and 16% respec-
tively. The OFV changed from 962.3 to 927.9. Calcu-
lated using the final model, the mean values (95% Con-
fioence Intervals) for CL in our population, were 0.0074 
(0.0070, 0.0078) LIb for neonates without oxygen sup-
port, and 0.0104 (0.0099, 0.0109) LIh for neonates re-' 
ceiving oxygen support. The mean (95% CI) value for V 
fO'r our neonates was 0.81 (0.77,0.85) L. This results in 
mean predicted population half-lives, without and with 
oxygen support, of 76 and 54 hours respectively. For 
comparative purposes the weight-normalized mean val-
ues for CL without and with oxygen are 0.0056 and 
0.0084 Uhlkg- respectively, and for Vis 0.63 Ukg. The 
relationship between the measured concentrations and 
.those predicted using the final model is shown in Figure 
1. The ?ias and precision of the base and final models, 
when compared with the post hoc estimates of CL and V 
. from the final model (taken as the "uue value"), are 
given In Table 3. It is evident that there is an improve-
THEOPHYlLINE IN PRE,\.fATURE NEONATES 601 





Interindividual variability in CL (%) 
Interoccasion variability in cL (%) 
Interindividual variability in V (%) 
Interoccasion variability in V (%) 
Residual error (%) 
OFV 









ment from base to final model in all categories. espe-
cially in the bias of CL. 
DISCUSSION 
The present study differs from previous population 
analyses of theophylline in the premature neonate as it 
describes the pharmacokinetics of the drug only during 
the first few days after birth. This is when theophylline is 
. most often used for the treatment of apnea of prematu-
rity. Other unique features of the present study are the 
all-black population and the high incidence of respiratory 
distress syndrome (92%). 
In the final model. an exponential function of weight 
was found to be an important determinant of CL. This is 
Measured vs Predicted 
theophylline concentrations: Final Model 
30r-------------------------------~ 

























FIG. 1. Measured theophylline concentration versus predicted concen-
tration: final model. 
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Best covariate Final model 
model (with interoccasion variability) 
0 .0056 (19) 0.0060 (14) 
1.61 (23) 1.47 (IS) 
O.5S (8) 0.63l7) 
60 (29) 56 (25) 
34 (77) 
53 (23) 47 (28) 
35 (29) 
29 (22) 16 (35) 
962.3 927.9 
in accordance with the other NONMEM studies of the-
ophylline in neonates (9-11). [n two of these studies 
(9.11) postnatal age was also important. but this was not 
the case in the present study. In comparison with the 
present study. these other NONMEM studies had much 
wider ranges of both postnatal ages (from 1 to 182 days) 
and weights (0.37 to 7.6 kg). 
The weight-normalized CL values for neonates with-
out and with oxygen support were 0.0056 and 0.0084 
L/h/kg respectively. These values are lower than those 
reported in other NONMEl\-[ studies. Both Lee et al (11) 
and Moore et al (9) found CL values greater than 0.012 
Llhlkg. The values obtained in the present study are 
closer to the clearances reported in some of the indi-
vidual analysis studies. These values ranged from 0.0043 
to 0.0299 Llhlkg (2.3.7). In these studies gestational ages 
and postnatal ages were close to those in the present 
study. 
In neonates. renal clearance of theophylline is rela-
tively more important than metabolic clearance. Ap-
proximately 50% of the drug is excreted unchanged com-
pared to about 14% in children and adults (19-21). The-
ophylline clearance and urinary metabolite patterns 
apparently reach adult values at 55 weeks postconceptual 
age (21). U nfonunately we were unable to assess renal 
function in our study. However. glomerular filtration rate 
is lower than normal in infants with respiratory distress 
syndrome (22); therefore the low CL values mav be re-
lated to the large number (92%) of neonates wi(h respi-
ratory distress syndrome. 
TABLE 3. Percellwge bias (111£1 precisiOIl (95% Cl) for che 
base alld filial models 
Clearance Volume 
Base model Final model Base model Final model 
Bias 24 (17. 31) 5 (0.12) 14 (5. 22) 8 (0.15) 
Precision 51 (39.58) 33 (29. 43) 52 (40. 58) 44 (35. 49) 
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In our study it was shown that neonates who received 
oxygen by headbox cleared theophylline 47% faster than 
those who did not. Although some of our neonates may 
have been classified as suffering from asphyxia, it was 
not possible to record this accurately in our situation, and 
therefore asphyxia could not be tested as a covariate. It is 
knOWil that hypoxia may decrease theophylline CL (23-
25), and that CL is lower in asphyxiated neonates (6,8). 
Gal et al (6) originally reported a 46% lower CL in 
asphyxiated than in nonasphyxiated neonates. In a sub-
sequent study Gilman et al (8) found a 19% lower CL in 
asphyxiated neonates. Asphyxia in these studies was de-
fined as a J - or 5-minute Apgar score of :53, a cardiac or 
respiratory arrest requiring resuscitation, apnea> J min 
requiring bag breathing, or an arterial oxygen pressure 
:53 torr. 
The weight-normalized value of V of 0.63 L/kg is 
lower than that found in other population studies that 
reported a range from 0.8 to 0.9 L/kg (9,11) . However, 
this lower value is within the range (0.18 to 0.95 L/kg) 
recorded in some of the individual analyses (2.3.5) that 
reported on babies with lower postnatal ages (I to 26 
days). 
Karlsson et al (16) reported that if interoccasion vari-
ability is not recognized, it may inflate interindividual 
variability and/or residual variability. Our results support 
this. as the introduction of interoccasion variability re-
duced interindividual variability on both CL and V and 
substantially decreased residual variability. 
However, the interpatient variability in CL remained 
high at 56% for the final model , despite testing all the 
available covariates. This value is higher than those ob-
tained in the other NONMEM studies. For example, 
Moore et al (9). Karlsson et al (10), and Lee et al (11) 
reported interpatient variability in CL of 16%. 25%, and 
30%, respectively. Various factors could account for this 
large interindividual variability in CL. The study was 
conducted during the flfst few days after birth when the 
premature neonate undergoes profound changes to adapt 
from fetal to neonatal physiology (26-28). During this 
time not all the neonates were at the same stage of 
change. For example 20% of the . patients had developed 
neonatal jaundice by day 2, and another 30% from day 3 
onward. On entering the study, the majority of the neo-
nates had respiratory distress syndrome. This usually re-
solves spontaneously, but slowly. after bilth and there-
fore would have differed from patient to patient. These 
changes, as well as the different stages of immaturity of 
the physiologic and biochemical systems, may be re-
sponsible for much of the variation found in the estima-
tion of CL (19.21,29,30). It could also perhaps be ex-
plained in part by the fact that the study was carrie.d out 
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in a busy third world hospital and thus the prevailing 
clinical circumstances (such as individual nursing care, 
ambient temperature. etc.) were sometimes variable . 
The interpatient variability (47%) on V was also high. 
but similar to the 44% obtained by Lee et al (11). The 
three phases of fluid and electrolyte homeostasis (27) 
and the shif~ of fluid from the extracellular to the intra-
cellular fluid compartments during the flfSt week of life 
(31.32) could all contribute to the high variability. 
The residual variability of 16% in the present study is 
similar to the 14% recorded by Lee et al (11) and within 
the range (9%-250/c, depending on concentration) found 
by Moore et al (9). 
The interoccasion variability on CL and V were 34% 
and 35% respectively. These values have been expressed 
as if they were random effects. but most likely they re-
flect systematic changes resulting from development of 
hepatic and renal function and changes in body compo-
sition. Because of the relatively short follow-up period 
and small sample size. we were unable to describe these 
changes as a function of time. With more data one would 
hope to be able to characterize these other systematic 
factors and thus minimize the interoccasion variability. 
In conclusion. CL of theophylline in the premature 
neonate in the first week of life is low, resulting in long 
half-lives. Small peak-to-trough fluctuations would be 
expected. even on once-daily dosing . Our study conflITns 
the high interindividual variability in theophylline phar-
macokinetics in the premature neonate. which is only 
partly explained by the contribution of interoccasion 
variability . This makes it difficult to predict concentra-
tions with the same degree of accuracy as in other popu-
lations. The interoccasion variability in CL of 34% is an 
indication of the size of variability in steady state con-
centration in an individual that cannot be improved by 
therapeutic drug monitoring. 
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The effect of theophylline on apnoea and hypoxaeniic 
episodes in the premature neonate during the 1st 3 days 
after birth 
M. J. DU PREEZ, J. H . BOTHA, M . L. McFADYEN* & M. ADHlKARl** 
DeparlmelllS of Pharlllacology, University of Nalal and * Dlirban-Iflcstvillc, and **D.:par{IIICIl{ of 
Paediatrics, University of Natal, Dw·ball, SaHlI! /1f11"ca 
(i\.:.:cp\cd J 0 March J ')'lH) 
Summary Although the efiect of theophylline on apnoea is well documented , its infim:nce on hypox-
aemic episodes in premature neonates is less well known. To investigate the inlluence of the drug on both 
parameters, 37 apnoeic neonates were monitored before and after theophylline treatment. Incidents and 
densities of pathological apnoea (cessation of nasal airllow ~ 20 seconds) were recorded . A fall of ~ 10% 
for > 10 seconds in peripheral oxygen saturation was classified as a hypoxaemic episode. Ethical constraints 
precluded the inclusion of a control group . Each infant served as its own control. Theophylline serum 
concentrations were 5.6 (3.4), 8 (7.1) and 8 (5 .3) mgll on days 1, 2 and 3, respectively. The apnoea 
incidents ancl densities decreased significantly (p ~ 0.0001) from baseline on all 3 days. The llltal number 
of hypoxacmic episodes, as well as those not associated with pathological apnoea, decreased , though not 
signific;Jlllly. However, those hypoxaemic episodes associated with pathological apnoea and a fall in pulse 
rate of ~ 20% decreased significantly from baseline on day 2 only. Throughout the study period, over 80% 
of hypoxaemic episodes were not associated with apnoea . It is concluded that in the doses used, 
theophylline was more eficctive in reducing apnoea than hypoxaemic episodes in premature neonates. 
Introduction 
Apnoea and hypoxaemic episodes are com-
1110n in the premature neonate . Most patho-
logical apnoea episodes, i.e. those lasting 20 
seconds or longer, are detected by apnoea 
monitors. However, the hypoxaemic episodes 
lhat arc unassociated with apnoea may go un-
noticed,I "\ depending on the type of equip-
ment used and the availability of nursing staff. 
Many studies have shown that theophylline is 
effective for treating apnoea in neonates:I" 15 
I Iowevcr,only two studies have included a 
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control group. II> I< Very few studies mention 
any influence of the drug, beneficial or other-
wise, on hypoxaemic episodes. One study 
found a significant reduction in the number of 
apnoeic spells and total duration of hypox-
aemia after theophylline was administered for 
2 days but an increase in both parameters 48 
hrs after withdrawal of the drug. b In another 
study, after 7 days of theophylline therapy, the 
number of hypoxaemic episodes decreased, al-
though not significantly. Itt The effects on the 
neo"nate of intermittent hypoxaemia of moder-
ate intensity and relatively short duration are 
as yet unclear. However, some authorities ad-
vise that intermittent hypoxaemia and abnor-
malities in peripheral oxygen saturation should 
be recognized and treated. I,18 
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Hypoxaemic episodes unassociated with ap-
noea or bradycardia could be due to the devel-
opment of intrapulmonary shuntS.2.1~ . 21 Many 
factors are implicated in intrapulmonory 
shunting2 and, through its wide range of phar-
macolobrical cffects, theophyl1ine might affect 
one or more of these factors. The present 
study invcstigated thc influence of 
theophyl1ine on apnoea as wel1 as on hypox-
aemic episodes, unassociated and associated 
with apnoea, in a group of premature 
neonates. 
Material and Incthods 
The study was approved by the Ethics Com-
mittee of The Faculty of Medicine, University 
of Natal and was conducted in the nursery of 
King Edward VIII Hospital. Informed written 
consent was obtained for each infant entered 
into the study. Any premature neonate who 
was not receiving mechanical ventilation or 
continuous positive airway pressure, and for 
whom theopl:yl1ine was likely to be prescribed, 
was eligible for the study. The neonates were 
studied irrespective of coneomitant diagnoses 
such as respiratory distress syndrome (ROS). 
Exclusion criteria were congenital malforma-
tions, intravcntricular haemorrhage of grade 
III or greater, and the administration of other 
drugs known to interact with theophyl1inc. If 
at least one pathological apnoea (a cessation of 
nasal airflow equal to or longer than 20 sec-
onds) was detected during an initial monitor-
ing period of at least 2 hours, the neonatc was 
entered into the study. 
Most of the neonates received penicil1in and 
an aminoglycoside for proven or suspected 
sepsis. Only two presented with a positive bac-
terial culture after the 3rd day of the study. 
The appropriate antibiotics were then pre-
scribed. Six of the mothers received dexam-
ethasone just before or during labour. None of 
the mothers smoked and no caffeine-contuin-
ing beverages were ingested shortly before or 
during labour. 
Ful1 demographic details were recorded. 
Gestational age, i[ not available from sonar 
scans or menstrual dates, was estimated using 
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the method described by Parkin22 and verified 
by comparison of birthweight, length and oc-
cipital frontal circumference on an anthropo-
metric chart developed by Lubchenco Cl af.2J 
Apgar score, development of neonatal jaun-
dice or sepsis, presence of hypo- or hypergly-
caemia, full blood count, values of urea and 
electrolytes, other drugs prescribed and al1 
clinical interventions were recorded. Any fac-
tors known to precipitate apnoea were 
identified and corrected if possible before 
monitoring. As bolus feeding is known to 
cause apnoea, monitoring was not done during 
or after a feed . Blood pressure and mean ar-
terial pressure were recorded at regular inter-
vals using a DinamapTM Plus Vital Signs 
Monitor. (Critikon, Tampa, Florida.) 
The neonates received aminophylline (Sa-
bax Aminophylline 250 mg/ml, Adcock-
Ingram) into the intravenous line, flushed in 
slowly with 2 ml normal saline. The loading 
doses varied from 4 to 7.7 mglkg. l\lainte-
nance doses ranged from 1.4 to 6 mg/kg per 
day and were given in two to [our divided 
doses. All doses were determined by the phys-
ician in charge and not by any requirements o[ 
the study. The neonates were monitored for as 
long as possible (usually 2-4 hrs) before the 
loading dose was given. These pre-dose 
recordings formed the baseline for the analy-
sis. After the loading dose, the neonates were· 
again monitored for 2-4 hrs and this period 
was termed day I. The neonates were then 
monitored before the early morning mainte-
nance dose on the next 2 days when possible 
(days 2 and 3). 
All neonates were positioned to prevent 
neck f1exion .2.1 Oral secretions were removed 
whenever present. ~') All neonates were kept in 
the same position throughout the monitoring 
period, usually in the supine. Handling and 
disturbance of the babies were kept to a mini-
mum .~".Ifany neonate required oxygen during 
the monitoring period, then this supply was 
kept constant while monitoring. The neonates 
were monitored using a Datex Oscar II SC-
123 Multigas Monitor (capnograph) and 
Pulse Oximeter (Datex, Helsinki, Finland) 
linked to a Datex Data Acquisition system, 
(Datex interface cable from the Serial and 
Analog connector for data recording with a 
computer, Chicony 386, programmed to read 
the serial data output.) Peripheral oxygen 
saturation (Sp02), pulse rate, inspired and ex-
pired carbon dioxide and respiratory rate were 
recorded. The neonatal pulse oximeter elec-
trodes were attached securely to the foot of the 
neonate and covered with a black sock to 
eliminate ambient light · and possible interfer-
ence with the signal. A neonatal sampling line 
taped in front of the nostrils monitored airflow 
and respiratory rate. The values from the pulse 
oximeter were validated with the oxygen satu-
ration of an arterial blood sample whenever 
such a sample was drawn for clinical purposes. 
The apnoea alarm setting was 20 secs. 
The following information was stored in a 
time ordered fashion on the computer by the 
Datex program and later downloaded for 
analysis: the volume percentage of inspired 
and expired carbon dioxide, respiratory rate 
per minute, percentage peripheral oxygen 
saturation, pulse rate per minute, and the 
clock time in- 10-sec intervals. The monitor 
gave a beat-to-beat display of the above 
parameters, a phlethysmographic pulse wave-
form and a respiratory waveform in a breath-
by-breath display. The instrument was 
calibrated each day before monitoring started. 
In 1991, Ruggins pointed out the inadequa-
cies of apnoea monitors, especially the prob-
lems of attachment, movement artefact and 
the failure to detect obstructive apnoea.27 
Therefore, a strict continuous manual record 
was kept of all incidents of cessation of breath-
ing (shown on the video screen of the cap-
nograph), any movements, mouth breathing, 
sneezes, yawning and any other interruptions 
and interventions. These were later used to 
confirm the computer printout. All apnoea 
events 20 sees or longer were signalled by the 
monitoring system. It was possible to identify 
the pathological apnoea events from the print-
out and to con/Inn them using the manual 
recordings and the alarm. The printout only 
gave a 10-sec resolution, i.e. an average of the 
recordings per 10 secs. Thus, it was imposs-
ible to identify from the printouts the absolute 
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length of the apnoea event, the precise change 
in oxygen saturation, pulse rate and respirat-
ory rate. The disadvantages of this system 
were overcome by using each infant as hislher 
own control. 
From the printout the following were calcu-
lated for each monitoring period and then 
averaged per hour, where appropriate: 
-the number of pathological apnoea inci-
dents (cessation of nasal airflow ;::: 20 sec-
onds); 
-the number of times the SpOz fell ;::: 10% 
for > 10 secs from the average over the 
previous uneventful minute (hypoxaemic 
episode); 
-the number of hypoxaemic episodes associ-
ated with movement, or pathological apnoea 
or pathological apnoea with a fall in pulse 
rate ~ 20°1t. (,associated with' was defined 
as an event that occurred within 30 secs of 
the onset of the hypoxaemic episode); 
-the average Sp02; 
-the number of times the pulse rate fell below 
100 beats per minute (episodes of brady-
cardia); 
-the average pulse rate; 
-apnoea densities were calculated as the per-
eentage of the time spent in apnoea com-
pared with total monitoring time. H 
Carefully timed blood samples were collected 
approximately 1 hr after the loading dose and 
each morning thereafter during the pre-dose 
monitoring period. The samples were cen-
trifuged immediately and the serum kept 
frozen at - 70°C until analysis. The 
theophylline and caffeine concentrations were 
measured by Emit Assay (Syva Company, 
Palo Alto, California). The Wilcoxon Sign 
Rank Test with a Bonferroni correction was 
used to compare the differences from baseline 
to days 1, 2, and 3. A probability value 
:S 0.017 . indicated signilicance. 
Hcsults 
Baseline recordings were obtained from 37 
neonates, 21 of whom were boys. The demo-
graphic details are shown in Table I. On days 
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TABl.E 1. Demographic data of infants (Il ~ 37,21 boys) Hypoxa':lIlic .:pisodes 
Median Range 
Weight (kg) 1.2'5 0.R·- 1.7 
Gestational age (weeks) 30 2H -34 
Postnatal age (days)" 1-2 
AI'GI\R-- l min . 7 2- 9 
APGAR- 5 min_ 9 '1-10 
"Postnatal age at start of monitoring. Day of birth taken 
as day I. 
1, 2 and 3, respectively, 31, 30 and 23 
neonates were monitored. The entry diagnosis 
for all patients was apnoea of prematurity. All 
infants also had mild-to-moderate respiratory 
distress syndrome. Ten had been born by cae-
sarean section and ten were one of a set of 
twins. Seven neonates required ventilation 
from day 2 and were then excluded from the 
study. Two of these died, one due to laryngo-
malacia and the other due to pneumothorax. 
Six other neonates died subsequent to the 3 
days of monitoring. Causes of death were ex-
treme premat~rilY (2) and pneumonia (4). 
1)r//,; sent/II wllee/ltmliOIlS 
Average (SD) serum theophylline concentra-
tions for days 1, 2 and 3 were 5.6 (3.4), 8.0 
(7.08) and 8.0 (5.3) mg/I, respectively. The 
average caffeine concentrations on the 3 days 
were 0.1 (0.17), 0.5 (0 .95) and 0.7 (1.02) 
mg/l, respectively. 
Pathological apnoea 
The results of the pathological apnoea densi-
ties and incidents per hour are given in Table 
II. Although there was a statistically significant 
decrease (p = 0.0001) in the densities and inci-
dents on all 3 days when compared with base-
line, individual responses varied. Seven infants 
showed an increase in the episodes or patho-
logical apnoea on some days, at which times 
the theuphylline concentrations ranged be-
tween 4 and 6.5 mg/1. These increases in ap-
noea incidents were not accompanied by 
hypoxaemic episodes. 
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Table II shows that the total number of hy-
poxaemic episodes decreased from baseline, 
but not significantly. Likewise, the number of 
hypoxaemic episodes un associated with ap-
noea also decreased, but not statistically 
significantly. At baseline, 79% of the hypox-
aemic episodes were unassociated with patho-
logical apnoea. This changed to 87%, 92%, 
and 97% on days 1, 2 and 3, respectively. The 
hypoxaemic episodes associated with patho-
logical apnoea and a ~ 20% fall in pulse rate 
decreased significantly (p:5 0.003) on day 2 
only. 
As theophylline is a central nervous system 
stimulant, it can increase motor activity . Be-
cause increased motor activity has been associ-
ated with increased hypoxaemia, 2~ we 
examined hypoxaemic episodes associated 
with movement. O\'erall, over the 3 days there 
was no significant change in the number of 
hypoxaemic episodes associated with move-
ment. However, one infant experienced a 
signiticant increase in these episodes un day 3. 
His theophylline concentration was 12 mg/l. 
Considering total hypoxaemic episodes, 
nine, eight and six infants had an increase on 
days 1, 2 and 3, respectively. Each of the latter 
six infants was one of twins. Nine infants de-
veloped neonatal jaundice, three on day 2 and 
six on day 3. The total number of hypoxaemic -
episodes, and those hypoxaemic episodes asso-
ciated with movement, increased in four of 
these infants. 
Avcrag.: SpOb putse rale, II/ean areen-at presSlIre 
(A'IAl~ alld episodes oj bradycardia 
The average SpO~, pulse rate and l\1AP per 
monitoring time, as wel1 as episodes of brady-
cardia per hour, arc shown in Table Ill. l11ere 
was no significant change in the average Sp02 
per moi1itoring time rwm baseline on :lI1y of 
the other days. As expected for infants on 
theophylline, the number of episodes of brady-
cardia per hour decreased significantly 
(p :5 0.001) over the 3 days, and the average 
pulse rate per monitoring time increased 
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T/\III.E II. Incidents and densities of pathological apnoea and hypoxaemic episodes per hour, 
median (range) 
Hypoxacmic 
Incidents of Densities of epis!,<\t;s 
pathological pathological I IYPllxaemic unass()ciatcd with 
Day apnoea apnoea ('Yo) episodes apnoea 
llasclinc (/I = 37) 3 (0.4-24) 2 . 1 (0.3·· 13 .5) 1.8 (0- 16) 1.2 (0-15) 
1 (/I = 31) I (0-8)· 0.8 (0-4.3)- 1.0 (0-6) 0.7 (0-9) 
2 (/I = 30) 0.5 (0-6.1)- 0.3 (0·-3.'\)- 1.1 (0-5 .2) 0.5 (0 - 8) 
3 (1/ = 23) o (0-2.1)· o (0- 1.6)· I (0- 23.2) o (0- 23.2) 
-Statistically significant (p <. 0.0(01) compared with baseline. 
si!,;nilicantly (1':~ 0.002) fWIll basdim: . MAP 
increased significantly (p :$ 0.002) on all days. 
Discussion 
The results of this study, which indicate that 
theophylline reduces apnoea in apnoeic infants 
with mild-to-moderate IllS, arc consistent 
with those obtained in premature infants with 
neonatal apnoea," H,ltl H,lh as well as 111 
neonates with concomitant disol'ders,",15,17 
Some of the neonates in this study experi-
enced a small increase in pathological apnoea 
incidents at some stage during treatment. 
Other researchers have also found a lack of 
response in some healthy neonates.I),H,I!> 
Thus, although any conclusions drawn from 
our study arc confounded by the lack of a 
control group, the significant decrease in ap-
noea incidents and densities over the 3 days 
suggests thal theophylline in the concentra-
tions used is effective in reducing apnoea in 
neonates with apnoea plus mild-lo-moderate 
IllS, 
A sharp drop in both incidents and densities 
of pathological apnoea from baseline to day 1 
was observed. Similar findings have been re-
ported by others investigating the effect of 
theophylline in neonates of a comparable ges-
tational age.",II,15,H, It is interesting that a 
sharp decline in apnoea incidents during the 
1 st 24 hours after birth has also been reported 
in neonates receiving no medication. lb,21) The 
profound changes in the physiology of the 
chemoreceptors and other systems controlling 
respiration in the I st few days after birth 30-32 
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make it Jiflicult LO attribute with eertaimy the 
decreases in apnoea in the present study to the 
intluence of theophylline alone, Incn:asing 
maturity could have influenced the results 
over the 3 days. Sims c[ al. have suggested that 
maturity plays a more significant role in de-
creasing the frequency of apnoea than does 
theophylline. 1<, However, Chen ct al. showed 
that brain stem conduction time decreased 
more 111 apnoeic neonates receiving 
theophylline than in an age-matched control 
group with no apnoea. II 
As yet, no consensus regarding the 
definition of a hypoxaemic episode has been 
reached. Our definition was influenced by the 
limitations of our equipment which gives a 
printout of the average over the previous 10 
sees. Our value of a fall in Sp02 of 2: 10% is' 
in accordance with the alarm limits for apnoea 
monitors suggested by Upton el at. q Our 
study demonstrated a reduction in hypox-
aemic episodes but it was not significant. 
Comparison with other studies is difficult due 
to experimental differences as well as differ-
ences in the definition of an episode. However, 
Finer c[ £II. reported a significant reduction in 
apnoea attack rates after 7 days of theophylline 
therapy (serum concentrations 6-19 mg/l) and 
no significant reduction in the number of falls 
oftcpOz greater than 3 mm (11.1 vs 7.2/h).10 
Peabody ct al., who also used tcpO~, observed 
significant decreases in the total duration of 
hypoxaemia after 2 days of theophylline treat-
ment (1/ = 10, serum concentrations 10-16 
mg/l). However, five of the six infants who 
received theophylline for only 2 days experi-
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TAIILE Ill. Average peripheral oxygen saturation (Sp02), pulse rate and mean 
;mcrial pressure pcr monitoring time, and number of episodes of hradycardia per 
hour, median (range) 
Mean arterial Episodes of 
Average Average pulse pressure hradycardia 
Day Sp02 ('Yu) rate (bpm) (mmHg) ( < 100 bpm) 
13ascline 96.4 134.4 34 3.0 
(II = 37) (83.6-98.5) (99- 159) (29-45) (0 - 151) 
1 96.4 143.0' 38 .5* 1** 
(n = 31) (89.8-98.3) (110- 170) (32-63) (0-59) 
2 96.4 143.3' 41' 0 .5"" 
(n ~ }O) (1\R.9 -911.1) (117- 18R.5) (:n50) (0 19) 
1 ')(l.tI 1'15' 46' 0" 
(n = 23) (90 .3 -98.5) (119-162.2) (30-67) (0 -5 .7) 
• f' ~; 0 .002 :Hld *. f' s 0 .00 I compared with baseline. 
enced an increase in apnoeic spells and hypox-
aemia 48 hours after drug withdrawa!.!> It was 
reported recently that caffeine, the other 
methylxanthine used for apnoea of prematu-
rity, did not protect the neonate against the 
development of hypoxaemia. '5 
As reported in other studies/,l,11> many hy-
poxaemic episodes occurred without apnoea 
and it has been suggested that these desatura-
tions unassociated with apnoea could be due 
to intrapulmonary shunts. 2,IIJ,211 This topic has 
been extensively reviewed by Poets at af. who 
suggest that any change in ventilation-perfu-
sion-ratio (V/Q) could lead to intrapulmonary 
shunting. 2 Bolivar at af. have shown that mOst 
hypoxaemic episodes in mechanically venti-
lated infants are triggered by an expiratory 
effort that produces a large decrease in lung 
volume. They suggest that this could lead to 
closure of small airways and the development 
of intrapulmonary shunts. 21 Many factors are 
implicated in intrapulmonary shunting2 and 
theophylline, through its wide range of phar-
macological effects, could possibly influence 
ventilation and/or perfusion. Theophylline 
could improve ventilation through its possible 
enhancement of alveolar ventilation 17 or its 
improvement of respiratory muscle function lH 
and reduction of diaphragmatic fatigue. 31) .. 10 
During hypoxia theophylline may prevent a 
fall in minute ventilation and respiratory 
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rate'-" The drug may also improve the regu-
lation of breathing through its stimulatory ef-
fect on the respiratory centre of the brain 
stem.}1 Theophylline might improve perfusion 
through its positive inotropic and chronotropic 
effects.-'2 A lack of surfactant, as found in 
lIDS, can also lead to VlQ inequalities.! Ante-
natal administration of theophylline has been 
shown to have a beneficial effect on surfactant 
production in fetal rabbits43 and lung matu-
ration in humans!' Postnatally, however, the 
drug had no appreciable effect on RDS.45 Our 
results suggest that theophylline did not have a. 
significant beneficial effect on hypoxaemic 
episodes. The limitation of the study, once 
again, was the lack of a control group. 
The average peripheral oxygen saturation 
over the 3 days showed no statistically 
significant change. These findings were con-
sistent with those obtained by Peabody ct al. 
using tcpO!.!> Not surprisingly, theophylline 
significantly decreased the episodes of brady-
cardia (pulse rate < 100 bpm) and increased 
the average pulse rale over the 3 days. Similar 
effects were noted by Shannon el al. 5 The 
mean lirterial pressun: showed a consistent 
increase from baseline on all 3 days. After 
treatment it remained above 30 mmHg in all 
cases, ensuring sufficient cerebral blood 
f1ow.-'u 
In summary, this study has shown that 
theophylline, in the doses used, is more effec-
tive in reducing apnoea than hypoxaemic 
episodes. The most pronounced effects on ap-
noea and hypoxaemia were seen on the 1 st day 
of treatment after the loading dose . The in-
clusion of a control group would .have been 
ideal, but ethical considerations precluded 
this. 
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GLOSSARY 
AP Apgar score at one minute 
AQ Apgar score at five minutes 
bpm beats per minute 
C concentration 
CI confidence intervals 
CL clearance 
renal clearance 
COND condition of the neonate 
plasma drug concentration 
CPAP continuous positive airway pressure 
DAY day 1, or 2, or 3 of monitoring 
J 
DV dependent variable 
EC50 the concentration of half maximal effect 
EO effect without the drug or baseline effect 
F bioavailability 
FEMAX maximum fractional reduction of apnoea counts 
FO first order estimation method 
FOCE first order conditional estimation method 
fraction unbound drug 
GA gestational age (weeks) 


























glomerular filtration rate 
hourly apnoea count 
the inhibitory concentration producing half maximal effect 
inter -occasion variability 
intravenous 
rate of drug absorption 
loading dose 
mean arterial pressure 
maintenance dose 
neonatal jaundice 
objective function value 
oxygen support 
covariate such as PCA or WGT etc 
postconceptual age (weeks) 
phannacokinetic and phannacodynamic 
postnatal age (days) 
pulse rate 
predictions 
respiratory depressant factor (hypothetical) 
respiratory distress syndrome 
peripheral oxygen saturation (%) 
volume of distribution 
weight 
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